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Chapter 1
INTRODUCTION 
1.1 Polymorphism in molecular crystals 
The term polymorphism is used in many different areas. Threllfall1 found 1.5 million hits 
in an internet search, 90 % of them referred to video games, of the remainder, 90 % referred to 
genetic polymorphism, which involves minor changes in protein and/or DNA sequences. Of 
references dealing with crystallographic polymorphism only 10 % deals with molecular crystals, 
the subject of interest of this thesis. McCrone defines a polymorph as ‘a solid crystalline phase of 
a given compound resulting from the possibility of at least two different arrangements of the 
molecules of that compound in the solid state’2. The amorphous state is sometimes also regarded 
as a polymorph. However, because amorphous forms are not crystalline, they consist of a 
disordered arrangement of molecules, and are not a true polymorph. In the area of 
crystallography Mitscherlich is regarded as the first to use the term polymorphism3, although in 
fact other researchers reported earlier more than one crystal form for a chemical compound; 
Klaproth described the fact that two different crystals, aragonite and calcite had the same 
chemical composition4, see figure 1, and Davey found that diamond was a form of carbon5, see 
figure 2. Figure 3 shows two different forms of sulphur, the monoclinic and the orthorhombic 
form. Polymorphism of elements is called allotropy. For a more elaborate overview of the 
history of the development of polymorphism see Bernstein6 and references therein.  
     
Figure 1: Two polymorphs of CaCO3, left calcite and right aragonite 
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Figure 2: Two forms of carbon, left diamond and right graphite 
 
          
Figure 3: Two forms of sulphur; left the orthorhombic and right the monoclinic form 
McCrone’s definition of polymorphism seems straightforward. It includes conformational 
polymorphism, in which flexible molecules can adopt different conformations in the different 
crystal structures, but dynamic isomerism and tautomerism are excluded because in these cases 
different molecules are formed. A safe criterion to classify a system as polymorphic would be: 
different crystal structures that form the same liquid and vapour states. A system for which the 
isomers (or conformers) can interconvert rapidly in solution, melt or vapour are considered 
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polymorphic according to this criterion. Dunitz stated that this definition in case of a chiral 
compound, a racemate and a conglomerate are classified as polymorphs, if the interconversion of 
the enantiomers in the melt or in solution is fast but as three different compounds in case the 
interconversion is slow7. A term that is related to polymorphism is pseudopolymorphism. The 
term is used to describe solvates of a compound, for which the solvent is part of the crystal 
structure. In case of water as solvent we speak of a hydrate. Despite the fact that the term 
pseudopolymorphism is widely accepted, especially in the pharmaceutical industry, it is better 
changed to solvate. In any case a solvate and an unsolvated crystalline form are constitutionally 
distinct and can therefore not be defined as polymorphs8.  
Two polymorphs of a compound have different unit cells. As a result of this different 
polymorphs can exhibit a variety of different physical properties; table 1 lists some of the 
properties that differ among different polymorphs. 
Table 1. List of some physical properties that can differ among different 
polymorphs. 
Molar volume and density 
Hygroscopicity 
Melting temperature 
Heat capacity 
Solubility 
Dissolution rate 
Stability 
Habit 
Hardness 
Compactibility 
  
In recent years polymorphism of drugs has been the subject for intense interest of the 
pharmaceutical industry, because the difference in solubility between polymorphs of a 
pharmaceutical ingredient can affect the efficacy, the bioavailability and the safety of the drug.  
A lot of effort is put in finding the most stable polymorph of a pharmaceutical ingredient, 
although no method can provide absolute confidence that the most stable polymorph has been 
found. A relatively recent example for which the diversity of the bioavailability of the drug 
proved to be important is Ritonavir. After having been on the market for almost two years, a new 
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thermodynamically more stable polymorph, with a lower solubility and hence a lower 
bioavailability, was found9.  
1.1 Thermodynamics 
The Gibbs free energy, G, of a system is defined by the following equation: 
G = H-TS. 
H represents the enthalpy, T the temperature and S the entropy. The entropy of a pure crystalline 
substance is zero at 0 K and increases with increasing temperature. The enthalpy also increases 
with temperature and this temperature dependence can be expressed by Cp, the heat capacity at 
constant pressure. The result of the relatively slow increase of H and S with increasing 
temperature is a decrease of G with increasing temperature T. The value of G at 0K is equal to 
the value of H at 0 K. A system at constant temperature and pressure tends to reach a minimum 
Gibb’s free energy.  Because the thermodynamic properties of different polymorphs are different 
it is expected that curves of G for different polymorphs are different. Two different types of 
polymorphic behaviour can be distinguished. Lehmann introduced the terms enantiotropic and 
monotropic to categorize polymorphic systems10. For an enantiotropic system there exists a 
transition point, the point were the G curves of two polymorphs cross, at a temperature below the 
melting point of the lower melting polymorph; figure 1a represents such a dimorphic 
enantiotropic system. Polymorph 4a is the stable polymorph below the transition point and 
polymorph 2 is the stable one above the transition point. For a monotropic system such a 
transition point does not exist. In that case polymorph 1 is the stable polymorph at all 
temperatures as presented in figure 4b.  
Considering these energy versus temperature diagrams, several rules of thumb can be 
derived which are useful for understanding and predicting the polymorphic behaviour11,12,13. An 
endothermic heat of transition, for instance, that is observed for a polymorphic transition on 
heating indicates that the two polymorphs are very probably enantiotropically related. If the 
observed transition is exothermic the polymorphs are almost invariably monotropically related. 
The heat of fusion rule states that if the heat of fusion of the lower melting polymorph is larger 
than that of the higher melting polymorph, the two polymorphs are enantiotropically related. 
Conversely, if the higher melting polymorph has the highest heat of fusion, the two polymorphs 
are monotropically related. These two rules can easily be derived from the curves in figure 4 and 
have been proven to be very reliable. 
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    (a)     (b) 
Figure 4. The energy versus temperature diagram of a dimorphic system. In (a) an 
enantiotropic system, and in (b) a monotropic system is presented. G is the Gibbs 
free energy, H the enthalpy. MP1 is the melting point of polymorph 1, MP2 the 
melting point of polymorph 2, Ttrs is the transition temperature. 
1.2 Kinetics 
Different polymorphs can be obtained by crystallization or precipitation from the solution, 
the melt or the gas phase. For the pharmaceutical industry crystallization and precipitation from 
solution are mostly used to obtain different polymorphs, employing various solvents and cooling 
regimes. Gay-Lussac observed that during crystallization often an unstable form was obtained 
first, that later transformed to the stable form14. Ostwald later explained this observation in terms 
of thermodynamics, formulating his law of successive reactions, also known as Ostwald’s step 
rule15. The rule states, “In all processes, it is not the most stable state with the lowest amount of 
free energy that is initially formed, but the least stable state lying nearest in free energy to the 
original state”. Although it is only a rule, it proved to be a good starting point to study the 
kinetics involved in the crystallization process of polymorphs.  
The crystallization process concerns various steps. First, in the nucleation stage tiny 
crystallites are formed in the supersaturated solution. Secondly, in the crystal growth stage these 
crystallites grow out to form macroscopic crystals until the solution is no longer supersaturated 
and equilibrium is reached. Smaller crystals have a slightly higher solubility than larger crystals 
according to the Gibbs-Thomson equation16. As a result, larger crystals grow at the expense of 
the smaller ones, a process which is called Ostwald ripening. Nucleation can be a homogeneous 
process, for which crystals are spontaneously formed in the supersaturated solution or a 
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heterogeneous process, when crystals are formed on foreign material. Both are stochastic 
processes which are governed by a competition between a volume term and a surface term in the 
free energy of the nucleus. See figure 5. These terms are different for different polymorphs. 
 
 
Figure 5: The activation energy barrier G* and the critical nucleus size r* according 
to classical nucleation theory.  γ is the surface free energy of the nucleus. 
The most critical step in the formation of different polymorphs is the nucleation step. 
Depending on the crystallization conditions, the nucleus of a certain polymorph that is formed 
first, will lead to the formation of that particular polymorph if it grows out fast enough. The 
conditions can, however, be such that in the supersaturated solution more than one kind of 
nucleus are formed at the same time17. This phenomenon is called concomitant polymorphism. If 
concomitant polymorphism is observed at temperatures that differ from the transition 
temperature, this always involves a non-equilibrium situation. Under the appropriate 
thermodynamic conditions a less stable polymorph, which was formed initially can be converted 
to a more stable one. The conversion rate depends on the activation energy and is often mediated 
by the solution, melt or vapour phase, but can also take place in the solid state itself. Solid-state 
transformations often have a high kinetic barrier, such that the metastable polymorph can be 
kinetically stable for very long times18.  
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1.3 Disappearing polymorphs 
Several well-documented examples are known in the chemical and pharmaceutical industry 
of crystal forms that were replaced by new, apparently more stable, polymorphs. Benzocaine 
picrate is an example; in first instance a crystal form with a melting point of 129-132 ºC was 
reported, later a higher melting modification was found19, 20 , for the chemical structure see figure 
6.  
H2N
O
O
HO NO2
O2N
O2N  
Figure 6: Chemical structure of benzoine picrate. 
An extraordinary fact was that once the stable polymorph was prepared in a laboratory the 
metastable polymorph could not be isolated anymore. This turned out to be possible again only if 
the laboratory was cleaned very thoroughly. Another example is xylitol, used as a sweetening 
agent in tablets, coatings and as substitute for sucrose in foods. Two polymorphs were known, a 
metastable monoclinic form with a melting point of approximately 61 ºC and a stable 
orthorhombic form with a melting point of 93-94.5 ºC21, 22, for the chemical structure see figure 
7. 
CH2OH
OHH
HHO
OHH
CH2OH 
Figure 7: Chemical structure of Xylitol 
Once a sample of the orthorhombic form was present in a laboratory in which the 
monoclinic form was prepared, this form transformed to the stable orthorhombic form on 
exposure to the air of the laboratory22. It was also not possible anymore to prepare the metastable 
form in these laboratories. Obviously the seeding effect of nuclei of the stable polymorph plays 
an important role in the crystallization process. 
A more recent example is ritonavir, a medicine which is used to treat AIDS23, for the 
chemical structure see figure 8. 
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Figure 8: Chemical structure of ritonavir 
The new drug application (NDA) for ritonavir was filed in 1995 and the medicine was 
introduced on the market in 1996. In 1998 some batches failed the dissolution test and a closer 
investigation revealed that a new and thermodynamically more stable polymorph was formed. In 
laboratories where samples containing the new polymorph were investigated, it was not possible 
to prepare the old polymorph anymore. A new formulation of the drug had to be developed. 
Later it proved to be possible to develop processes to control the polymorph formation. In the 
light of Ostwald’s step rule it is likely, but not certain, that a newly emerged polymorph is 
thermodynamically more stable than the previous one.  The phenomenon of a seemingly 
spontaneous replacement of a polymorph for a more stable polymorph is called “disappearing 
polymorphs”. Despite the fact that a certain polymorph disappeared, it is generally assumed that 
any polymorph once obtained can be obtained again; it is only a matter of finding the right 
conditions. 
1.4 Form versus habit 
In the crystallographic literature two terms are often used to describe crystals; form and 
habit. Form refers to the internal structure of the crystal, therefore polymorphic forms or simply 
polymorphs involve different crystal structures of the same chemical entity. Habit refers to the 
shape of a particular crystal and depends on the growth rates along different directions of the 
crystal. Unfortunately the use of the terms form and habit in the literature is sometimes 
ambiguous.  
It is important to stress the fact that differences in habit, or morphology, of a crystal do not 
necessarily imply a change in the crystal structure or polymorphic form.  
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Morphology is the result of a combination of the way crystals are packed i.e. the 
polymorphic form, and the conditions during the crystallization process. Morphology plays an 
important role in the pharmaceutical industry; it can have an effect on the bioavailability and on 
the processability of the active pharmaceutical ingredient (API).  
 
           
Figure 9: Scanning electron microscopy images showing the morphology difference 
between polymorphs I and II of Venlafaxine hydrochloric acid salt 
Bioavailability of an API is among others determined by the dissolution rate. Other 
examples of processes that are influenced by the morphology of the crystals are filtering, drying 
and tabletting. In the pharmaceutical industry sphere like crystals are mostly preferred.  
During the last century several methods have been developed to predict the crystal 
morphology. Some well known methods have been developed by Bravais, Friedel, Donnay and 
Harker (BFDH)24,25, Hartman and Perdok26, 27, 28 and later by Hartman and Bennema29. The 
availability of fast computers has facilitated the use of numerical modelling techniques to study 
crystal growth. The program Monty is a development for which Monte Carlo growth simulations 
can be performed for any crystal structure in any crystallographic orientation as a function of the 
driving force for crystallization30; for an example see figure 10. 
In models for crystal growth the step free energy γstep plays an important role during birth 
and spread growth as well as for spiral growth. To combine the importance of steps in crystal 
growth with morphology modelling, recently an automated procedure, Steplift, was developed to 
find the molecular configuration that makes up a step31.  
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Figure 10: Monte Carlo growth rate simulations for polymorph I of Venlafaxine free 
base as a function of the driving force  Δμ/kT. 
1.5 Solubility 
Knowledge of the solubility of a compound in different solvents is important. For instance 
chemical engineers need solubility data to design systems for chemical separation and 
purification processes. Product and reactant solubilities are usually determined before solvent 
systems are selected for chemical reactions. Several methods have been developed, in the past 
decades, to predict solubilities32, 33, 34. Different solvents used for crystallization can lead to 
different polymorphic forms e.g. in case of 5-fluorouracil water as solvent leads to polymorph I 
and when nitromethane is used polymorph II is obtained35. The outcome of the crystallization is 
determined by the initial aggregation induced by the solvent used. Moreover, solvates can be 
formed depending on the solvent used and the conditions applied. Since solubility and drug 
dissolution rates of individual polymorphs can be different, resorption and bioavailability in the 
body can also be different36. For this reason the issue of solubility is of paramount importance 
for the pharmaceutical industry. Recently the role of solvent in the polymorphic outcome of a 
crystallization process was described1. One of the conclusions was that it is necessary to 
determine solubility curves and metastable zone widths to be able to control polymorph 
crystallization.  
Interconversion of polymorphs can be accomplished via solvent or gas phase mediated 
transformation or directly via a solid-solid phase transformation. Depending on the kinetic 
barriers, the transformation time can range from instantaneous to infinitely long.  
Determination of the precise polymorph transition temperature for an enantiotropically 
related system is often a laborious task. For such a system the solubility of two polymorphs is, 
however, equal at the transition point. Therefore solubility data can be used to determine the 
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transition temperature and the stability region of the polymorphs. Assuming that the solution 
shows more or less ideal mixing behaviour for the solute and solvent, solubility data will show 
up as linear curves in a van ‘t Hoff plot. Extrapolation of solubility curves that deviate from the 
ideal curve can, however, lead to erroneous assignments of the transition temperatures and 
stability regions of the polymorphs. For an example of solubility curves for a monotropic and an 
enantiotropic polymorphic system see figure 11. 
 
Figure 11: Solubility curves for a monotropic and an enantiotropic polymorphic 
system. The solubility is plotted versus the temperature. 
1.6 Outline of the thesis 
The work presented in this thesis is mainly focussed on the polymorphic behaviour of 
Active Pharmaceutical Ingredients; Venlafaxine and Ondansetron in particular.  
After a general introduction of the phenomenon of polymorphism in chapter 1,  a general 
thermodynamic theory of solubility of molecular crystals is reviewed with the emphasis on 
solutes showing polymorphism is given in chapter 2. In the third chapter a study of the solubility 
behaviour and the thermodynamic relations between the different forms of the free base of 
Venlafaxine is given. For Venlafaxine, which is used as an antidepressant, two polymorphs were 
known and the thermodynamic relation between the two forms was poorly understood. It was 
found that an enantiotropic relation exists for all forms. The solubility in heptane, toluene and 
methanol shows a large deviation from ideal behaviour. It was demonstrated that the deviations 
are to a large extent determined by the temperature dependence of the difference in fusion 
enthalpy of the undercooled melt and the solid. In chapter 4 the topotactical solid-solid transition 
from a racemate to a racemic conglomerate of two forms of the free base of Venlafaxine is 
described. In chapter 5 the results of a morphology prediction of the three forms of Venlafaxine, 
using three different methods, is presented. A comparison with the experimentally observed 
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morphologies is made. The results are semi-quantitative for form I and II. In case of form III the 
overall shape is reproduced but the experimentally observed indices do not match with the 
predicted ones. The polymorphism of Ondansetron is studied in chapter 6. Together with the 
elucidated crystal structure of a vapour grown crystal and the results of molecular modelling, X-
Ray Powder Diffraction and solid state Nuclear Magnetic Resonance experiments it was found 
that the different forms of Ondansetron are in fact locally ordered solid solutions of enantiomers.  
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Chapter 2
SOLUBILITY OF MOLECULAR CRYSTALS 
- POLYMORPHISM IN THE LIGHT OF SOLUBILITY THEORY - 
 
 
 
Abstract 
 
The thermodynamic theory of solubility of molecular crystals in solvents is reviewed with 
an emphasis on solutes showing polymorphism as in case of many pharmaceuticals. The relation 
between solubility and binary phase diagrams of the solute solvent system is treated. The 
astonishing variety of possible solubility curves as a function of temperature is explained using 
simple models for the solution thermodynamics assuming no mixing between the solvent and 
solute in the solid phase, though including the case of solvates or pseudo polymorphs. In passing 
a new method is introduced that allows to estimate the transition temperature of enantiotropically 
related polymorphs from melting temperatures and enthalpies of the polymorphs. 
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2.1 Introduction 
The first practical understanding of solubility dates back to 1900-19301,2,3. Since the 
introduction of the concept of a regular solution by Hildebrand in 19293, later resulting in the 
solubility parameter and Scatchard-Hildebrand theory of regular solutions, numerous new 
models have been proposed in order to describe the non-ideal behavior of solutions more 
correctly. Predictive methods can be very useful tools to reduce the amount of experiments 
needed to determine solubilities, and the development of reliable, transferable and quick methods 
is in continuous progress4,5. Although it might seem as if 1930 is long ago, the theories described 
before that date still contain the essentials of current solubility models. Modern models have 
astonishing capabilities, but they are not complete and experimental data are still needed. 
Especially for multicomponent mixtures, however, experimental methods are not only time-
consuming4, but expensive and difficult as well. 
Compared to vapor liquid equilibria (VLE), much less attention has been given to SLE 
(solid liquid equilibria) and solubility, one of the reasons being the much larger importance of 
rectification as compared to crystallization5,6. Still, SLE and solubility of solids in liquids are of 
great interest: crystallization processes are used, e.g. for the separation and purification of 
thermo labile compounds or isomeric compounds with a very similar vapor pressure7. Moreover, 
the link between solid phase diagrams and solubility is rarely recognized in literature and 
certainly not generally known. Of course, for solubility behavior showing complete eutectic 
behavior, it is not so relevant to make this link, but when polymorphism occurs, phase diagrams 
are becoming useful. Especially for pharmaceutical compounds both fields, solubility of organic 
compounds in various solvents and polymorphism, have attained an increasing interest in recent 
years as both are essential, for instance during the development of a new drug8. 
It is the aim of this paper to make the connection between (binary) phase diagrams and 
solubility starting from simple thermodynamics relevant for the solubility behavior of solids in 
liquids and to apply it to the solubility of polymorphic forms. In that light it is not the aim to 
describe predictive models for the solubility of molecular crystals but rather to use simple 
models to describe the thermodynamics behind the astonishing variety of solubility curves found 
in practical situations. The relation with polymorphism of molecular crystals will be emphasized. 
Starting from the simplest of all models, the ideal solution model, the complexity of the models 
will be gradually increased, in all cases limiting the analysis to the essentials. 
The need for quantitative solubility data, on the other hand, has led to a variety of models for 
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predicting solubility, each with its specific emphasis; in the following a short overview is given. 
The first widely applicable predictive model for solubility and solutions is the regular solution 
theory4. This method makes use of a single solubility parameter, which can describe the real 
behavior of mixtures of non-polar compounds9. A disadvantage is that the regular solution 
assumptions cannot describe mixtures of polar molecules, and although some empirical 
modifications can extend the use of the regular solution model10 (a well known example is the 
Hansen solubility parameter approach11), it is in many cases replaced by more sophisticated 
methods. Nowadays, the modified UNIFAC(Do) method12 is in general the most used method 
available for predictions. In 1978 already it has been shown that the original UNIFAC is capable 
of predicting SLE and solubility13, but only for a limited number of compounds. Originally, 
UNIFAC, being based on a large database of thermodynamic data, was developed for VLE in the 
temperature range 290-400 K and predictions for SLE or below 290 K can lead to poor results. 
To increase the temperature range, in modified UNIFAC(Do) the temperature dependence was 
incorporated and SLE data were used as supporting information, improving the results 
considerably12. For simple compounds, modified UNIFAC(Do) is a helpful tool for predicting 
solubility14, but for more complicated molecules, other models have to be used. An example 
from the pharmaceutical field is the mobile-order-disorder theory, a relatively unknown method 
that can describe solubility behavior of complex drug based molecules8. Another upcoming 
approach is predicting real solution behavior with the help of quantum-chemical methods, such 
as COSMO-RS14. Such models can describe more systems than database-limited methods such 
as UNIFAC, but they are not yet sophisticated enough for accurate applications14,15. 
Despite the advances that have been made, the predictive capability for solubility is still 
limited. UNIFAC and modified UNIFAC(Do), for example, both make use of equations derived 
for eutectic systems and although most SLE are indeed eutectic16, systems with for example 
peritectic behavior cannot be described. The main reason for this limitation is that these models 
have been developed for temperature ranges relevant for VLE phase diagrams; extension to 
solid, solid-liquid or solid-solid behavior is difficult. Little attention has been given to SLE or 
solubility compared to VLE, but still much less attention has been given to the mixing properties 
in solids. 
In the following sections first the link between the thermodynamics of solubility and SLE 
phase diagrams will be treated. Using the thermodynamic basis underlying these phase diagrams 
a number of models, which highlight various solubility curves one can encounter, will be 
analyzed. Finally, the models will be generalized, to include the cases of polymorphism and 
solvates. 
Chapter 2 
 - 22 - 
In all cases equilibrium phase diagrams are treated, that is, kinetic effects have been 
neglected. Especially for crystallization using fast cooling, kinetics cannot be neglected. In 
recent work, Los et al. have developed methods to determine kinetic phase diagrams. For that the 
reader is referred to17,18,19. 
For solutes that have a chiral center, which is of indisputable relevance for 
pharmaceuticals, the reader is referred to the book by Jacques et al.20. 
2.2 The theory of solubility 
In this section the thermodynamic background of solubility theory is treated. A rigorous 
thermodynamic derivation of the solubility of a solid phase in a solvent up to the case of (quasi) 
regular solutions is given. For the latter a mean field model is used. Special emphasis is put on 
the relation between solubility curves and phase diagrams. 
2.2.1 Solubility and phase diagrams 
To discuss the relation between solubility curves and S(olid)-L(iquid) phase equilibria first 
a typical S-L phase diagram is discussed briefly. For a treatment of the thermodynamics of phase 
diagrams in general the reader is referred to the excellent book by Stølen and Grande21. The 
discussion is limited to the case of binary mixtures of compounds A and B, without loss of 
generality. When these compounds, besides in the liquid phases, also mix in the solid phases, a 
situation which is in contrast with the case of solubility to be treated in the main body of the 
present paper, the simultaneous presence of a solid and a liquid phase in thermodynamic 
equilibrium implies the chemical potentials in these phases to be equal for both components: 
,s lA Aμ μ=       (1) 
,s lB Bμ μ=       (2) 
 
where μ  is the chemical potential and l and s  label the liquid phase and the solid phase, 
respectively. In terms of the activity a of the components A and B  these equations become 
 
* *ln ln ,s s l lA A A ART a RT aμ μ+ = +     (3) 
* *ln ln ,s s l lB B B BRT a RT aμ μ+ = +     (4) 
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where *μ  is the chemical potential of the pure compound. In these equations the implicit 
variables T, P and the compositions of the phases are omitted for convenience. Throughout the 
text it is assumed that the pressure is constant, say P PΘ= , that is, standard pressure and the 
temperature is considered as a variable. 
 
S-L ideal phase diagrams 
First the situation is considered for which the mixing is ideal both in the liquid and in the 
solid phase. This implies that in equations (3) and (4) the activities can be replaced by the mole 
fractions ( ; , ; ,p pi ia x i A B p s l= = = ). Then, both in the liquid and in the solid phase the 
components A and B can be mixed in any ratio. For the solid phase this leads to a so-called solid 
solution. 
The resulting phase diagram is given in figure 1.  
 
Figure 1: Typical S-L phase diagram of a binary mixture, ideally mixing in both 
phases. The hatched area is forbidden because of Gibbs' phase rule; there the lever 
rule applies. 
The temperature T and the composition 1B Ax x= −   are the variables at the chosen 
pressure. At high temperatures one finds the well-mixed liquid phase, with no solid phase 
present. In this region the chemical potential of the solid phase is larger than that of the liquid 
phase for both compounds ( ; ,s li i i A Bμ μ> =  ). The stability domain for only a liquid phase is 
bounded from below by the liquidus line connecting the fusion temperatures of both (pure) 
components. Below the liquidus a solid solution starts being formed in combination with the 
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liquid phase. In equilibrium, the compositions of these two phases follow the liquidus and the 
solidus (lower limiting line of the hatched area), respectively on the right-hand and left-hand side 
of the hatched area. This implies that a composition in the hatched area is never realized1. The 
well-known lever rule determines the amounts of the liquid and solid phases. The size of the 
hatched area is determined by the fusion entropies and the difference in fusion temperatures of 
the two (pure) compounds. Below the solidus only the solid solution is present 
( ; ,s li i i A Bμ μ< = ). The ideal mixing phase diagram of figure 1 is typical for metals or 
semiconductors, for which the fusion entropies of the pure compounds are usually comparable. 
For organic crystals, even in case of ideal mixing behavior, the melting entropies can be quite 
different, leading to a more pronounced phase diagram. Figure 2 shows an example of such a 
phase diagram, for which the two compounds still mix in all proportions in both phases. 
 
 
Figure 2: Typical S-L phase diagram of a binary mixture for which the mixing is ideal, 
but the melting entropies of the pure compounds differ considerably. The hatched 
area is forbidden because of Gibbs' phase rule; there the lever rule applies. 
S-L eutectic phase diagrams 
Next the case that the compounds A and B are well miscible in the liquid phase but limited 
miscible in the solid phase, as a result of a relatively large positive enthalpy of mixing in the 
solid phase, is considered. This leads to solid solutions that are either rich in A, which are 
                                                 
1 Gibbs' phase rule, 2F C P= − + , for a two component system ( 2C = , namely A and B ) and the 
presence of two phases ( 2P = , namely s and l ) implies that for a chosen pressure P equilibrium is described by a 
curve in the ( ,Bx T )-diagram. As a consequence, in the hatched area two phases are present. 
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denoted as α or rich in B, denoted as β. In figure 3 the resulting eutectic phase diagram is drawn. 
For the eutectic composition, Ex , the liquid phase solidifies at ET  to form both solid solutions. 
For temperatures below the eutectic temperature, ET , only two solid solution phases, α and β, are 
present each following the solidi. On the right-hand side of the solidus of compound B the 
system consists of a single solid solution (β) phase. The area on the left-hand side of the solidus 
of the compound A represents a single α phase. Note, that in the latter two areas, because of the 
presence of a single phase, Gibbs' phase rule allows both T and Bx  as variables. In the hatched 
areas, again, the lever rule determines the amounts of the liquid and solid phases with 
compositions determined by the liquidus and solidi bordering these areas. 
 
 
Figure 3: S-L phase diagram of a binary mixture completely miscible in the liquid 
phase but almost immiscible in the solid phase. The hatched areas are forbidden 
because of Gibbs' phase rule; there the lever rule applies. Phase α is a solid solution 
rich in A and β is a solid solution rich in B. 
2.2.2 Solubility phase diagrams 
Now, consider a solvent A in which a solute B is dissolved. A solubility curve is the curve 
( )x T  that describes the maximal amount of solute B that can be dissolved in the solvent A at a 
temperature T. In case of a typical solubility problem the fusion temperature of the solvent, AfusT , 
is relatively low as compared to that of the solute, that is, the solvent does not solidify within the 
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temperature range relevant for the solution. Moreover, the solvent, in most cases, does not mix 
with the solute in its solid phase2. For such systems the phase diagram looks like that in figure 4. 
 
 
Figure 4: Typical S-L phase diagram of a binary mixture well miscible in the liquid 
phase but immiscible in the solid phase. The hatched area is forbidden because of 
Gibbs' phase rule; there the lever rule applies. The dashed part of the liquidus of the 
solute B represents the solubility curve described in the present paper. 
In this figure the solubility curve, which is nothing else than the liquidus line, is drawn as a 
dashed line. The solidus line of the solute is running along the 1Bx =  -axis because of the 
assumption that the solid phase does not include solvent molecules. The solidus of the solvent is 
not drawn as it is not relevant because it is assumed that the temperature is always far above the 
fusion temperature of the solvent, AfusT . As a result, the solid phases are pure phases, either of 
compound A or B, denoted as As  and Bs , respectively. Note, that the position of the eutectic 
composition, Ex , does not necessarily lie close to the 0Bx = -line. In terms of the phase diagram 
of figure 4, the present paper aims to describe the solubility curve for temperatures well above 
the eutectic temperature ET , indicated as the dashed liquidus in the figure. 
Thus, the solubility curve is nothing else than the line that in a ( )T x phase diagram divides the 
phase region consisting of a liquid mixture of A and B, for which no solid phase is present, and 
the region where a liquid mixture of A and B is present together with a pure solid phase of the 
solute B. In other words, thermodynamic equilibrium for a saturated solution is achieved when 
                                                 
2 Solvates are an exception to that; in the case of solvates the composition of the solid phase is fixed. 
Solubility of molecular crystals - polymorphism in the light of solubility theory - 
 - 27 - 
the solid phase B is in contact with a saturated solution at a given temperature T and pressure P. 
Equilibrium along the solubility curve implies that the chemical potential of the solute in the 
solid phase is equal to that of the solute in the liquid phase. In other words, thermodynamic 
equilibrium as described by equations (3) and (4), for the case of a solubility curve is determined 
by 
* * ln ,s l lB B BRT aμ μ= +      (5) 
 
as the presence of a solid phase of the solvent A is not considered and the pure solid phase 
implies 1sBa = . In terms of the activity coefficient 
l
Bγ  and the mole fraction lBx  of the solute in the 
solution equation (5) becomes 
 
* * *ln ln ln ,s l lB B B B B B BRT x RT x RTμ μ γ μ γ= + = + +    (6) 
 
where the label l  in the right-hand terms is omitted for convenience. This expression can be 
rearranged to find the solubility of the solute in terms of its mole fraction Bx : 
 
* *
ln ln
s l
B B
B Bx RT
μ μ γ−= −     (7) 
    
The second term on the right-hand side of eq. (7) involves the generally very complex 
chemistry of the interactions between the solute and the solvent molecules. The first term on the 
right-hand side involves only properties of the pure solute, for which the difference in chemical 
potential can be described in terms of the Gibbs free energy difference (per mol) 
*
* B
B
Gg
n
= , 
where n  is the total number of moles in the system, according to 
 
** * * * ( )s l s l s l BB B B B g Tg g
RT RT RT
μ μ →Δ− −
= = −     (8) 
 
The Gibbs free energy * ( )s l Bg T→Δ   at the system temperature is not easily determined 
experimentally. Usually a thermodynamic cycle that is depicted in figure 5 is used for that22,23,24. 
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Figure 5: Alternative thermodynamic cycle for the transition from the solid state of 
the solute to its undercooled liquid state at temperature T. 
In this figure, as an alternative for the direct path 1 4→  which involves * ( )s l Bg T→Δ , the 
solute is heated from the system temperature  to its fusion temperature (1 2→ ), transformed to 
the liquid phase ( 2 3→ ) and subsequently cooled down in the liquid state back to the system 
temperature (3 4→ ), resulting in the supercooled liquid3. Conservation of free energy implies4 
 
* * * * *
1 4 1 2 2 3 3 4( ) ( )s l B B B B Bg T g T g g g→ → → → →Δ = Δ = Δ + Δ + Δ   (9) 
 
As at the melting temperature fusT  the liquid and solid phase are in thermodynamic 
equilibrium it follows that 
 
* *
2 3 ( ) 0B fus B fusg g T→Δ = Δ =      (10) 
 
Combining equations (8) to (10) results in 
 
** * * *
' ' '
1fus fus
fus
T TTs l s l
s l bB B B B
T T T
gg gd d d
RT RT RT R T
μ μ →⎛ ⎞⎛ ⎞ ⎛ ⎞ Δ−
= − − = ⎜ ⎟⎜ ⎟ ⎜ ⎟⎝ ⎠ ⎝ ⎠ ⎝ ⎠∫ ∫ ∫   (11) 
                                                 
3 Prausnitz9 consequently uses the triple point temperature tripleT instead of the fusion temperature  because of 
the possible presence of a gas phase, implying a system pressure equal to the triple point pressure. 
4 If a solid state phase transition occurs before the melting point the Gibbs free energy change of that phase 
transition should be added in the cycle of figure 5; this is the case for a solute showing polymorphism which is 
treated in section 3. In addition, if the solid sublimes before melting the sublimation transition should be used 
instead of the fusion transition. 
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In this equation 'T  is used as a dummy variable for the integration to avoid confusion with 
the system temperature T . Because the system is assumed to be at constant pressure P one can, 
subsequently, use24 the Gibbs-Helmholtz equation5 
 
2 ,
P
G H
T T T
⎛ ∂ ⎞⎛ ⎞
= −⎜ ⎟⎜ ⎟∂ ⎝ ⎠⎝ ⎠      (12) 
 
to rewrite expression (11) to 
 
( )
** *
'
2
1 .
'
fusTs l
s l BB B
T
h dT
RT R T
μ μ →⎛ ⎞Δ−
= − ⎜ ⎟⎜ ⎟⎝ ⎠∫    (13) 
 
To obtain experimental values for this difference in chemical potential of the pure solute 
the transition enthalpy *s l Bh→Δ   has to be measured between the system temperature  T and the 
melting temperature  fusT , which is still difficult but, in principle, more accessible than 
measuring the transition Gibbs free energies from equation (8) as *s l Bh→Δ  can be determined by 
measuring the heat of solidification of supercooled melts at various temperatures. 
If equation (13) is combined with equation (7) one finds a general expression for the solubility of 
a solid phase B in a solvent A at temperature T and constant pressure P, under the assumption 
that the amount of A dissolved in the solid phase B is negligible, reading  
 
( )
( )
* '
'
2'
1ln ln ,
fusT
s l B
B B
T
h T
x dT
R T
γ→
⎛ ⎞Δ⎜ ⎟
= − −⎜ ⎟⎝ ⎠
∫    (14) 
 
where * ' * ' * '( ) ( )l ss l B B Bh T h T h T→Δ = − . 
In appendix A some approximations for the first term on the right-hand side of equation 
(14) are discussed. The second right-hand term in this expression, ln Bγ , which describes the 
thermodynamics of the solute dissolved in the solvent as a deviation from ideal mixing, is 
generally rather involved. To include the effect of mixing the undercooled liquid phase of the 
                                                 
5 The Gibbs-Helmholtz equation, strictly spoken, only holds for equilibrium situations, that is, at fusT ; here, it 
is assumed that the equation also holds for ' fusT T T< < . 
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solute B with the solvent A in the scheme of figure 5 the path has to be extended. The additional 
path 4 5→   is drawn in figure 6. 
 
 
Figure 6: Alternative thermodynamic cycle for the dissolution of a solid B in a solvent 
A at a temperature T. 
The path description used allows for an alternative formulation of equation (5) 
 
( )* *1 4 4 5 0l sB B B B mix Bμ μ μ μ μ→ →Δ + Δ = − + Δ =      (15) 
 
describing the equilibrium between the solid solute and the dissolved solute. Comparison with 
equations (5) and (13) leads to 
 
( )
*
'
2'
ln ln ln .
fusT
s l B
B B B mix B
T
hRT a RT x RT T dT
T
γ μ →
⎛ ⎞Δ⎜ ⎟
= + = Δ = − ⎜ ⎟⎝ ⎠
∫   (16) 
 
From a thermodynamic point of view there is an essential difference between mixtures of 
liquid phases or solid phases in equilibrium with their vapor mixtures and the solubility of a solid 
compound in a solvent. This becomes clear when one compares the mixing thermodynamics of 
an undercooled liquid phase of a solute in a solvent, which will be treated further on, with the 
mixture of two liquids. In the latter case one can establish thermodynamic equilibrium by mixing 
the two (or more) liquids by equating the chemical potentials of all components with their 
chemical potentials in the gas phase as is usually done for (L)iquid-(V)apor phase diagrams. For 
determining the solubility of a solid phase in a solvent, however, the mixing term depends, in 
general, not on the gas phase chemical potential (see footnote I). In figure 6, one can not speak of 
an equilibrium between the undercooled solute and the solvent; only the final solution and the 
solid phase can be in thermodynamic equilibrium. This is expressed by equation (5) for the 
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solute B . In that light the present models are a limited subset of the situations modeled by Pelton 
and Thompson25. In the latter paper the phase diagram of a binary system is studied in 
dependence of the mixing parameters both of the liquid and of the solid (solution) phase; in other 
words of solid-liquid equilibria. 
In the following sections three models for the mixing term will be considered in more 
detail, namely ideal mixing, a regular solution model and a quasi regular solution model. An 
important reference model is that of the ideal solution for which there is no enthalpy of mixing 
( 0idealmix HΔ = ) and a mere mixing entropy contribution
ideal
mix SΔ  representing the ideal 
configurational entropy of mixing. All deviations of this ideal solution model are covered by so-
called excess contributions, defined as 
 
,E E E idealmix mix mix mix mixG H T S G GΔ = Δ − Δ ≡ Δ − Δ or    (17) 
 
   Emix mixH HΔ ≡ Δ  and 
E ideal
mix mix mixS S SΔ ≡ Δ − Δ .    (18) 
 
In table 1 an overview of the models is given. 
Table 1: The various approximations for the mixing enthalpy and entropy 
considered in the present paper; the athermal and general situation will not be 
discussed in detail. 
 mixHΔ mixSΔ  EmixHΔ
E
mixSΔ  
ideal 0 ideal
mix SΔ  0 0 
regular reg
mixHΔ
ideal
mix SΔ  
reg
mixHΔ 0 
athermal 0 ideal qu reg
mix mixS S
−Δ + Δ 0 qu regmix S
−Δ  
quasi regular reg
mixHΔ
ideal qu reg
mix mixS S
−Δ + Δ regmixHΔ
qu reg
mix S
−Δ  
general E
mixHΔ
ideal E
mix mixS SΔ + Δ  
E
mixHΔ
E
mixSΔ  
2.2.3 Ideal solutions 
Ideal solutions already offer a lot of insight in the problem of solubility. For an ideal 
solution, the solubility curve is the liquidus of the solute B of a phase diagram of two compounds 
A and B that are immiscible in the solid phase and perfectly miscible in the liquid phase. On a 
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molecular level this implies that the reaction energy for the mixing reaction 2AA BB ABφ φ φ+ →  
between the solute and solvent molecules is zero 
 
( )1 0
2AB AA BB
φ φ φ− + =     (19) 
 
where AAφ  is the interaction energy between the solvent molecules, BBφ between the solute 
molecules and ABφ  represents the heterogeneous interaction energy. In other words, 0idealmix HΔ =  . 
Then, the only contribution of the mixing to equation (16) is an ideal configurational entropic 
term, idealmix SΔ , as a result of the mixture of  An mol of solvent and Bn  mol of the (supercooled) 
liquid solute. The total Gibbs free energy of mixing is26 
 
( )ln ln ,ideal idealmix mix A A B BG T S nRT x x x xΔ = − Δ = +   (20) 
 
where A Bn n n= + . The ideal mixing contribution to the chemical potential change of the solute 
can be found by differentiating equation (20) with respect to Bn resulting in 
 
, ,
ln
A
ideal
ideal idealmix
mix B B
B T P n
G RT x
n
μ ⎛ ⎞∂ΔΔ = =⎜ ⎟∂⎝ ⎠
   (21)  
Substituting this result in equation (16) one obtains for the activity coefficient 1Bγ = . Using 
equation (15) this leads to the ideal solubility equation 
 
( )
( )
* '* *
'
2'
1ln .
fusTs l
s l Bideal B B
B
T
h T
x dT
RT R T
μ μ →Δ−
= = − ∫    (22) 
 
Note, that this solubility equation for an ideal solution only depends on pure solute 
parameters. 
 
Interpretation of the ideal solubility curve 
As long as it is assumed that the solution is ideal the solubility curve can be described by 
equation (22) for temperatures above the fusion temperature of the solvent and compositions 
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with B Ex x>  . In most cases, for which 
solv
fusT << 
( ) ,Bfus ET x  is very small. As mentioned before, 
therefore, the solubility curve is considered to be represented by the liquidus of the solute for 
compositions in the range  0 1Bx≤ < . 
Assuming that the fusion enthalpy of the pure solute is independent of the temperature for 
all values of interest for Bx , equation (22) reduces to 
 
* 1 1ln ,fus BidealB
fus
h
x
R T T
⎡ ⎤Δ
= − −⎢ ⎥⎢ ⎥⎣ ⎦
    (23) 
 
Equation (23), when plotted as lnx versus 1/T, a representation of solubility curves often 
referred to as van 't Hoff curves, leads to a linear solubility curve which will be the reference 
curve in section 2.4 dealing with regular solutions. 
In the limit of very high concentrations, 1Bx ≈ , the solubility curve can be interpreted as a 
result of freezing point depression, the solvent acting as an impurity. Note that this approach is 
an alternative treatment of freezing point depression as it usually is considered for the case of a 
liquid with a dissolved solid or liquid acting as the impurity. For 1Bx ≈  and using 
( )ln ln 1B A Ax x x= − ≈  equation (23) becomes 
 
2
* ,
fus
fus A
fus B
RT
T T x
h
− =
Δ
     (24) 
 
which is the standard equation for the linear freezing point depression, with the solvent 
acting as the impurity. As the solid is usually dissolved at temperatures T far below the fusion 
temperature, the approximation used to arrive at equation (24) can usually not be made. 
In practice, *fus BhΔ  will depend on temperature, as a result of which even for ideal solutions a 
classical solubility curve of ln Bx  versus 1/T does not result in a linear curve. In practice, 
however, the temperature range studied is rather limited, such that this curve is usually close to 
linear. In that case the slope of this curve should not be interpreted as * /fus Bh RΔ  but rather as 
( )* exp /s l Bh T R→Δ , sometimes denoted as /diss Bh RΔ , where expT  represents the average 
experimental temperature27. 
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To get an impression of the more general case of an ideal solubility curve the temperature 
dependence of ( )*s l Bh T→Δ  in equation (22) is considered in appendix A in terms of a linear 
temperature dependence of the molar heat capacity according to 
 
( ) ( ) ( ) ( )0 1 .l ss l p p p p p fusc T c T c T c c T T→Δ = − = Δ + Δ −    (25) 
 
Here the case for which 1 0pcΔ =  will be considered. Then equation (51) becomes 
 
* 01 1ln ln 1 .pC fus B p fus fusB
fus
h c T T
x
R T T R T T
⎡ ⎤Δ Δ ⎡ ⎤
= − + − −⎢ ⎥ ⎢ ⎥⎢ ⎥ ⎣ ⎦⎣ ⎦
   (26) 
 
This equation is plotted for a few values for 0pcΔ  in figure 7. The common point of the 
solubility curves in this figure is the fusion temperature of the pure solute, marked by the dashed 
black lines. For the limiting case that fusT T= , equation (26) reduces to  ln 0Bx = , that is  1Bx = , 
corresponding to the pure liquid solute. The straight black lines in the van 't Hoff plots (figures 
7c and d) represent the ideal solubility situation for 0pcΔ =0 . The red curves in figure 7 represent 
the situation for which 0pcΔ >0. In that case the solubility is larger than the reference straight line, 
showing a minimum solubility for a temperature given by  
 
*
min 0
fus B
fus
P
h
T T
c
Δ
= −
Δ
  ( )0 0PcΔ >     (27) 
 
The blue curves show the situation for 0 0PcΔ < , resulting in a lower solubility and a non-
linear van 't Hoff curve as a result of the increasing contribution of the 0PcΔ  term in equation (26) 
with decreasing temperature. A negative value for 0PcΔ  is quite rare; an exception might have 
been found for pyrene28. Usually, ( ) ( )l sP Pc T c T>  for temperatures below the fusion temperature. 
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 (a) (b) 
 
               
 (c) (d) 
Figure 7: The solubility curves according to equation (26) for a) *fus BhΔ =20 kJ/mol 
and fusT =370 K and b) 
*
fus BhΔ =100 kJ/mol and fusT =570 K. The dashed black lines 
indicate fusT . The heavy black lines represent the ideal solubility case for which 
0
pcΔ =0 . The red lines show the values 
0
pcΔ =100, 200 and   500 J/mol K and the blue 
lines 0pcΔ = -100 and -200  J/mol K, respectively. The figures (c) and (d) show the 
corresponding van 't Hoff curves of (a) and (b) respectively. 
Although a negative value for 0PcΔ  is rare, a positive value for
0
PcΔ   large enough to lead to 
a minimum in the van 't Hoff curve at an accessible temperature can not be ruled out, a priori. 
For temperatures minT T<   the solubility increases with decreasing temperature. This 
phenomenon is known as retrograde solubility. The limiting case for which 1Bx =  below the 
fusion temperature, obviously, is non-physical. To get an idea of the quantitative effect of 
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( )s l Pc T→Δ  on the solubility curve the case of a pharmaceutical compound, venlafaxine, is 
considered in detail in appendix B. 
In conclusion, in almost all cases ( ) 0s l Pc T→Δ > , leading to an increase in solubility and a 
deviation from the linear van 't Hoff curve. For large positive values a minimum in the solubility 
can occur. Equation (27) can be used as an indication for such behavior. There are, however, 
other causes of retrograde solubility. In section 2.6 the issue of retrograde solubility will be 
touched upon in more detail. 
2.2.4 Regular solutions 
As mentioned before, approximations for the solubility, or in general mixing of phases, 
beyond the ideal case are expressed in terms of excess contributions, like ,E Emix mixG HΔ Δ  and 
E
mixSΔ , as in equations (17) and (18). Accordingly, the excess mixing chemical potential 
difference is given by 
 
, ,
ln
mix
A
E
E idealmix
mix B mix B B B
B T P n
G RT
n
μ μ μ γ⎛ ⎞∂ΔΔ = = Δ − Δ =⎜ ⎟∂⎝ ⎠
.  (28) 
 
Regular solutions6 are a special case defined by the restriction that 0EmixHΔ ≠   and 
0EmixSΔ = . On a molecular level this restriction implies that for the mixing reaction 
2AA BB ABφ φ φ+ → , it holds that ( )12AB AA BBφ φ φ≠ +  . For the limitations of regular solution models 
the reader is referred to Prausnitz et al.9. 
The regular solution model treated here is based on the mean field model. In the mean field 
model it is assumed that the occurrence of the various interactions in the solution, ABφ , AAφ  
and BBφ  is randomly distributed, independent of the values of the interaction energies7. To 
simplify the statistics of the neighboring interactions further, the solvent is divided in cells which 
are either filled with a solute molecule B or a solvent molecule A. Each cell has Z interactions, 
with neighboring cells. Depending on the concentration of solute Bx  the number of AB 
                                                 
6 The term regular solutions was first introduced by Hildebrand34 and further restricted by Prausnitz et al.9. 
7 This assumption will obviously be too crude for situations where ABφ , AAφ and BBφ  differ too much. 
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interactions, each having an energy ABφ , between the cells in the model equals 
( )1B A B BZx x Zx x= − . Therefore the total excess enthalpy now becomes 
 
( ) ( )11 ,
2
reg E
mix mix B B AB AA BBH H Znx x φ φ φ⎡ ⎤Δ = Δ = − − +⎢ ⎥⎣ ⎦   (29) 
 
where the superscript reg refers to the present mean field model for a regular solution and the 
molecular interaction energies are chosen to be negative. Defining the excess interaction energy 
by 
   ( )1
2
E
AB AA BBφ φ φ φ≡ − + and reg Emixh ZφΔ ≡     (30) 
 
and combining equations (20) and (29) one obtains 
 
( ) ( )1 ln ln .reg regmix B B mix A A B BG nx x h nRT x x x xΔ = − Δ + +   (31) 
Differentiating this expression with respect to Bn one obtains for the chemical potential 
change of the solute 
 
( )2
, ,
1 ln .
A
reg
reg regmix
mix B mix B B
B T P n
G h x RT x
n
μ ⎛ ⎞∂ΔΔ = = Δ − +⎜ ⎟∂⎝ ⎠
  (32) 
 
Substituting this result in equation (16) one obtains for the solubility equation of the 
regular mean field solution 
 
( )
( ) ( )
* '
2'
2'
1ln 1 .
fusT reg
s l Breg regmix
B B
T
h T hx dT x
R RTT
→
⎛ ⎞Δ Δ⎜ ⎟
= − − −⎜ ⎟⎝ ⎠
∫   (33) 
 
The activity coefficient in equation (16) is, thus, determined through 
 
( )2ln 1 .regreg regmixB Bh xRTγ
Δ
= −      (34) 
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To show the effect of regmixhΔ  on the solubility it will be assumed that 
*
s l Bh→Δ  is independent 
of temperature, implying 
 
( )2* 11 1ln .regreg Bfus Breg mixB
fus
xh hx
R T T R T
⎡ ⎤
−⎡ ⎤Δ Δ ⎢ ⎥= − −⎢ ⎥ ⎢ ⎥⎢ ⎥⎣ ⎦ ⎣ ⎦
   (35) 
 
This equation is plotted for a few values for regmixhΔ   in figure 8. 
Again, the straight black lines in the van 't Hoff plots (figures 8c,d) represent the ideal 
solubility situation described by equation (23). The blue curves show the situation for 0regmix BhΔ >  
which can, according to equation (29), be interpreted as ( )1
2AB AA BB
φ φ φ> + , a situation which is 
sometimes referred to as less than equivalent wetting, equivalent wetting referring to the ideal 
case. The red curves represent the situation for which ( )1
2AB AA BB
φ φ φ< + , or more than 
equivalent wetting. The reduced affinity between the molecules A and B for the blue curves 
leads to a lower solubility at a given temperature as compared to the ideal solubility curve. The 
reverse holds for the red curves. In the limit of low concentrations of the solute, that is 0Bx → , 
equation (35) becomes 
 
* 1 1ln .
reg
fus Breg mix B
B
fus
h hx
R T T RT
⎡ ⎤Δ Δ
= − −⎢ ⎥⎢ ⎥⎣ ⎦
    (36) 
 
which in the van 't Hoff plot leads to straight lines with a slope ( )* /regfus B mix Bh h RΔ + Δ  instead of 
* /fus Bh RΔ  for the ideal solubility curve, as can be seen in figure 8c. 
According to equation (35) the freezing point depression for small Ax becomes 
2
2
* * ,
reg
fus mix B fus
fus A A
fus B fus B
RT h T
T T x x
h h
Δ
− = −
Δ Δ
    (37) 
 
showing an extra term as compared to equation (24). 
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 (a) (b) 
               
 (c) (d) 
Figure 8: The solubility curves according to equation (35) for a) *fus BhΔ =20  kJ/mol 
and fusT =370 K and b)
*
fus BhΔ =100  kJ/mol and fusT =570 K. The dashed black lines 
indicate fusT  . The heavy black lines represent the ideal solubility case for which 
0.regmix BhΔ =  The blue lines show the values 1,10
reg
mix BhΔ = and 20 kJ/mol and the red 
lines 1regmix BhΔ = − and -5 kJ/mol, respectively. The figures c) and d) show the 
corresponding van 't Hoff curves of a) and b), respectively. 
Another important feature in figure 8 is that for large enough positive values of regmix BhΔ , the 
solubility curves show a horizontal plateau in the T versus x  curves (figures 8 a,b). For these 
values of regmix BhΔ a particular situation occurs. The solubility equation described by equation (23) 
would show a maximum and a minimum in the Bx  interval of the plateau. In between this 
maximum and minimum, however, the system is not stable due to liquid-liquid, (L-L), 
separation, for which a diluted solution and a concentrated solution are in equilibrium. As a 
result, the solubility curve has to be replaced by the horizontal lines in an appropriate interval for 
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the mole fraction. According to Gibbs' phase rule for a two component system, considered here, 
three phases can only coexist for a single point in the ( ,T x ) phase diagram. The end points of 
the horizontal lines correspond to two solutions in equilibrium with the solid phase of the solute. 
In the van 't Hoff plots the L-L separation temperature corresponds to the vertical part in the blue 
lines. Often the term oiling out is used for L-L separation29. The occurrence of L-L separation 
has not been reported often for molecular compounds. For pharmaceuticals this might be 
explained by the, often, classified information of the data, see e.g.  Deneau and Steele30. Papers 
with full details on this topic were published by Laferrère et al. 31,32.  
In case of protein crystallization, although strictly spoken not a binary system as a result of 
the presence of additional salts, L-L separation is a common feature often a result of kinetic 
effects33. In appendix C the thermodynamics behind the cause of L-L separation are explained; 
there, also the conditions for L-L separation for the present regular solution model will be given. 
For negative values of regmix BhΔ  no extrema are found in the solubility curve within the 
present model. 
2.2.5 Beyond regular solutions 
In the strict definition of a regular solutions as introduced by Hildebrand34 the excess 
entropy of mixing, EmixSΔ , is zero (cf. Table 1). In this section a non-zero term for 
E
mixSΔ  will be 
added to the regular solution model. For that it will be assumed that the excess entropy, like in 
the mean field model for the regular solution, will depend on the number of heterogeneous 
interactions between the solvent molecules A and the solute molecules B, leading to a Gibbs free 
energy of mixing equal to 
 
( ) ( )ln ln 1 .qu reg reg qu regmix A A B B B B mix mixG nRT x x x x nx x h T s− −⎡ ⎤Δ = + + − Δ − Δ⎣ ⎦  (38) 
 
This excess entropy term should therefore be interpreted as being mainly due to a change 
in the vibrational and rotational degrees of freedom of the molecules, but also containing extra 
configurational contributions. This model is sometimes referred to as the quasi regular solution 
model, explaining the superscript in the equation21. Differentiating equation (38) with respect to 
Bn  one finds analogously to the case of regular solutions, neglecting the temperature dependence 
of ( )*s l Bh T→Δ , for the solubility equation 
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( )2* 11 1ln .qu regreg qu reg Bfus Bqu reg mix B mixB
fus
xh h T sx
R T T R T
−
−
−
⎡ ⎤
−⎡ ⎤Δ ⎛ ⎞Δ − Δ ⎢ ⎥= − −⎢ ⎥ ⎜ ⎟ ⎢ ⎥⎢ ⎥ ⎝ ⎠⎣ ⎦ ⎣ ⎦
 (39) 
 
The activity coefficient in equation (16), for the quasi regular solution model, thus 
becomes ( )( )2ln / / 1reg qu reg qu regB mix mix Bh RT s R xγ − −= Δ − Δ − . The resulting solubility curves are plotted 
in figure 9 for several of the parameters of figure 8b and a realistic value of qu regmix s
−Δ =10 J/mol K. 
In the van 't Hoff plots the slopes for the lower limit of Bx  are still given 
by ( )* /regfus B mix Bh h RΔ + Δ   as in the regular solution case. Comparing figures 8b,d and figure 9 
shows that positive values of the excess entropy suppress the deviation from ideality of the 
excess enthalpy, while negative values amplify the deviation. 
 
        
 (a) (b) 
Figure 9: The solubility curves according to equation (39) for *fus BhΔ =100 kJ/mol 
and fusT =570 K. The dashed black lines indicate fusT . The heavy black lines represent 
the solubility case for which 0reg qu regmix B mixh s
−Δ = Δ =   . The blue lines show the 
values regmix BhΔ =1, 10 kJ/mol and
qu reg
mix s
−Δ  =0 . The green curves show the 
corresponding situations for  qu regmix s
−Δ =10  J/mol K; the red curves for qu regmix s
−Δ = -10 
J/mol K. a) the ( x , T )-diagrams and b) the corresponding van 't Hoff curves. 
A positive and negative value for the excess entropy can be interpreted as an increase, 
respectively decrease, in vibrational and rotational entropy in the solution as a result of the 
difference between the A-B interactions as compared to the  A-A and  B-B interactions. In other 
words, any excess enthalpy, either positive or negative, will imply a change in excess entropy. In 
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many cases regmix BhΔ  and
qu reg
mix s
−Δ  have the same sign35 resulting in a mutually compensating effect 
in equation (39), which in turn leads to a smaller deviation from the ideal solubility curve. 
2.2.6 Deviations from mean field models 
In the previous two sections the solubility of solutes has been discussed on the basis of a 
mean field model assuming a random distribution of the solute and solvent molecules, with 
isotropic interaction between them. Relatively strong homogeneous interactions lead to 
clustering of A or B molecules resulting in deviations from the mean field approximation. The 
case of hydrogen bonds in solutions and complexes formed in electrolytic solutions are notorious 
for that. Both situations are not well described by the simple models presented here. More 
sophisticated models as referred to in the introduction deal with clustering effects, but are 
beyond the scope of this paper as they depend too much on the specific compound and solvent 
used. However, the special case of retrograde solubility will be treated briefly in the following 
section. 
2.2.7 Retrograde solubility 
As was pointed out in section 2.3 retrograde solubility, i.e. decreasing solubility with 
increasing temperature within a certain temperature interval, can in exceptional cases be 
explained by a temperature dependence of the difference in heat capacity of the undercooled 
molten solute and the solid solute. Also the (quasi) regular solution models cannot describe this 
phenomenon without taking such a difference in heat capacity into account. In general two 
causes can be distinguished for retrograde solubility.  
A difference in heat capacity, ( )s l Pc T→Δ , between the undercooled liquid phase and the 
solid phase of the solute as described in section 2.3 might lead to a retrograde solubility. 
Although in appendix B it is shown that this effect is not large enough for the case of the 
pharmaceutical compound venlafaxine, there might exist examples of more complex organic 
molecules for which ( )s l Pc T→Δ  is large enough. Equation (27) shows that a retrograde solubility 
can be expected in case of a solute that has a relatively small heat of fusion *fushΔ   combined 
with a large difference in heat capacities ( )s l Pc T→Δ . Calculations similar to the ones performed 
in appendix B, for fat crystals (SSS), e.g., showed a fully negligible effect of the relatively large 
value of ( )s l Pc T→Δ ,  ranging from 400 J/molK at T=300 K to 100 J/molK at fusT T= , caused by 
the large enthalpy of fusion, *fushΔ =196 kJ/mol
36. In general, a strong effect is to be expected for 
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compounds that have a large number of degrees of freedom in the (undercooled) liquid phase as 
compared to the solid phase. 
A decrease in entropy in the solution as a result of strong solvation interactions can also 
lead to retrograde solubility. Such an effect should be included in EmixSΔ  with an appropriate 
temperature dependence. Examples are found for aqueous solutions of salts. Small cations like 
Li+ and Ca2+ result in large ordered hydration shells leading to strong heterogeneous interactions 
between the solute and solvent. The same holds for some cases of transition metal ions forming 
complexes like Co4+ in the salt [N(CH3 )]2 CoCl4 . No retrograde solubilities were found to be 
reported for salts of pharmaceuticals, possibly because in most cases the counter ion is an anion 
for these salts. 
Hexamethylenetetramine (HMT), used in explosives and plastics industries, is an example 
of a molecular crystal that shows retrograde solubility37,38. The hydrate of the compound (C6 
H12N4.6H2O) shows a eutectic behavior in the aqueous phase diagram, which dissolves 
incongruently at 286 K to form the anhydrate (C6H12N4). The solubility curve of the anhydrate, 
although nearly temperature independent, is a retrograde39. As a result of the presence of a 
hexahydrate, it is tempting to attribute the retrograde behavior to the formation of complexes 
with the solvent37; lack of thermodynamic data, makes it difficult to determine the effect of the 
heat capacity difference ( )s l Pc T→Δ . 
There is another case of retrograde solubility, beyond the scope of this paper. In case of 
solid solutions the mixing thermodynamics of the solvent in the solute has to be included and 
one has to consider the equations (3) and (4) instead of equation (5). Even for a regular solution 
model this leads to an additional term reg smix HΔ , where the superscript s refers to the solid solution 
phase. This additional parameter is enough to lead to retrograde solubility as was shown for solid 
solutions of Sb and Cu in Si and Ge40. Such a retrograde solubility curve is visible in figure 3 for 
the solidus of the solid solution phase β.  
Solid solutions are quite common in alloys and mixtures of similar organic molecules like 
alkanes or fats35, but rarely observed for molecular crystals like pharmaceuticals dissolved in 
common solvents. If solid solutions play a role, retrograde solubilities can occur. Solid solutions 
should not be confused with solvates for which the solvent and solute are built-in in a 
stoichiometrical relation in the solid phase Solvates, therefore lead to a very different phase 
diagram as will be discussed in section 3.1. 
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2.3 Solubility and polymorphism 
Polymorphism is the phenomenon that a compound, the solute B , can crystallize in more 
than one crystal structure under seemingly identical conditions. Although there is only one 
thermodynamically stable phase for a given temperature and pressure, often metastable 
crystalline phases are formed that can persist for long times. Eventually, these phases will 
transform to the stable phase. This behavior is usually interpreted in terms of Ostwald's rule of 
stages41. If the solute exhibits polymorphism, the various polymorphic forms will have a 
different solubility. In general, the solubility of the metastable forms will be higher than that of 
the stable form. To keep the reasoning simple, situations of compounds showing only two 
polymorphic forms are discussed. The generalization to cases of more than two polymorphic 
forms is straightforward. The thermodynamics of polymorphic systems is treated in detail and 
illustrated with various experimental examples by Burger and Ramberger42,43. Methods to 
determine the relative thermodynamic stability of polymorphs have been treated by Yu44,45. The 
effect of kinetics that favors the formation of metastable forms is discussed in terms of 
metastable zones by Threlfall46. In terms of the thermodynamics of solutions there is an 
important difference between monotropic and enantiotropic polymorphism. For a monotropic 
system there is only one stable form at all temperatures at a given pressure. In that case, in 
thermodynamic equilibrium, the metastable phase will always be dissolved and the stable form 
can be in equilibrium with the solution as described by equation (5). For an enantiotropic 
polymorphic system, however, there is a phase transition temperature  below which one of the 
two polymorphic forms (say form I) is stable and the other one is metastable, while above that 
temperature form II is stable and form I is metastable. This implies that at the temperature trsT  it 
holds that ( ) ( )s sBI trs BII trsT Tμ μ= . Any polymorphic form has its own (metastable) S-L phase 
diagram. In case of an enantiotropic polymorphic compound B the equilibrium phase diagram 
shows an additional feature as depicted in figure 10 as compared to figure 4. At the transition 
temperature, trsT , indicated as 
B
trsT  in figure 10 the solubility (liquidus) curves for the two 
polymorphs cross. In the latter figure the liquidi of both phase diagrams are only shown above 
the transition temperature. 
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Figure 10: Typical S-L phase diagram of a binary mixture well miscible in the liquid 
phase but immiscible in the solid phase, for an enantiotropic polymorphic system of 
the solute B . The dashed part of the liquidus of the solute  represents the solubility 
curve described in the present paper. At BtrsT  a solid-solid phase transition between 
the polymorphic forms I and II occurs. 
Only at the transition temperature both polymorphic solid forms can be in equilibrium with 
the solution: 
 
( ) ( ) ( ) ( ) ( )* lns s l l lBI trs BII trs B trs B trs B trsT T T T RT a Tμ μ μ μ= = = + .   (40) 
 
Note, that this equation is independent of the solvent used47.8 This implies that in 
thermodynamic equilibrium the solubility vs. temperature curves of different polymorphs always 
cross each other at the same transition temperature trsT . In this light, situations where 
concomitant polymorphism48 is observed for temperatures that differ from the phase transition 
temperature trsT , always represent non-equilibrium situations. 
A further consequence of enantiotropic polymorphism is that for temperatures below the 
transition temperature the integral in equation (14) contains a contribution ( )* 2/trs B trs trsh T TΔ  for 
each of the models discussed above. For example, for the case that the difference in molar heat 
                                                 
8 Here it is assumed that surface free energy contributions as a result of solvent-solid interactions can be 
neglected, which is, usually, reasonable for practical crystal sizes, even in the case of precipitation. For most 
molecular crystals the surface energy becomes comparable to the bulk energy for crystal diameters of the order of 
some 1-10 nm. 
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capacity is independent of the temperature between and the fusion temperature of the solid phase 
melting at the highest temperature, equation (26) has to be replaced by 
 
** 1 1ln ln 1 ln .fus B fus fustrs B s l PB B
trs trs fus
h T Th cx
RT R T T R T T
γ→
⎡ ⎤Δ ⎡ ⎤Δ Δ
= + − + − − −⎢ ⎥ ⎢ ⎥⎢ ⎥ ⎣ ⎦⎣ ⎦∑  (41) 
 
Although, strictly a non-equilibrium situation, the presence of the metastable polymorphic 
form in a solution, possibly concomitant with the stable polymorph, can, in many cases, persist 
for a long time; long enough to determine a solubility curve ( x vs.T ) for both polymorphic 
forms. Such cases are found both for monotropic49,50 and enantiotropic51 systems. In principle, a 
metastable polymorph corresponds to a local minimum in the Gibbs free energy. The metastable 
solid phase cannot find kinetic pathways to transform to the stable form in the time allowed by 
the experiment. The solubility of both polymorphs can, therefore, be described by equation (7), 
be it with the appropriate parameters for the two polymorphs according to 
* *
( )
( )ln ln
s l
BI II B
BI II Bx RT
μ μ γ−= −     (42) 
    
Note, that the term ln Bγ , describing the non-ideality of the solution, is the same for both 
polymorphs at any temperature T ; the same holds for the chemical potential of the pure liquid 
solute, *lBμ . This implies that the difference in solubility of the two polymorphs at a temperature  
offers valuable information of the difference in chemical potential of their solid phases 
[ ]* * ln ln .s sBII BI BII BIRT x xμ μ− = −     (43) 
As this equation involves pure compounds the chemical potentials can be rewritten in 
terms of the differences in enthalpy and entropy of the two polymorphs according to 
 
* * ln .II I II I II I Bh T s RT x→ → →Δ − Δ = Δ     (44) 
 
Assuming a negligible temperature dependence for both  *II I h→Δ and 
*
II I s→Δ ,
9 this 
equation can be used to determine *II I h→Δ  and 
*
II I s→Δ as the slope and intercept with the  y-axis 
                                                 
9 Note, that this assumption is much more realistic as compared to the assumptions discussed when 
considering freezing point depression as it only concerns temperatures for which the solubility curves are 
determined, which are usually far below the fusion temperature of the solute. 
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in a ln BxΔ  vs. 1/ RT  plot for the temperatures considered. This was used, for example by Stoica 
et al. to determine the dissolution enthalpy and entropy of two polymorphic forms of a steroid50. 
Moreover, equation (44) implies that the transition temperature for an enantiotropic system is 
determined by 
*
*
II I
trs
II I
hT
s
→
→
Δ
=
Δ
      (45) 
 
as for any equilibrium phase transition. This temperature, when neglecting the difference in heat 
capacity between the two polymorphs in the temperature range between the transition 
temperature trsT and fusT , is given by 
* *
* */ /
fus BII fus BI
trs II I
fus BII fus fus BI fus
h h
T
h T h T
Δ − Δ
=
Δ − Δ
    (46) 
 
Therefore the transition temperature can, besides from solubility curves, be estimated from 
DSC measurements as long as no solid-solid transition between the polymorphic forms occurs 
during such an experiment. This has been successfully applied to three enantiotropically related 
polymorphs of venlafaxine52. 
In case the transition can not be avoided and the transition temperature trsT  and the 
corresponding enthalpy change *trshΔ  are available, e.g. from accurate DSC experiments, one can 
use this information to estimate the solubility ratio of the polymorphs using the method 
described by Mao et al.53. 
2.3.1 Pseudo polymorphs and solvates 
The term pseudo polymorphism was originally used for crystal structures that can contain 
guest molecules in various amounts, e.g. solvent molecules, not influencing the structure of the 
host lattice. Solvates are crystals for which the crystal structure contains a stoichiometric amount 
of solvent molecules at well-defined crystallographic positions. In the case of water being the 
solvent the term hydrates is used. Solvates can therefore be considered as compounds of the form 
ApBq, where A represents the solvent and B the pure solute. In the field of polymorphism the 
term pseudo polymorphs is often used referring to solvates. Figure 11 shows a typical 
composition-temperature phase diagram of such a system for which, two solid phases are stable: 
a pure solid phase B and a solvate AB. As before, the solid phase of the solvent  is not 
considered as it is out of the experimental temperature range as indicated by the dashed solubility 
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curves. The maxima in the solubility curves correspond to the fusion temperatures of the solid 
phases. Starting from these maxima the solubility curves can, again, be considered as freezing 
point depression curves as a result of the admixture of one of the other phases to the liquid phase, 
the curves ending in the eutectic points Ex  at the temperatures 
,A AB
ET  and 
,AB B
ET , respectively. 
Within the hatched areas the lever rule can be applied to determine the amounts of the two 
phases in equilibrium. In figure 11 the phase diagram limited to the composition interval  
0 0.5Bx< <  can be interpreted as an S-L phase diagram comparable to that of figure 4 with B 
replaced by AB; a same comparison can be made for the interval 0.5 1Bx< < , A and B  being 
replaced by AB and B, respectively. Concentrating on the composition interval 0.5 1Bx< <  the 
negative slope of the solubility curve bounding the  ABl s+  region should not be interpreted as a 
retrograde solubility in this case. In practice, more than one solvate or pseudo polymorphic form 
can be stable in various temperature and composition intervals, leading to as so many maxima 
and eutectic points in the phase diagram54. 
 
Figure 11: Typical S-L phase diagram of a binary mixture well miscible in the liquid 
phase but only stoichiometrically miscible in the solid phases, leading to a pure solid 
phase B and a solvate AB; in case of molecular crystals such a solvate is often called 
a pseudo polymorph. 
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2.4 Conclusion 
Although many methods have been developed for a quantitative prediction of vapor liquid 
equilibrium (VLE) phase diagrams in the last century, much less attention has been given to 
solid liquid equilibria (SLE). SLE phase diagrams contain the essential information for 
determining the solubility of a compound in a solvent. Solubility has been studied in great detail 
at the beginning of the last century. The thermodynamic basis of solubility theory seems to have 
lost attention since then. In the last few decades solubility of especially organic molecules has 
regained interest as a result of the discovery of many new organic molecules in the field of 
pharmaceuticals. Not only the synthesis and purification of these compounds ask for suitable 
solvents and therefore solubility data, but also the frequent appearance of various polymorphic 
crystal forms of these compounds, often related to the solubility properties in different solvents, 
have led to an increasing demand for reliable solubility data. 
In this paper the thermodynamic basis of solubility theory is reviewed and the link with 
binary phase diagrams is emphasized for that. Starting from the simplest solubility model, i.e. the 
ideal solubility case, models with increasing complexity are treated. For that a mean field 
approach is used. The resulting solubility curves as a function of temperature are presented for 
various values of the relevant thermodynamic parameters. Special situations, like liquid-liquid 
separation (oiling out) and retrograde solubility are highlighted. It is, for example, shown that the 
difference in heat capacity between an undercooled melt and the solid, a parameter which is 
almost always neglected, in the case of more complex molecules like many pharmaceuticals, can 
have a considerable effect on the solubility. Special attention is given to the solubility phase 
diagrams of monotropic and enantiotropic polymorphic forms as well as solvates (pseudo 
polymorphs). In passing a new method is introduced that allows to estimate the transition 
temperature of enantiotropically related polymorphs from melting temperatures and enthalpies of 
the polymorphs, which can be determined using standard calorimetric techniques. 
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2.5 Appendix A. The pure solute parameters 
The general solubility equation (14) involves a pure solute parameter, *s l Bμ→Δ , according to 
 
( ) ( ) ( ) ( )
( )
* '* * *
'
2'
1 .
fusTl s
s l Bs l B B B
T
h TT T T
dT
RT RT R T
μ μ μ →→ ⎛ ⎞ΔΔ − ⎜ ⎟
= = ⎜ ⎟⎝ ⎠
∫   (47) 
 
Although, as mentioned before, *s l Bh→Δ  can be determined as a function of the temperature 
by measuring the heat of solidification of the supercooled liquid, various approximations have 
been made in the literature to come to an expression in terms of an experimentally more 
accessible parameter. Usually, such approximations are made for the molar heat capacity Pc , 
rather than for *s l Bh→Δ . Therefore, first equation (14) is rewritten in terms of the molar heat 
capacity Pc , using ( ) ( )
'
'
fus
T
fus P
T
h T h T c dT= + ∫  as 
( )
'
''
*
'
2'
1 1 1ln ,
fus
fus
T
s l PT
Tfus B
B
fus T
c dT
h
x dT
R T T R T
→
⎛ ⎞
Δ⎜ ⎟⎡ ⎤Δ ⎜ ⎟
= − −⎢ ⎥ ⎜ ⎟⎢ ⎥⎣ ⎦ ⎜ ⎟⎜ ⎟⎝ ⎠
∫
∫   (48) 
 
where l ss l P P Pc c c→Δ = − ; Equation (48) applies as long as the solute does not sublime before 
melting and there is no solid state phase transition between T and fusT . The term ln Bγ  is set equal 
to zero as only the pure solute terms are considered in this appendix. In equation (48) the first 
term on the right-hand side describes the contribution to the solubility due to the jump in the 
enthalpy as a result of the fusion process at the fusion temperature; the second term accounts for 
the differences in enthalpy going from the temperatureT to fusT . In figure 12 these contributions 
are illustrated. 
 
The sharp peak in figure 12b and the corresponding jump in figure 12a mark the phase 
transformation and are an idealization of the more spread behavior found in calorimetric 
measurements. In practice, the transition from the solid to the liquid phase always starts 
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immediately at fusT during heating, while the liquid phase can, often, be undercooled below the 
fusion temperature. Therefore, the difference in heat capacity s l Pc→Δ  cannot be determined above 
the fusion temperature, while for temperatures below fusT  a non-zero value can be measured. The 
temperature dependence of s l Pc→Δ  from T to fusT is described by the second term on the right-
hand side of equation (48). Although the temperature dependence of the heat capacity of the 
solid phase and the undercooled liquid phase can be far from linear it is to be expected that the 
difference of these, that is s l Pc→Δ , is only moderately dependent on the temperature. Below, 
some of the approximations found in the literature for the temperature dependence of s l Pc→Δ are 
mentioned. 
      
Figure 12: Schematic illustration of the fusion transition of the solid B ; the red and 
blue curves represent the properties of the stable liquid and solid phase respectively; 
the black curves represent the equilibrium properties of the solute; a) The enthalpy 
of the solute. b) The heat capacity of the solute in case of a quadratic temperature 
dependence of the enthalpy; the sharp peak at fusT T=  is an idealized 
representation of the phase transformation. 
Equation (23) describes the solubility curve when the difference in molar heat capacity is 
neglected between T and fusT , leading to a linear relation between ln Bx  and 1/T in a classical 
solubility plot for ideal solutions. 
Often an expansion of the difference in molar heat capacity for both phases, in powers of 
the temperature T, around fusT  is made. Here, only a linear dependence on the temperature as 
suggested in figure 12b, according to 
 
( ) ( ) ( ) ( )0 1l ss l P P P P P fusc T c T c T c c T T→Δ = − = Δ + Δ −    (49) 
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is considered. This leads to a quadratic temperature dependence of the difference in molar 
enthalpy according to 
( ) ( ) ( )1 2* * 0 .
2
P
s l B fus B P fus fus
ch T h c T T T T→
ΔΔ = Δ + Δ − + −   (50) 
 
Substituting equation (50) in equation (47) leads to the ideal solubility equation 
 
* 101 1ln ln 1 2ln .
2
fus B fus fus P fus fus fusP
B
fus fus
h T T c T T Tc Tx
R T T R T T R T T T
⎡ ⎤ ⎡ ⎤Δ Δ⎡ ⎤Δ
= − + − − + − +⎢ ⎥ ⎢ ⎥⎢ ⎥⎢ ⎥ ⎢ ⎥⎣ ⎦⎣ ⎦ ⎣ ⎦
 (51) 
 
The non-zero difference in enthalpy at the transition temperature fusT  is covered by the first 
term on the right-hand side of the equation. In all these approximations the temperature is limited 
to fusT T≤  and it is assumed that the transition to the liquid phase is instantaneous, or in other 
words, the temperature is increased slowly enough to allow the solid to melt in the experimental 
time. For a discussion of the effects of too fast temperature runs in a DSC experiment the reader 
is referred to55. 
2.6 Appendix B. CP-contribution: Venlafaxine as an example 
To get an impression of the contribution of the difference in molar heat capacity of the 
undercooled liquid and the crystal, ( )s l Pc T→Δ , to the solubility expression (26) the heat 
capacities for venlafaxine52 were measured using a Mettler Toledo DSC822e. For that 
measurement 15 mg of venlafaxine was loaded to one of the calorimeter cups, the reference 
vessel left empty. The material was >99.9 % grade. The sample was heated at a rate of  10º min-1 
starting from room temperature up to a temperature well above the melting temperature 
( 348.1fusT = K), subsequently cooled down to a temperature at which the undercooled melt did 
not recrystallize yet. Starting from that temperature a second heating run was performed, again, 
up to a temperature well above the melting temperature. To determine the heat capacities 
accurately, the measurement was preceded by two runs using the same cups; one performed for 
two empty cups and a second one for which one of the vessels was loaded with Al2O3 as a 
reference sample. The final temperature dependence of the Pc -values of venlafaxine was 
determined using the equation 
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( ) ( )2 3
2 3
2 3
, , ,
Al Osample empty
P sample P Al O
Al O empty sample
mHF HF
C T C T
HF HF m
−
=
−
   (52) 
 
where HF is the measured heat flow as a function of the temperature and m is the mass of the 
sample. The resulting curves are shown in figure 13. 
 
Figure 13: The measured  -curves of venlafaxine for a heating run (black trace) 
starting at room temperature up to a temperature well beyond the melting 
temperature ( 348.1fusT = K), followed by a cooling run down to a temperature at 
which recrystallization did not occur (not shown). The second heating run (red trace) 
for the undercooled melt was made again up to temperatures well beyond the 
melting temperature; the deviations at low temperatures are an artifact of the 
measurement. 
The deviations at low temperatures are an artifact due to the non-reliable data obtained 
with the device used at the start of any heating run. Undercooled venlafaxine can be cooled down 
to a temperature of approximately 310 K without solidification. The difference in heat capacity 
between solid venlafaxine and its undercooled liquid phase turns out to be almost independent of 
temperature over the entire range from 310 K up to fusT  and is determined to 
be ( ) 0 145s l P Pc T c→Δ ≈ Δ =  J/mol K. Using this value together with 348.1fusT = K 
and * 27.2fus BhΔ =  kJ/mol in equation (26), the effect of  ( )s l Pc T→Δ on the solubility can be 
calculated. In figure 14 the results are shown. 
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Figure 14: The solubility curves according to equation (26) for venlafaxine 
using * 27.2fus BhΔ =  kJ/mol and  348.1fusT =  K. The heavy black curve represents the 
ideal solubility case for which 0PcΔ =0. The green line shows the results for 
venlafaxine for which 0PcΔ  was determined to be 145 J/mol K. For comparison the 
blue curve shows the case for 0PcΔ =200 J/mol K. The dashed black line indicates fusT .  
Figure b) shows the corresponding van 't Hoff curves of a). 
The figure shows that for the case of venlafaxine the solubility deviates considerably from 
the ideal solubility curve for which 0PcΔ =0.  Moreover, it shows that for somewhat larger values 
for 0PcΔ  retrograde solubility can occur within an accessible temperature range. 
As a second example, for naphthalene the same measurement was performed, although its 
liquid phase could be undercooled only some ten degrees below its fusion temperature. In this 
case ( )s l Pc T→Δ  is relatively small and slightly increases with decreasing temperature. The 
estimated average value of  ( ) 20s l Pc T→Δ ≈  J/molK leads only to a very small deviation from 
the ideal solubility curve as can be seen in figure 15. 
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 (a) (b) 
Figure 15: The solubility curves according to equation (26) for naphthalene using 
* 19.1fus BhΔ =  kJ/mol and   fusT =353.4 K. The heavy black curve represents the ideal 
solubility case for which 0PcΔ =0, the green line the case of naphthalene for 
which 0PcΔ ~20  J/mol K. For comparison the blue curve shows the case for 
0
PcΔ =200 
 J/mol K. The dashed black line indicates fusT .  Figure b) shows the corresponding 
van 't Hoff curves of a). 
2.7 Appendix C. Liquid-Liquid separation 
In the regular solution model discussed in section 2.4 figures 8a,b show a horizontal 
plateau in the solubility curves beyond a critical positive value of regmix BhΔ . For the corresponding 
temperature the solubility curves have to be replaced by horizontal lines in the ( ),x T  diagrams, 
resulting in the coexistence of an A-rich and a  B-rich solution in thermodynamical equilibrium 
with the solid phase. The coexistence of two liquid phases is also known as Liquid-Liquid (L-L) 
separation. Here, the thermodynamics behind L-L separation will be reviewed shortly. In figure 
16a,b the solubility curve according to equation (35) for two of the curves in figure 8b have been 
redrawn without the horizontal lines. According to equations (32) and (35) the solubility curve 
describes the dependence of the chemical potential of the solute in the liquid phase, regmix BμΔ , on 
the mole fraction Bx  up to a constant. As a result of the minimum free energy in thermodynamic 
equilibrium, it holds that 
2
2
, , , ,
0
A A
l
B
B BP T n P T n
G
n n
μ⎛ ⎞ ⎛ ⎞∂∂
= ≥⎜ ⎟ ⎜ ⎟∂ ∂⎝ ⎠ ⎝ ⎠
    (53) 
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as has been demonstrated in detail by Landau and Lifshitz56. The equality in equation (53) 
corresponds to a set of critical points, that define the borders of an instable situation. Substituting 
eq. (32) one obtains for this equality condition 
 
( )2 1 .
reg
mix
B B
hT x x
R
Δ
= −     (54) 
 
The corresponding curves, known as spinodals, have been drawn as the green lines in 
the ( ),x T diagrams of figures 16a and b. Note, that these spinodals describe the behavior of the 
liquid phase. In case of the presence of also a solid phase B, the critical points intersect with the 
solubility curve at certain temperatures, exactly in the extrema of the solubility curve. In between 
these minimum and maximum values the slope of the solubility curves is negative, which 
therefore corresponds to a thermodynamically instable situation. 
 
The red curves in figures 16a and b correspond to the values in the ( ),x T diagram 
where regmix BμΔ =0 or, in other words, the Gibbs free energy of mixing in the liquid phase is 
minimal. These curves are defined by 
 
( )
( )
2 1
ln 1 ln
reg
Bmix
B B
xhT
R x x
−Δ
=
− −
    (55) 
 
and known as the binodals. For a liquid mixture without a solid phase present, the binodal 
defines the region in the ( ),x T diagram below which L-L separation takes place. When also a 
solid phase is present, in the present case the solid B, Gibbs' phase rule restricts this region to a 
single temperature, which is defined by the intersection between the binodal and the solubility 
curve. The values of Bx  of the two intersection points cannot be determined in an analytical form 
because it involves a transcendental equation. These have been determined numerically for the 
parameters of figures 16a and b, leading to the figures 16c and d where the vertical scale has 
been blown up to show the intersection points more clearly and the horizontal lines in the 
corrected blue solubility curve have been added10. 
                                                 
10 Note, that within the L-L separation interval for  the areas of the deviating solubility above and below the 
horizontal line are not equal, in contrast to the well-known example of the liquid-gas phase equilibrium of e.g. the 
van der Waals equation, where the so-called 'Maxwell equal area rule holds' 
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 (a) (b) 
 
       
 (c) (d) 
Figure 16: Two of the solubility curves (blue lines) of figure 8b according to equation 
(35); *fus BhΔ =100   kJ/mol and fusT =570 K. The red lines show the function of equation 
(55), the green lines that of equation (54) for a) regmix BhΔ =10 kJ/mol and b) 
reg
mix BhΔ =20 
kJ/mol. Note, the different ranges for T in a) and b. The graphs c) and d) show an 
enlarged vertical scale for a) and b), respectively; in these graphs the metastable 
solubility lines are indicated as dotted black lines. 
The binodal and spinodal in the present model are symmetrical in Ax  and Bx  . The top of 
both at 1/ 2Bx =  is given by   
2
reg
mixhT
R
Δ
=       (56) 
Substituting this value in the solubility equation (35) one finds for the critical value of 
reg
mixhΔ  for L-L separation 
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which for the parameters of figure 16 yields regmixhΔ =9.392  kJ/mol, which is slightly smaller than 
the middle blue curve in the figure. 
In section 2.5 an additional excess entropy was introduced leading to a so-called quasi 
regular solution model in the meanfield approximation. For this model the binodal and spinodal 
are still symmetrical in Ax  and Bx . The top of both at 1/ 2Bx =   is now given by 
 
,
2
reg
mix
qu reg
mix
hT
s R−
Δ
=
Δ +
     (58) 
 
leading to a critical value of regmixhΔ for L-L separation 
 
( )
( )
*
reg
mix *
4 1 2 /
2ln 2 1 2 /
qu reg
fus B mix
fus B fus
h s R
h
h RT
−Δ + Δ
Δ =
− + Δ
.    (59) 
 
For the parameters of figure 9 this leads to regmixhΔ =15.040 kJ/mol for 
qu reg
mix s
−Δ =10  J/mol K. 
This explains the absence of a plateau, indicating L-L separation, in figure 9a for regmixhΔ =10 
kJ/mol and qu regmix s
−Δ =10 J/mol K. 
Summarizing, only at the temperature where the solubility curve intersects the binodal two 
liquid phases with mole fractions corresponding to the intersection points are in thermodynamic 
equilibrium with the solid phase of the solute B. For temperatures and mole fractions above the 
solubility curve but below the binodal (red line) the liquid also separates in two liquid phases, 
with no solid phase. For temperatures and mole fractions above the binodal only a single liquid 
phase is present. 
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Chapter 3
THE SOLUBILITY BEHAVIOUR AND THERMODYNAMIC RELATIONS OF THE 
THREE FORMS OF VENLAFAXINE FREE BASE 
 
 
 
Abstract 
 
The polymorphic and solubility behavior of the active pharmaceutical ingredient 
Venlafaxine free base, which is used as an antidepressant, is studied. Using Differential 
Scanning Calorimetry and slurry experiments, an enantiotropic relation between the three forms 
was found. Transition temperatures were determined using solubility data and compared with 
calculated transition temperatures based on the melting enthalpies and temperatures of the 
different forms. The solubility of Venlafaxine in heptane, toluene and methanol shows a large 
deviation from ideal behavior. The deviations are to a large extent determined by the temperature 
dependence of the difference in fusion enthalpy of the undercooled melt and the solid. 
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3.1 Introduction 
Polymorphism is a major concern for the pharmaceutical industry during the development 
of a new drug1,2. Polymorphism is the ability of substances to crystallize in two or more 
crystalline phases. Each of these crystal structures, or modifications, has the same chemical 
composition, but differs in the arrangement and/or conformation of the molecules in the crystal 
lattice. As a result, polymorphic forms have different physical properties, e.g. melting point, 
solubility, dissolution rate, habit and stability. These different physical properties may affect the 
therapeutic efficacy, toxicity, bio-availability, pharmaceutical processing and stability of the 
drug product.  An important part of the investigation of a new form of a pharmaceutical product 
is the comprehensive study for polymorphs. Firstly, because it may prevent patenting problems3 
and secondly, it is recommended by regulatory bodies4. 
Two distinct types of polymorphic systems are known; monotropic and enantiotropic 
systems. When the free energy curves of the stable polymorph and any other observed 
polymorph do not cross as a function of temperature, and consequently only one polymorph is 
stable below the melting point, one deals with a monotropic system. When the free energy curves 
as a function of temperature of two polymorphs do cross below the melting point, different 
polymorphs are stable below and above the transition point, and one speaks of an enantiotropic 
system. Knowing the number of phases and their thermodynamic relationships in the context of 
crystallization is a basic pre-requisite in understanding the phase diagram of a polymorphic 
system. 
During crystallization it is possible that a less stable form crystallizes out first, which can 
be transformed to a more stable one later. This is known as Ostwald’s rule of stages5. The 
formation of metastable polymorphic crystals is a kinetic effect, which is usually attributed to the 
nucleation stage6,7. Nevertheless, examples are known, for which the metastable phase is formed 
heterogeneously on the stable phase crystals either in a random orientation8, 9 or epitaxially10, 11.  
Interconversion of polymorphs can be accomplished via solvent or gas phase mediated 
transformation or directly via a solid-solid phase transformation. Depending on the kinetic 
barriers, the transformation time can range from instantaneous to infinitely long. Determination 
of the precise polymorph transition temperature for an enantiotropically related system is often a 
laborious task. For such a system the solubility of two polymorphs is, however, equal at the 
transition point. Therefore solubility data can be used to determine the transition temperature and 
the stability region of the polymorphs. Assuming that the solution shows more or less ideal 
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mixing behaviour for the solute and solvent, solubility data will show up as nearly linear curves 
in a van ‘t Hoff plot1. If the polymorphic transition rate is low, it is possible to determine the 
solubility of both polymorphs even in the region in which the polymorphs are metastable12.  
In the following we report a study of the phase behaviour of the free base of the drug 
Venlafaxine. The polymorphic phase diagram as well as the thermodynamic relations between 
the three forms were investigated using X-ray powder diffraction (XRPD), differential scanning 
calorimetry (DSC), slurry experiments and solubility measurements. The solubility of 
Venlafaxine was studied in different solvents, with the emphasis on deviations of the solubility 
with respect to the van ‘t Hoff equation for ideal behaviour. The deviations turn out to be such 
that the assignment of the stability regions of polymorph I and II of Venlafaxine, on the basis of 
solubility data, would lead to a contradiction. This is due to a concave form of the solubility 
curves, a shape that was recently described in detail in terms of a thermodynamic treatment of 
solubility13. In that paper an equation to calculate the transition temperature of two 
enantiotropically related polymorphs was published. For this equation only the melting point and 
the melting enthalpy, which are relatively easy to determine using DSC, are necessary. The 
resulting transition temperatures for Venlafaxine free base are compared with those derived from 
the solubility data and the shape of the curves is interpreted in terms of the mixing properties in 
the solution. The concave shape is explained by a non-negligible difference in the temperature 
dependence of the enthalpy of fusion. 
3.2 Venlafaxine 
Venlafaxine is the common name for the compound 1- [2-(dimethylamino)-1-(4-
methoxyphenyl)-ethyl]cyclohexanol. The molecular structure is given in figure 1.  
 
OHO
H3C
N
CH3
H3C
 
Figure 1: The molecular structure of Venlafaxine. 
The product is marketed as the hydrochloric acid salt. It is used for treating depression and 
thymoanaleptic and anxiolytic disorders. Especially because Venlafaxine hydrochloride is 
relatively aggressive towards handling equipment and it is irritating to the skin, it would be 
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beneficial to have other forms of Venlafaxine at one’s disposal. The free base is one of the 
promising candidates.  
Until a few years ago, little was reported regarding Venlafaxine free base, the information 
being restricted to patents14,15. In these disclosures Venlafaxine was never precipitated as a free 
base, but obtained as an oily/solid residue in the synthesis, after evaporation of the solvent. This 
procedure generally does not lead to a useful pharmaceutical solid form, as impurities and the 
solvent are likely to be present. Later, Venlafaxine free base was isolated as a solid via 
evaporation of the solvent and the resulting residue was recrystallized from hexane or heptane16. 
The fact that it can be isolated in multiple forms was recently described17. According to this 
publication, two polymorphs, A and B, of the free base of Venlafaxine exist. The crystal 
structures were not known and the thermodynamic behaviour was only poorly understood. 
Polymorph A was expected to be the stable form at room temperature. 
Very recently it was reported that three forms of Venlafaxine free base exist and their 
crystal structures were determined using single crystal X-ray diffraction18. This showed that in 
case of polymorphs I and II one deals with racemic compounds; form I is composed of 
alternating layers of R and S enantiomers, in case of form II the crystal is composed of 
alternating bi-layers of R and S enantiomers. Form III, a racemic conglomerate, is composed of a 
stacking of thick layers of R and S enantiomers, in other words, form III crystallizes as an 
epitaxial conglomerate. We will use the same labels as in ref. [18]. 
3.3 Solubility theory 
In the following we summarize some of the theoretical considerations concerning 
solubility of (molecular) crystals13 that are relevant for the present study. The solubility curve of 
crystals, as a function of the temperature T, in case of an ideal mixing behaviour of the solute 
and the solvent and assuming that the fusion enthalpy of the pure solute, *fushΔ  , is independent 
of the temperature follows from: 
 
* 1 1ln fusideal
fus
h
x
R T T
⎡ ⎤Δ
= −⎢ ⎥⎢ ⎥⎣ ⎦
,     (1) 
 
where x is the mole fraction of the solute in the solution. If ln x  is plotted versus 1
T
 this leads to 
a linear solubility curve, often referred to as a van‘t Hoff curve. In practice, however, there will 
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be a temperature dependence of *fushΔ , which results, even for an ideal mixing in solution, in a 
deviation of the linear curve. Figure 2 presents an overview of the different shapes solubility 
curves can adopt. When ( )*fush TΔ is expressed in terms of a linear temperature dependence of 
the molar heat capacity according to: 
 
( ) ( ) ( ) ( )0 1l sp p p p p fusc T c T c T c c T TΔ = − = Δ − Δ − ,   (2) 
 
where the superscript l denotes the (undercooled) melt and superscript s the solid phase, the 
solubility becomes: 
 
      
* 0 11 1ln ln 1 2ln
2
pC fus Cp fus fus p fus fus fus
fus fus
h T T c T T TTx
R T T R T T R T T T
Δ Δ⎡ ⎤ ⎡ ⎤Δ⎡ ⎤
= − + − − + − +⎢ ⎥ ⎢ ⎥⎢ ⎥⎢ ⎥ ⎢ ⎥⎣ ⎦⎣ ⎦ ⎣ ⎦
. (3) 
 
If ( )Pc TΔ  is positive, the solubility is larger than the ideal solubility, if ( )Pc TΔ  is 
negative the solubility is lower. As a result, the solubility curve changes from a straight line for 
the ideal case, to a non linear curve; concave in case ( )Pc TΔ  is positive and convex in case 
( )Pc TΔ  is negative. Note that this deviation is independent of the solvent used. 
Deviations from ideal behaviour are usually expressed in terms of excess parameters, 
E
mixHΔ and 
E
mixSΔ . In case of a regular solution
19, for which EmixSΔ =
reg
mixSΔ = 0, and 
( )1E regmix mixH nx x hΔ = − Δ , the solubility is: 
 
* 21 1 (1 )ln
reg reg
fusreg mix
fus
h h xx
R T T R T
⎡ ⎤Δ ⎡ ⎤Δ −
= − −⎢ ⎥ ⎢ ⎥⎢ ⎥ ⎣ ⎦⎣ ⎦
.   (4) 
 
If the regular solution model is extended, to include an excess mixing entropy, 
E
mixSΔ =
qu reg
mix S
−Δ , a quasi-regular solution model results for which the solubility is given by: 
 
( )2* 11 1ln qu regreg qu regfusqu reg mix mix
fus
xh h T sx
R T T R T
−
−
−
⎡ ⎤
−⎡ ⎤Δ ⎛ ⎞Δ − Δ ⎢ ⎥= − −⎢ ⎥ ⎜ ⎟ ⎢ ⎥⎢ ⎥ ⎝ ⎠⎣ ⎦ ⎣ ⎦
.  (5) 
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The parameters regmixhΔ and
qu reg
mix s
−Δ are assumed to be independent of the temperature in the 
range of interest. An important conclusion from figure 2 is that for a negligible Δcp value the 
solubility curves adopt a linear behaviour well below the melting temperature of the solute, as 
long as mixhΔ and mixsΔ are independent of the temperature, whereas a non-negligible (positive) 
value of Δcp leads to a concave shaped curve. If all parameters are included: ( )Pc TΔ , EmixHΔ  and 
E
mixSΔ , the solubility equation becomes: 
 
( )
* 0 1
2
1 1ln ln 1 2ln
2
1
.
fus Cp fus fus p fus fus fusall
fus fus
reg qu reg
mix mix
h T T c T T TTx
R T T R T T R T T T
xh T s
R T
Δ Δ
−
⎡ ⎤ ⎡ ⎤Δ⎡ ⎤
= − + − − + − + −⎢ ⎥ ⎢ ⎥⎢ ⎥⎢ ⎥ ⎢ ⎥⎣ ⎦⎣ ⎦ ⎣ ⎦
⎡ ⎤
−⎛ ⎞Δ − Δ ⎢ ⎥⎜ ⎟ ⎢ ⎥⎝ ⎠ ⎣ ⎦
 (6) 
 
In case of an enantiotropic polymorphic system the transition temperature, Ttrs, is given by 
the following equation: 
      
*
*
trs
trs
trs
hT
s
Δ
=
Δ
,     (7) 
where *trshΔ  and 
*
trssΔ are the enthalpy and the entropy change respectively, for the transition 
between the polymorphic forms at the transition temperature. Assuming ideal behaviour, 
according to equation (2), this temperature can be approximated by the following equation13: 
 
      
* *
* *
, ,
fus fus
trs
fus fus
fus fus
h h
T
h h
T T
α β
α β
α β
Δ − Δ
=
Δ Δ
−
,    (8) 
 
where *fus h αΔ and 
*
fus h βΔ  are the melting enthalpy of forms α  and β , respectively, and 
,fusT α and ,fusT β are the respective absolute fusion temperatures. 
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Figure 2: Overview of the shapes solubility curves can adopt when various 
thermodynamic  parameters are included in the calculations. The black curve 
represents the ideal case, equation (1); the green curve represents the case for 
which a temperature dependence of ( )*fush TΔ is included, equation (3); the blue 
curve represents the case for which only regmixhΔ  is included, equation (4); the yellow 
curve represents the case for which both regmixhΔ and a
qu reg
mix s
−Δ are included, equation 
(5) and the red curve represents the case for which all parameters are included; 
equation (6). The following parameters are used for the calculations: Tfus = 373 K, 
fushΔ =30 kJ/mol, 
0
PcΔ =150 J/molK, 
1
PcΔ =0, mixhΔ =5 kJ/mol and mixsΔ = -5 J/molK. 
3.4 Experimental Procedures 
Venlafaxine with a purity of 99.9%, according to High Pressure Liquid Chromatography 
(HPLC), was supplied by Synthon BV. The solvents used (pa) were purchased from Aldrich and 
were used without further purification. 
All the solubility experiments were started using polymorph I. Crystals were obtained by 
dissolving Venlafaxine in heptane at reflux temperature, crystallizing the different polymorphs 
by cooling the clear solution to the desired temperature, and isolating the formed crystals at that 
temperature.  
For the determination of the solubility two different techniques were used. The most 
accurate, but time consuming, approach is an in situ method. For that a closed thermostated glass 
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cell was filled with a known amount of solute and solvent. The growth and dissolution of the 
crystals was observed using an optical transmission microscope (Zeiss Axioplan 2). By varying 
the temperature the saturation temperature for different concentrations was determined; after 
nucleation at low temperatures all the crystals were dissolved by increasing the temperature 
except for one very small one, in order to minimize the effect on the solute concentration20. This 
crystal was subsequently grown and etched a few times to determine the saturation temperature 
of the solution. Besides being a time consuming method a disadvantage of the method is that it is 
difficult to determine the polymorphic form of the crystal studied.  
The fast, but less accurate, method is the saturation shaken flask method. For that, a slurry 
of a given polymorph and a saturated solution was stirred for several days at a well defined 
temperature, allowing the appropriate polymorph to be formed. The residue was filtered off and 
the polymorph obtained was determined using X-ray powder diffraction. A certain amount of the 
clear solution was weighed and the solvent was evaporated using a rotary evaporator. From the 
weight of the residue and the weight of the solution the amount of solvent and solute was 
determined.  
Differential scanning calorimetry was performed using a Mettler Toledo DSC 822e. 
Nitrogen was used as an inert purge gas. The samples were analyzed using 40 μl aluminium pans 
with a pierced lid. The heating rate varied between 0.1 and 10 °C/min. Further calorimetric 
measurements were performed using a Setaram C-80 micro calorimeter. In this case a heating 
rate of 0.01 or 0.001 °C/min was used. The heat capacity of polymorphs I, II and III was 
determined using a Mettler DSC 822e apparatus. The thermograms were recorded using 40 μl 
aluminium pans with a heating rate of 10 °C/min. Sapphire was used as standard. 
X-ray powder diffraction patterns were recorded using a Bruker Vario-1 diffractometer in a 
Bragg-Brentano geometry. The patterns were collected in the range from 2 to 35° 2θ using a 
VÅNTEC detector. Samples were measured in reflection mode using a silicon zero background 
wafer or a sampleholder with a silicon cavity. Cu Kα-2 radiation was used at a voltage of 40 kV 
and a current of 40 mA.  
3.5 Results and Discussion 
3.5.1 X-ray powder diffraction. 
Figure 3 shows the X-ray powder diffractograms of the three forms of Venlafaxine. 
Comparing these with the diffractograms given in the patent, ref [18], of the forms called A and 
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B in that reference, we notice that polymorph I is identical to polymorph A. The XRPD pattern 
of form III resembles the pattern of form B, although extra peaks are visible in the pattern of 
form B. After careful comparison of the pattern of form B with the patterns of forms II and III, 
we conclude that form B is a mixture of forms II and III. 
 
Figure 3: XRPD patterns of forms I, II and III of Venlafaxine free base. 
3.5.2 Slurry experiments. 
To obtain a first impression of the mutual stability of the three forms at different 
temperatures, slurry experiments were performed, starting with different forms. For the results of 
these experiments see table 1. Under the right conditions, in a slurry, all the different forms can 
be converted into each other. It can be concluded from these slurry experiments that an 
enantiotropic relation exists between all the three forms. The stability regions are as follows; 
below ~20 °C form I is stable, above ~55 °C form III is stable. In a region somewhere between 
these temperatures, form II is stable. 
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Table 1: Results of the slurry experiments. 
starting polymorph isolated polymorph conditions 
I II stirring at 42° C, for 7 
days 
II I stirring at 20° C, for 7 
days 
I III stirring at 55° C, for 7 
days 
III II stirring at 42° C, for 7 
days 
III I stirring at 20° C, for 7 
days 
II III stirring at 55 °C, for 7 
days 
 
In section 5.4 we will compare these calculated phase transitions temperatures with more 
precise transition temperatures determined using solubility data. 
3.5.3 Thermographic analysis 
A DSC study was performed to determine the thermodynamic behaviour of the 
polymorphs. A DSC thermogram of Venlafaxine free base, polymorph I, with the usual heating 
rate of 10°C/min showed one broad melting peak at 76 °C. There was no sign of a solid-solid 
transformation. Because solid-solid transformations can be difficult, due to kinetic barriers, the 
DSC measurements of polymorph I, were therefore repeated at lower heating rates. For the 
resulting thermograms see figure 4. When the heating rate is lowered from 10 to 1°C/min, two 
endothermic peaks are visible in the DSC thermogram, of which the first can be attributed to the 
melting of polymorph I, and the second one is the result of melting of another polymorph. In 
between these two endotherms, a small exothermic recrystallization peak is visible.  Lowering 
the heating rate to 0.1 °C/min yields a small endothermic peak and a small exothermic peak, 
separated by only 0.3 degrees; the melting and the recrystallization processes now take place 
almost simultaneously. The complete sample is thus converted to another polymorph, which 
melts at ~ 78.7°C, with a melting enthalpy comparable to that of the fast run; for data see table 2. 
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Figure 4: DSC thermograms of polymorph I heated at 10, 1, 0.1 and 0.01 °C/min; for 
the sake of clarity the vertical axis of the traces have been enlarged; by a factor of 
20 for the 0.01 °C/min trace, by a factor of 10 for the 0.1 °C/min trace and by a 
factor of 5 for the 1 °C/min trace. 
Table 2:  Thermal data obtained from the DSC scans of figure 4, the most right 
column states the sum of the thermic events.  
heating 
rate 
°C/min 
T onset 
first peak °C 
∆ H 
(J/g) 
T onset  
second peak °C 
∆ H 
(J/g) 
T onset melting 
peak  °C 
∆fusH 
(J/g) 
Total ∆ H 
(J/g) 
10     76.0 100.9 100.9 
1 74.5 87.9 77.5 - 0.5 78.3 14.6 102 
0.1 74.4 7.4 74.7 - 1.9 78.1 93.2  98.7 
 
An experiment with an even lower heating rate of 0.01°C/min, performed with a C-80 
Setaram calorimeter, resulted in a considerable shift of the first endotherm to 60°C with a heat of 
2.9  J/g. The sign and the magnitude of the first endotherm are in accordance with the value of a 
solid-solid phase transition to an enantiotropically related polymorph21. To verify this 
assumption, a sample was heated to 70°C in the C-80 Setaram calorimeter, as described above 
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(0.01 °C/min), and cooled to room temperature, after which an XRPD was recorded of the 
sample. The XRPD pattern showed that form III was isolated.  
A DSC heating run of polymorph II with a heating rate of 10 °C/min or 1 ºC/min showed 
only a melting endotherm at 78 °C. For an overview of the thermograms of polymorph II see 
figure 5.  
 
Figure 5: DSC thermograms of polymorph II heated with different heating rates, 10, 
1, 0.1 ºC/min and 0.01 ºC/min; for the sake of clarity the vertical axis of the traces 
have been enlarged; by a factor of 20 for the 0.01 °C/min trace, by a factor of 10 for 
the 0.1 °C/min trace and by a factor of 5 for the 1 °C/min trace. 
Lowering the heating rate to 0.1 °C/min did not show any further peaks, only the onset of 
the melting peak was shifted to 77° C. Further lowering of the heating rate to 0.01 °C, using the 
C-80 Setaram calorimeter, did not lead to a well-resolved recrystallization exotherm and no 
solid-solid transformation is visible. The XRPD pattern of a sample of polymorph II, heated to 
75° C with 0.01° C/min and then cooled to room temperature, was identical with the pattern of 
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the starting polymorph II, showing that no transformation had taken place. Starting with form III, 
the thermograms show only the melting peak of that polymorph, whatever heating rate was used. 
The results given above show that a precise determination of the melting points and the 
melting enthalpies is difficult, especially for polymorph I. The result is an overestimation of the 
melting temperatures of polymorph I when a high heating rate is used. If a lower heating rate is 
used, the endothermic melting peak overlaps the exothermic crystallization peak of form III and 
as a result of that, it is not possible to determine the melting enthalpy accurately. To find a 
compromise with a reasonable accuracy, a heating rate of 3° C/min for polymorph I was used 
which resulted in the formation of only small amounts of form III. Likewise, overlapping peaks 
make it difficult to determine the melting enthalpy of polymorph II. The melting points and the 
melting enthalpies of all three polymorphs, thus obtained, are summarized in table 3.  
Table 3: melting temperatures, melting enthalpies and heat capacity data of 
forms I, II and III of Venlafaxine. Δcp is determined from measurements between 
Tfus and 40ºC (section 5.4). 
 Tfus ( °C) ∆fusH (J/g) 0pcΔ (J/molK) 
1
pcΔ (J/molK) 
Polymorph I 74.9 98.1 136.4 -0.3355 
Polymorph II 76.5 95.3 100.1 -0.3283 
Form III 78.1 87.9 96.0 -0.109 
 
Table 3 shows that the melting point of polymorph II is higher than that of polymorph I. 
Using the Burger and Ramberger thermodynamic “rules” for polymorphs22, this suggests that 
polymorph II has a lower free energy than polymorph I, at least near the melting point. The same 
reasoning is valid for forms III and II. These conclusions are in accordance with the results found 
in the slurry experiments. 
3.5.4 Solubility experiments 
3.5.4.1 Solubility of Venlafaxine in Heptane 
Heptane, is used in the large scale purification of Venlafaxine free base, and was therefore 
included in this study. The polymorphic transition rate in this solvent is too high to determine the 
solubility of the polymorphs in their metastable regions. The solubilities of all three forms were 
determined using the saturation shaken flask method and are presented in figure 6.  
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Figure 6: van ‘t Hoff solubility plots of polymorphs I (open symbols) and II (closed 
symbols) in heptane, determined using the saturation shaken flask method, with 
extrapolated dashed trend lines. 
A transition temperature between polymorphs I and II, of 35.7 °C and between form II and 
III at 51 ºC was determined by extrapolating the trendlines, assuming a linear relation. 
Surprisingly, the extrapolated solubility line of polymorph I, which is stable at low temperatures 
according to the slurry experiments, shows that polymorph I has the lowest solubility above the 
transition temperature. For polymorph II a similarly surprising result is found for temperatures 
below that temperature. To investigate the cause of this anomalous behaviour, the solubility of 
Venlafaxine was determined over a wider temperature range, from -76 to 60 °C and compared 
with the van ‘t Hoff solubility curve for ideal solutions. To test the reliability of the saturation 
shaken flask method, solubility data for polymorph II were also determined using the in situ 
method. The combined solubility data, are presented in figure 7, in a van ‘t Hoff plot. In this 
figure the solubility of VFX is presented together with the various solubility curves calculated 
using the measured parameters presented in table 3, for polymorph I (solid curves) and II 
(dashed curves).  From the determined solubility of Venlafaxine free base it is obvious that 
except for temperatures just below the melting point of the solute, the data deviate considerably 
from the ideal solubility behavior. 
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Figure 7: Solubility data of the three forms of Venlafaxine in heptane, determined 
down to 197 K; diamond symbols: data determined using saturation shaken flask 
method; square symbols: data determined using the in situ method; the solid and 
dashed black curves, represent the ideal solubility curves for polymorph I and II 
respectively (equation (1)), the red curves represent the solubility curves for 
polymorph I and II respectively for which a temperature dependence of ( )*fush TΔ is 
included using the data of table 3;  the blue curves represent a fit for which all 
parameters are included, combining equation (6), the data of table 3 and 
mixhΔ =26.5 kJ/mol and mixsΔ = 72 J/molK. 
The observed lower than ideal solubility could be accounted for by less favourite 
interactions between solvent and solute molecules. If the solubility data would be fitted using 
equation (5), which includes mixing terms only, the agreement would still be not very good, 
because as is shown in figure 2, the mixing terms in the equation can not account for the 
observed concave shaped curve in the solubility at lower temperatures. The concave shape 
suggests an effect of a temperature dependent *fushΔ . To determine
*
fushΔ , the difference of the 
molar heat capacity of the undercooled liquid and the crystal was measured. For most 
compounds it is rather difficult to determine this difference, because the undercooled liquid can 
usually be maintained only in a limited temperature range below the melting point. For 
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Venlafaxine, determination of ΔCp turned out to be quite well possible down to 40 ºC for the 
undercooled liquid. For that, a sample of Venlafaxine was heated to a temperature 10 °C above 
the melting point, cooled to 40 °C (without crystallization of the liquid) and the undercooled 
liquid was again heated to 10 °C above its melting point. As an example the resulting curves for 
polymorph I are shown in figure 8.  
 
 
Figure 8: Cp-curves of Venlafaxine. Heating run for the crystal (black curve), and 
heating run for the undercooled liquid (red curve). Deviations in the curves at low 
temperatures are artefacts of the measurement. 
Fitting the Cp-data to equation (2) resulted in parameters 0pcΔ and 
1
pcΔ  for the three forms 
as presented in table 3. Including a temperature dependence for *fushΔ in the solubility equation, 
results in the red curves in figure 7. Combining the effect of the measured temperature 
dependence of *fushΔ , an enthalpy of mixing and an excess entropy, as parameters to fit the 
solubility data, and using equation (6), the agreement between the calculated and the measured 
solubility is reasonable (blue curves in figure 7). The fit parameters used for these curves are 
presented in table 4. 
 
The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base 
 - 77 - 
Table 4: Fit parameters found for the different solvents using equation (6) and 
data of table 3.  
 mixhΔ ( kJ/mol) mixsΔ ( J/molK) 
heptane 26.5 72 
toluene 0.5 1 
methanol 1.6 10 
 
Note that the mixing parameters in the solution are independent of the form I, II or III. The 
agreement between the calculated and the observed solubility is especially good from 40 up to ~ 
60 ºC. Below 40 ºC the observed solubility shows a higher solubility than calculated. The 
positive deviation of the solubility could be the result of a more complex temperature 
dependence of ΔCp at lower temperatures. After all it was not possible to measure ΔCp below 40 
ºC. Although the concave shape of the solubility curves is described rather well by the 
temperature dependence of the heat of fusion difference, the order of the curves for polymorph I 
and II is swapped on including this difference.  
3.5.4.2 Solubility of Venlafaxine in Toluene 
To investigate the effect of different solvents on the solubility behaviour of Venlafaxine 
free base, the solubility was also determined in toluene, a solvent with physical parameters 
comparable to heptane; small difference in dipole moment and boiling point. The solubility of 
venlafaxine free base was determined in toluene using the saturation shaken flask method, in the 
temperature range of -25 °C to 60 °C, see figure 9. In case of toluene it was very difficult to 
measure the solubility at temperatures below -25 °C, because the solution became so viscous, 
that it was almost impossible to filter the solution keeping it at the right temperature. Like for 
heptane, the solubility behaviour of venlafaxine in toluene deviates considerably from ideal 
behaviour, but this time the deviation is positive compared to the ideal linear van ‘t Hoff curve. 
The shape of the solubility curve is still concave, as expected for a temperature dependent 
contribution of *fushΔ to the solubility. When equation (6) is used as a model to fit the solubility 
data, the agreement is very good. The fit parameters found, using the data from table 3, are 
presented in table 4. Over the complete experimental temperature range the measured solubility 
follows the calculated curve very well. As for heptane, however, the order of the solubility 
curves of polymorph I and II is swapped. 
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Figure 9: Solubility of Venlafaxine free base in toluene. Open diamond symbols 
represent data determined using the saturation shaken flask method, the solid and 
dashed black curves, represent the ideal solubility curves for polymorph I and II 
respectively, the red curves represent the solubility curves for polymorph I and II 
respectively for which a temperature dependence of ( )*fush TΔ is included and the 
blue curves represent the case for which all parameters are included. For the 
calculations data from table 2 were used and mixhΔ =0.5 kJ/mol and mixsΔ = 1 J/molK 
were obtained from the fit. 
3.5.4.3 Solubility of Venlafaxine in methanol 
To study the behaviour of Venlafaxine free base in a polar solvent, the solubility was 
measured in methanol. The results are presented in figure 10. The data show that the solubility 
behaviour is not ideal, but the deviation from ideal behaviour is not large, besides the data point 
at low temperature, which deviates considerably, like in the case. Using equation (6), to fit the 
data, the results are in a reasonable agreement between the observed and the calculated 
solubility. The fit parameters using the data from table 3, are presented in table 4. 
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Figure 10: Solubility data of the three forms of Venlafaxine in methanol, open 
diamond symbols, data determined using the saturation shaken flask method; the 
solid black curve represenst the ideal solubility curves for polymorph I the red curve 
represent the solubility curve for polymorph I for which a temperature dependence 
of ( )*fush TΔ is included; and the blue curves represent the case for which all 
parameters are included. For the calculations data from table 2 were used and 
mixhΔ =1.6 kJ/mol and mixsΔ = 10 J/molK were obtained from the fit. 
3.5.5 Discussion 
From the comparison between the measured and the calculated solubility of Venlafaxine it 
is clear that the temperature dependence of *fushΔ has a large effect on the solubility. That this 
effect is independent of the solvent used, is clear from the fact that the resulting concave shape 
of the solubility curve was observed both for polar and apolar solvents. For Venlafaxine it was 
possible to measure Δcp down to 35 degrees undercooling. For polymorph I the measurement of 
Δcp is less accurate because during the first heating cycle part of the solid can transform to 
polymorph II via a melt-recrystallization process. The same effect makes it difficult to determine 
the precise melting temperature and melting enthalpy for polymorph I. Together with the 
instrumental errors, these effects might account for the observed swap of the position of the 
calculated ideal solubility curves of polymorph I and II on including the effect of Δcp. 
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A solution of Venlafaxine free base in toluene behaves almost as an ideal solution, when 
including the temperature dependence of the fusion enthalpy, which means that the solvent-
solute interactions are very similar to the solvent-solvent and the solute-solute interactions. In 
case of heptane, a solvent molecule without a significant dipole moment, the intermolecular 
interactions are due to van der Waals forces. For Venlafaxine free base, a more polarizable 
molecule, the dipole moment is larger, but it also forms an intra-molecular hydrogen bond 
between the OH and the dimethylamino group. These two effects can account for the large mixhΔ  
(26.5 kJ/mol) found from the solubility data fit. The solvent-solvent and solute-solute 
interactions are preferred compared to the interaction between solvent and solute molecules. In 
other words the mixing energy is positive and large. 
For methanol, a solvent with a hydrogen bonded structure, the molecular properties are 
more similar to those of Venlafaxine free base; the solvent-solute interactions are more 
comparable to the solvent-solvent and the solute-solute interactions, resulting in a smaller mixhΔ  
(1.6 kJ/mol) to fit the solubility data.  
Remarkably, the solution of Venlafaxine free base in toluene, a molecule without a 
significant dipole moment and no possibility to form hydrogen bonds, behaves almost as an ideal 
solution; the observed and the calculated solubility fit very well and only a small mixhΔ  (0.5 
kJ/mol) was necessary to fit the data, suggesting a strong π−π interaction between the solvent 
and solute molecules.  
By extrapolating solubility trendlines of the respective polymorphs in the ideal van ‘t Hoff 
plots, transition temperatures can be calculated. This temperature for the transition of polymorph 
I to II is 35.7 ºC. For the transition of polymorph II to III this temperature is 51 ºC. When we 
apply equation (8) to calculate the transition temperatures for our system, using the 
thermodynamic data of table 3, we find a temperature for the transition of polymorph I to 
polymorph II of 28°C, and 56°C for the transition of polymorph II to form III. These calculated 
transition temperatures agree reasonably with the results of the solubility experiments. 
3.6 Conclusions 
The three forms of the free base of Venlafaxine were studied. All three forms were isolated 
and characterized using different techniques; DSC and X-ray powder diffraction and solubility 
experiments.  From slurry experiments it was found that all the three forms have a distinct 
temperature range where they are stable, in other words there exists an enantiotropic relation 
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between the three forms. The results of measuring DSC thermograms of a compound with 
different heating rates of 10 ºC/minute and lower, show that several phenomena can be missed 
like solid-solid transitions and/or melt-recrystallizations. Although this is a well established fact, 
it is still common practice to measure DSC thermograms with heating rates of 10 ºC/min or 
more.  
The solubility curves of Venlafaxine free base in different solvents could be only described 
when the temperature dependence of *fushΔ was included. This term, which is independent of the 
solvent, was determined by measuring the difference in heat capacity of the solid and 
undercooled melt of the solute. It was shown that using solubility data in the form of van ‘t Hoff  
curves to draw conclusions about the stability regions of two enantiotropic related polymorphs 
can lead to paradoxical situations if the temperature dependence of *fushΔ  is not considered. 
Although this temperature dependence is almost always neglected, the present results show that 
care should be taken in doing so, especially in the case of pharmaceutical compounds. These 
often have a large number of degrees of freedom due to the complex structure of the molecules, 
and consequently a non-negligible Δcp can be expected between the undercooled melt and the 
solid phase. 
Finally, a recently derived expression for the transition temperature of two enantiotropic 
forms in terms of the heat of fusion and the melting temperatures of the forms, as determined by 
for example DSC measurements, was validated for Venlafaxine. The results agree reasonably 
with the experimental transition temperatures. This is remarkable because in case of the 
calculated transition temperatures the non-negligible temperature dependence of *fushΔ , as was 
found for Venlafaxine, was not taken into account.  
Chapter 3 
 - 82 - 
3.1 References
 
1 H. G. Brittain, Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, 1999 
2 J. Bernstein, Polymorphism in Molecular Crystals, Clarendon press, Oxford, 2002 
3  Byrn, S.; et al. Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, 
Pharm. Res, (1995), Vol. 12, No 7  
4  Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism, July 2007  
5 Ostwald, W., Z. Physik. Chem., (1897), 22, 289-330  
6  Deij, M. A.; ter Horst, J. H.; Meekes, H.; Jansens,  P. and Vlieg, E., J. Phys. Chem. B, 
(2006), 111, 1523-1530 
7  Davey, R. J., Current Topics in Materials Science, (1982), 8, 429- 479 
8  Yu, L. J. Am. Chem. Soc., (2003), 125, 6380-6381 
9  Ferrari, E. S., Davey, R. Cryst, Growth & Des., (2004), 4, 1061-1068 
10  Boistelle, R.; Rinaude, C. J. Crystal Growth, (1981), 53, 1-9 
11 Stoica, C.; Tinnemans, P.; Meekes, H.; Vlieg, E.; van Hoof, P. and van Kasperen, F., Crystal 
Growth & Design, (2005), 5, 975-981  
12  Park, K., ; Evans, J. M. B. and Myerson, A. S., Crystal Growth & Design (2003), 3, 991-995 
13  Bennema, P.; van Eupen, J.; van der Wolf, B. M. A.; Los, J. H. and Meekes, H., Int. J.  
Pharm. (2008), 351, 74-91 
14 US patent, 4,535,186 
15  US patent, 6,197,828 
16 WO patent 00/76955 
17  WO patent 03/082806 
18  van Eupen, J. Th. H.; Elffrink, W. W. J.; Keltjens, R.; Bennema, P.; de Gelder, R.; Smits, J.; 
van Eck, E. R. H.; Kentgens, A. P. M.; Deij M. A.; Meekes, H., and E. Vlieg, Crystal 
Growth & Design (2008), 8, 71-79 
19  Hildebrand, J. H.; Prausnitz, J. M.; and Scott, R. L., (1970), Regular and related solutions, 
Van Nostrand Reinhold Company 
20  Boerrigter, S. X. M.; van den Hoogenhof C. J. M.; Meekes, H.; Bennema, P.; Vlieg, E. and 
van Hoof, P. J. C. M.,  J. Phys. Chem. B (2002), 106, 4725-4731 
21  Burger, A. and Ramberger, R., Mikrochim. Acta II, (1979), 259-271 
 
  - 83 - 
Chapter 4
POLYMORPHISM AND MIGRATORY CHIRAL RESOLUTION OF THE FREE BASE 
OF VENLAFAXINE. 
A REMARKABLE TOPOTACTICAL SOLID STATE TRANSITION FROM A 
RACEMATE TO A RACEMIC CONGLOMERATE. 
 
 
 
Abstract 
 
The unique behaviour of the active pharmaceutical ingredient Venlafaxine free base, used 
as an anti-depressant, with respect to polymorphism and chiral resolution is reported. Using 
several complementary techniques, three crystal structures of Venlafaxine were identified and 
isolated. All three structures are composed of virtually identical enantiomeric pure layers with 
different stacking modes. In the crystal structure with the highest melting point, the enantiomeric 
separation is complete, leading to a racemic conglomerate. The conglomerate can be grown from 
solution or via a solid-solid phase transition of the lowest melting racemic compound. 
Remarkably the crystal shape is conserved during the transition. The corresponding chiral 
resolution is achieved via a local melting process, allowing for a long range migration of the 
molecules between layers.  
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4.1 Introduction 
Polymorphism, crystallization and chiral resolution are phenomena that are of great 
industrial relevance. Here we study a pharmaceutical compound, which combines these 
phenomena as a result of different stacking sequences of enantiopure layers of the compound in 
its various crystal structures. 
The phenomenon of polymorphism, the ability of a substance to exist in two or more 
crystalline phases that differ in the arrangement and/or conformation of the molecules in the 
crystalline lattice, has important commercial and/or industrial implications in various fields1. The 
pharmaceutical industry and the photographic and imaging industry are two examples. 
Polymorphs consist of the same chemical compounds, but have different crystal packings, and as 
a result they can show different physical properties2. The occurrence of polymorphism is high, 
and McCrone stated that, in general, the number of polymorphic forms known for a given 
compound is proportional to the time and money spent in research on that compound3. Although 
the existence of different polymorphs of a certain compound is frequently observed, determining 
the conditions for their appearance usually is laborious. Most polymorphs are found as a result of 
serendipity rather than through systematic searches. The possibility to predict if and how many 
polymorphs exist of a compound is of great importance. Therefore, several computer programs 
with that aim have been developed, each of them with their specific advantages and 
limitations4,5. Most of these methods combine a random generation of crystal structures with an 
energy minimization step. An alternative way to predict the structures of possible polymorphs is 
the Derived Crystal Packing (DCP) approach developed by Coquerel et al6.  The DCP procedure 
comprises two steps: first the extraction of periodic fragments (PF) from a known polymorphic 
form, secondly, three dimensional structures are generated by the application of symmetry 
operators. New phases are then built as low energy structures by minimizing the energy using 
molecular mechanics software. Recently the DCP method was successfully put into action to 
resolve the crystal structure of a metastable polymorph of Modafinil7. 
Crystallization is often the final purification step for an active pharmaceutical ingredient 
(API). Until recently most of the API’s were marketed as racemates. As a result of regulatory 
aspects more and more effort is put into bringing medicines enantiopure to the market. In many 
cases this can be achieved by an enantioselective synthesis. Nevertheless, in an increasing 
number of cases this would involve too many synthetic steps for the process to be economically 
viable. Chiral separation by crystallization can be an alternative.  
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Crystalline racemates mainly belong to two classes. When both the enantiomers are present 
in equal amounts in the unit cell the compound is called a racemic compound or a true racemate, 
which is the most common type. In 5-10 % of the cases racemic mixtures crystallize as racemic 
conglomerates, solids in which a single enantiomer is present in the unit cell. In these instances a 
spontaneous segregation takes place. Often one only considers a physical mixture of enantiopure 
crystals8 as a racemic conglomerate. However, systems in which crystals are built up from 
macroscopic enantiopure layers, racemic twins, can also be considered as racemic 
conglomerates. This phenomenon was described by Gervais et al.9. They investigated a 
compound which crystallizes as a racemic conglomerate, but experienced a lot of trouble during 
separation by preferential crystallization. Isolated crystals, shaped as single crystals, showed no 
or almost no enantiomeric excess, a measure for the enantiomeric purity. This phenomenon was 
also observed by Green et al.10. The initially considered (ordinary) macroscopic twinning along a 
growth direction was rejected as a result of dissolution experiments performed with the obtained 
crystals. Gervais et al.9 explained the phenomenon as the repeated formation of epitaxial layers 
(macro twinning) of crystals of the two enantiomers. Detailed study of the crystals revealed that 
the crystals were built up from thick alternate layers of R and S molecules, formed via an 
oscillating crystallization mechanism. An analogous case of spontaneous oscillating 
crystallization of R and S enantiomers was described by Potter et al.11 and Berfeld et al.12.  
All these cases are a special case of epitaxial crystal growth. Usually epitaxy is observed as 
the oriented nucleation and growth of crystalline layers of a compound on a specific crystalline 
surface of another compound. This will often lead to large stresses and strains, as a result of the 
lattice mismatch. However, in the case of the epitaxy of enantiomers, a layer of, for example, S 
molecules grows epitaxially on top of a crystalline substrate of R molecules, without any 
significant lattice mismatch as a result of the enantiomeric relation between the two crystal 
structures. Note that the two layers do not need to be mirror images of each other. Nevertheless, 
the similarity between the two enantiomerically related structures can lead to a very low 
interfacial stress, resulting in a relatively low barrier for the epitaxial nucleation and growth. 
Epitaxial nucleation of strongly related crystalline phases was recently also found for 
polymorphs, that is, different crystal structures of the same compound13,14. In this case the 
metastable polymorph of a hormone was found to grow epitaxially on the stable polymorph. In 
later studies it was even found that the reverse process was also possible15. Both polymorphic 
forms consisted of almost identical layered structures. For the metastable polymorph, with 
spacegroup P1, only one conformer of the molecule was present, while the stable polymorph, 
with spacegroup P21, consisted of four layers, successive layers having a different conformer of 
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the molecule. Such a situation can be considered as a special case not easily covered by the 
DCP-approach, as it involves different conformers of the molecule. Furthermore, in this case the 
small structural difference between the layers resulted in a small barrier for epitaxial nucleation. 
The major difference with enantiomeric epitaxial crystallization, however, is the fact that the 
polymorphic epitaxial layers of the metastable polymorph were able to transform via a solution 
mediated mechanism to the stable polymorph structure. Giovannini et al16 describe a transition of 
a true racemate to a racemic conglomerate. A racemic dihydrate of Zopiclone is dehydrated 
forming a metastable anhydrate which, upon further heating, melts and the racemic conglomerate 
phase crystallizes out. A solid-solid transition of a racemic conglomerate to a true racemate is 
described by Mercier et al17. Racemic conglomerate crystals of the compound 
[{H3N(CH2)2SS(CH2)2NH3}PbI5].H3O) changed conformation of half of the disulfide moieties upon 
heating to 75 °C, leading to a true racemate. The transition back to the racemic conglomerate 
could also be accomplished. One has to note, however, that the chirality of "chiral disulfides" 
often results from configurationally chiral ligands linked to the chalcogenide atoms and that 
racemisation occurs in solution as a result of the relatively low barrier of rotation of the S-S bond 
between both enantiomeric conformers. 
Here we study Venlafaxine free base, which shows both polymorphism as well as chiral 
resolution as a result of different stacking sequences of enantiopure layers of the compound. 
Venlafaxine is an antidepressant of the class of phenethylamines that inhibits the reuptake of 
serotonin, norepinephrine, and to a lesser extent, of dopamine. It is administrated orally as the 
hydrochloric acid salt and is marketed as a racemate. Both enantiomers are reported to be active. 
The common name for the compound Venlafaxine is: 1- [2-(dimethylamino)-1-(4-
methoxyphenyl)-ethyl]cyclohexanol. The molecular structure of the free base is given in figure 
1.  
* OHOH3C
N
CH3
H3C
 
Figure 1: The molecular structure of Venlafaxine; * denotes the chiral carbon atom. 
Two polymorphs of the free base were known, and a previously performed extensive study 
of the thermal behaviour of the free base yielded one new crystal structure18. It turned out that an 
enantiotropic19 relation exists between all three crystal structures, implying that below a certain 
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transition temperature one form is stable, and above that temperature another one is stable. Form 
I is stable below 40 °C, form II between 40 and 50 °C and a third form above 50 °C. The present 
study of the structural relation between the three crystal structures shows that forms I and II are 
true racemates built up of sequences of enantiopure R and S bi-layers, and enantiopure double 
bi-layers respectively, and therefore true polymorphs while form III consists of alternate 
macroscopically thick layers of R and S molecules. Therefore, form III is an epitaxial racemic 
conglomerate and not a real polymorph in the strict sense of the definition. Furthermore, we 
investigate the metastable solid-solid transition (peritectoid) between the racemic compound 
form I and the racemic conglomerate, form III. Remarkably this transition is topotactical, as the 
shape of the crystal does not change during this racemate to racemic conglomerate 
transformation. 
4.2 Experimental  
Venlafaxine with a purity of 99.9%, according to High Pressure Liquid Chromatography 
(HPLC), was supplied by Synthon B.V.. The solvents (pa) were purchased from Aldrich and 
used without further purification. Crystals of the three polymorphs were obtained by cooling  a 
solution of Venlafaxine in heptane saturated at reflux temperature. The various forms were 
obtained by quickly cooling the clear solution to a temperature for which the desired form is 
stable18, and isolating the formed crystals at that temperature. When isolating single crystals of 
forms II and III, a layer of the low melting polymorph(s) is easily deposited on the crystal. To 
avoid the formation of these layers water of the right temperature was poured in the reaction 
flask to separate the hot heptane solution from the crystals as fast as possible. After filtration of 
the suspension, the water attached to the crystals was removed by drying the crystals in a 
vacuum desiccator using phosphorus pentoxide to trap the water.  
It was difficult to obtain suitable single crystals of the high melting form III for two 
reasons. Firstly, crystallizing form III from solution often leads to very small crystals or an 
agglomerate of crystals. Secondly, form III is only stable above 50°C and because the solubility 
is very high at that temperature, 38 g of Venlafaxine “dissolves” in 10 g of heptane at 59°C. 
Moreover, the liquid layer surrounding the isolated crystals cools quickly during isolation, and 
the resulting high supersaturation easily leads to the formation of a layer of polymorph I and/or 
polymorph II on top of the crystals of form III. Seeding a supersaturated solution above 50°C 
with small crystals, isolated from a former experiment and washed to remove the layers of the 
other forms, resulted in the formation of large single crystals of form III. 
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Scanning Electron Microscope (SEM) photos were taken using a JEOL JSM 6330F Field 
Emission SEM. Optical rotations were measured with a Perkin Elmer 343 polarimeter at 589 nm 
and 20 °C. The polarimeter was used with the micro aperture set-up.  
For the single crystal X-ray diffraction experiments measurements, single crystals were 
mounted in air on glass fibres. A course structure determination was performed at room 
temperature for each form. The final intensity data were collected at -65°C; only a small 
contraction of the unit cell was observed. A Nonius Kappa CCD single-crystal diffractometer 
was used (ϕ and ω scan mode) using graphite monochromated Mo-Kα radiation. Intensity data 
were corrected for Lorentz and polarization effects. For absorption correction the Siemens Area 
Detector ABSorption correction program (SADABS)20 was applied. All structures were solved 
by the program CRUNCH21 and were refined with standard methods using SHELXL9722 with 
anisotropic parameters for the nonhydrogen atoms. The hydrogens attached to the methyl and 
hydroxy groups were initially refined as rigid rotors to match maximum electron density in a 
difference Fourier map and were freely refined subsequently. All other hydrogens were initially 
placed at calculated positions and were also freely refined subsequently. For crystals of the 
enantiopure compound as well as crystals of form III (grown from solution or obtained by 
conversion of crystals of polymorph I after heating) the absolute structures could not be 
determined reliably by refinement of the Flack parameter in SHELXL97. However, based on the 
assignment of the chirality of Venlafaxine as in relation to the optical rotation as described by 
Yardley et al., we assigned the R conformation to the structure of the enantiopure compound23. 
Cross Polarization Magic Angle Spinning (CPMAS) 13C solid state NMR spectra24,25 were 
acquired on a 400 MHz Chemagnetics Infinity spectrometer. A 4 mm and a 3.2 mm double 
resonant probe were used, tuned to 100.58 MHz for carbon and 399.95 MHz for protons. 
Measurements on polymorphs I, II and the as-grown form III were done on the 4 mm probe with 
8.0 kHz MAS. Here, variable amplitude cross polarisation (VACP)26 with a contact time of 2 ms 
was used with a radio frequency (RF) field strength of 64 kHz on protons and 56 kHz on carbon 
and a +1 to -1 kHz linear ramp on protons. During acquisition the protons were decoupled with a 
two pulse phase modulation (TPPM) pulse sequence27 with a 110 kHz RF field, a pulse duration 
of 5.3 μs and a phase modulation of 15 degrees. Partially dissolved form III and enantiopure 
form III were measured with the 3.2 mm probe at a spinning speed of 12.5 kHz. VACP was used 
with a 62 kHz field with a +/- 0.6 kHz ramp on 1H, and a 62 kHz field on 13C. For proton 
decoupling the continuous modulation (CM) scheme28 was used with a modulation amplitude of 
0.12 radians, a period of 8.4 μs and an RF field strength of 110 kHz. Peak intensities were 
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obtained by deconvolution of the spectra using a Voigt lineshape. The data were processed using 
the MatNMR processing package which runs under Matlab29. 
Molecular energies, lattice energies and surface energies were calculated using the Cerius2 
modelling environment30. The crystal structures were minimized using the Dreiding force field 
with 3D-Ewald summation for the Coulomb contribution. Charges were determined using a 
Restricted Electrostatic Potential (RESP) charge fitting scheme31. The Van der Waals 
interactions were calculated using a spline function with on and off-distances at 12 and 13 Å 
respectively. To calculate the lattice energy, the energy of individual molecules with the bulk 
conformation was calculated and subtracted from the energy found for the crystal structures. For 
the calculations of surface energies the crystal structure was cleaved. Using the same settings as 
for the bulk crystals, only now with a 2D-Ewald summation, the surface energies were calculated 
by subtracting the lattice energy of the full crystal from that of the cleaved semi-infinite crystals 
without relaxation. 
4.3 Results and Discussion  
4.3.1 X-ray single crystal structure determination 
The crystal structures were determined using single crystal X-ray diffraction. Polymorphs I 
and II crystallize in the monoclinic spacegroups P21/n and P21/c, respectively. Note, that the 
latter spacegroup represents an alternative setting of the former one. Form III crystallizes in an 
orthorhombic structure, spacegroup P212121. For an overview of the crystal data of the three 
polymorphs see table 1. 
The crystal structure determinations of forms I, II and III showed that all stuctures are built 
up from similar enantiopure layers parallel to the (001) surface. The crystal structure of 
polymorph I is in agreement with the previously published structure32(Cambridge Crystal 
database reference code; OCALAG) . In case of polymorph I, alternating layers of R and S 
molecules make up the structure, for polymorph II alternating bi-layers of R and S molecules are 
present and for form III only layers of one enantiomer make up the complete crystal packing. 
Polymorphs I and II are true racemates because R and S molecules are stoichiometrically, ratio 
(1:1), present in the unit cell. For the unit cells of forms I, II and III see figure 2. 
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Figure 2: Projections of the unit cells of forms I, II and III of Venlafaxine; for form I 
and III the a and c axes and for form II the b and c axes are indicated. 
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Table 1: Crystal data of forms I, II and III (grown from solution), III (after 
transformation) and of one of the pure enantiomers of Venlafaxine free base, all 
structures were measured at -65 °C. 
 space  
group 
a 
(Å) 
b 
(Å) 
c 
(Å) 
α β γ Z V 
(Å)3 
Form I  P21/n  8.82 21.61 90 92.22 90 4 1586.4 
Form II  P21/c 8.84 8.27 43.75 90 90.97 90 8 3198.6 
Form III (grown) P212121 8.22 8.86 22.27 90 90 90 4 1622.7 
Form III  
(transformed) 
P212121 8.23 8.87 22.33 90 90 90 4 1630.5 
Pure enantiomer   P212121 8.15 8.80 22.30 90 90 90 4 1599.3 
 
The crystallographic relationship between molecules in the enantiopure layers of forms I, 
II and III differ slightly. In form I the molecules in the enantiopure (mono)layers are related by 
translational symmetry in the a- or b-direction or by a twofold screw axis in the b-direction. In 
form II the molecules in the enantiopure layers are related by translational symmetry in the a- 
and b-direction or by a pseudo-twofold screw axis in the a-direction. In form III the molecules in 
the layers are related in the same way as in form I. The consequence is that the molecular 
arrangement in the a-direction of form I is similar to the arrangement in the b-direction of form II 
and similar to the a-direction of form III. And, vice versa, the molecular arrangement in the b-
direction of form I is similar to the arrangement in the a-direction of form II and similar to the b-
direction of form III. This relationship is also visible from the unit-cell parameters of the three 
forms. The crystallographic relationship between layers consisting of different enantiomers is in 
both form I and II the inversion symmetry. The relation between layers of the same enantiomer 
that make up bi-layers in the structures of forms II and III is a two-fold screw axis, for form II in 
the b-direction and for form III in the a-direction. This means that inverting an enantiopure layer 
must yield a resulting layer that is structurally very similar to a layer obtained by applying a two-
fold screw axis (in the proper direction), at least with respect to the structure of the interface 
between to enantiopure layers. This structural resemblance is visible in figure 3 in which an 
overlay is shown of R and S layers that have a similar contact to other enantiopure layers. 
Clearly the overall structure of the interfaces is very similar although the layers are made up of 
different enantiomers. The crystal structure of form III pointed to the presence of only one 
enantiomer, although we used the same racemic starting material as for the crystallizations of 
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polymorphs I and II. This indicates the formation of a racemic conglomerate, as will be 
discussed below.  
 
 
Figure 3: Overlay of the unit cells of polymorph I (green), polymorph II (yellow) and 
form III (red). 
4.3.2 Solid State NMR characterisation 
Using 13C solid state NMR all three forms were investigated. Figure 4 shows the spectrum 
of a microcrystalline powder of a pure enantiomer grown from a heptane solution. These crystals 
have the same structure as form III. The assignment of the carbon spectrum was done based on 
chemical shifts and dipolar dephasing experiments (not shown here)33. Peaks stemming from 
carbon 6 and 7a/b are somewhat broader due to the residual dipolar coupling to 14N. Stacking 
effects are clearly present in the spectrum as carbon atoms that would be equivalent in solution 
now have different chemical shifts (up to 10 ppm for carbon 10a/b).  
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Figure 4: 13C CPMAS NMR spectrum of Venlafaxine in form III, grown from an 
enantiopure solution. The numbers on top of the peaks correspond to the carbon 
atom labels in the molecular structure. 
Figure 5 displays the 13C spectra of the microcrystalline powders which were grown from a 
racemic solution. Polymorphs I and II are shown in 5a and 5b while the spectrum of the as-
grown form III and the partially dissolved form III are displayed in 5c and in 5d. Clear 
differences can be seen between the different forms. One can observe three sets of chemical 
shift; those shared between polymorphs I and II, those shared by forms II and III and those 
shared by all 3 forms. Combining this with the crystal structures, it is straightforward to conclude 
that the chemical shifts shared between polymorph I and II are associated with the stacking of 2 
different enantiomer layers, i.e the RS interface between an R bi-layer and an S bi-layer, while 
those shared between II and III are unique for the stacking of like enantiomer layers, i.e. an R bi-
layer stacked on another R bi-layer (or an S bi-layer on another S bi-layer). The difference in 
chemical shift between an unlike interface (RS) and the like interface (either RR or SS) are most 
noticeable for peaks stemming from carbon 1 and 12 and a little less for the other 6-ring carbons 
(2a/b, 3a/b and 4). From the crystal structure, see figure 2, these are actually the carbon atoms 
that are lying at the interface of the bi-layers. Quantification of 13C CPMAS spectra has to be 
done with care and is usually not straightforward. In this case, however, no differences in CP 
dynamics between the different forms could be observed. For polymorph II we know that half 
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the peaks originate from the like interface and half from the unlike interface. Inspection of the 
spectrum of form II shows that intensities of for instance the two peaks of carbon 12 appear in a 
1:1 ratio. Hence, quantification of the relative amounts of the layer types based on the VACP 
measurements was possible. 
 
Figure 5: 13C CPMAS NMR spectra of the different forms of Venlafaxine, grown from 
a racemic solution: a) form I, b) form II, c) form III, as-grown, and d) form III, rinsed.  
Chemical shifts are listed in table 2. Spinning sidebands are indicated with an 
asterisk. MAS speeds were 8 kHz in a, b and c and 12.5 kHz in d.  
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Table 2: 13C Chemical shifts for the different forms, carbon atoms are numbered 
according to figure 4. 
Carbon 
Atom 
Form I 
δ (ppm) 
Form II 
δ (ppm) 
Form III 
δ (ppm) 
2 a/b 
22.7 22.7 22.7 
 22.7 22.7 
23.2 23.2  
1 28.2 28.3   26.9 27.0 
3a/b 
31.5 31.5 31.4 
37.6 37.5  
 38.0 38.0 
7a/b 43.6 43.6 43.4 47.8 48.0 48.3 
5 52.3 52.4 52.5 
12 53.5 53.5   54.7 54.7 
6 62.7 62.3 62.0 
4  75.2 75.3 75.5 75.5  
10a/b 109.1 109.1 109.2 119.1 119.3 119.2 
9a/b 130.4 130.1 129.9 132.8 133.1 133.5 
8 134.3 134.2 134.1 
11 159.6 159.9 156.0 
4.3.3 Dissolution experiments of grown crystals 
The X-ray data of form III of Venlafaxine pointed towards the formation of a racemic 
conglomerate, with single crystals composed of enantiopure fragments. Furthermore, both the X-
ray crystallography and the NMR results indicate that the structure of form III grown from the 
racemic solution is identical to the one grown from an enantiopure solution.  
A possible explanation of the observation is that somehow during the process an 
enantiomeric resolution took place, and separate crystals of R and S were formed. To examine 
this possibility several large single crystals were isolated, and the optical rotation of the single 
crystals was measured separately. In all cases the optical rotation was negligible. From this result 
it was concluded that (almost) equal amounts of both enantiomers were present in the crystals.  
Therefore, during low supersaturation conditions the single crystals have to grow via the 
successive formation of enantiopure fragments. A mechanism, which accounts for the formation 
of single crystals consisting of macroscopic layers of enantiopure fragments, via oscillating 
crystallization, was already described in the literature9,11. During the growth of a face only one 
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enantiomer is inserted and as a result of that the local supersaturation of the other enantiomer is 
increasing until a certain threshold value. Then nucleation of the other enantiomer on top of the 
already existing enantiopure fragment results in the growth of a new enantiopure fragment of the 
opposite handedness. Gervais et al. were able to overcome the problem of the formation of 
crystals by slowly stirring the solution. In that case the diffusion rate is large enough to keep the 
supersaturation of the other enantiomer below the threshold of 2D nucleation. Instead of trying to 
avoid this oscillating growth behaviour, we study the composition of the as-grown crystals in 
more detail. 
To further investigate the composition of the single crystals selective dissolution 
experiments were performed as proposed by Toyokura et al.34 which offers a simple method to 
study the enantiomeric composition of the single crystals of form III. A crystal of form III which 
was grown from a heptane solution containing racemic Venlafaxine, was added to a saturated 
solution of one of the pure enantiomers in heptane at room temperature. Assuming ideal 
solubility mainly fragments containing the R enantiomer should dissolve in a solution saturated 
with the S enantiomer at a temperature for which form III crystals are metastable. The 
dissolution process was followed in situ using optical microscopy. After several hours the 
crystals were isolated and analysed using scanning electron microscopy (SEM). In Figure 6 the 
left image gives an overview of a crystal before etching. A striped pattern is visible on top of the 
crystal, suggesting a fragmented composition of the crystal present before etching. This pattern is 
shown enlarged in the insert and can be compared with the SEM image of a crystal after etching, 
shown on the right in Figure 6. 
 
Figure 6: SEM photographs of single crystals of form III before (left; scale bar = 
1mm) and after (right; scale bar =0.1 mm) a dissolution experiment in a heptane 
solution saturated with one of the enantiomers. The insert shows a part of the 
crystal surface with the same magnification as for the image on the right. The 
orientation of the b and c-axis are indicated. 
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Some crystals were left in the solution saturated with the S enantiomer for 16 hours. The 
optical rotation of the isolated fragments showed an enantiomeric excess of more than 80 %. 
This result confirms that mainly fragments containing R enantiomers dissolve. From a 
comparison of the SEM images it is obvious that intermediate layers of the crystal, with opposite 
handedness, dissolved during the dissolution experiment. Moreover the images confirm that that 
the as-grown single crystals of form III are composed of enantiopure fragments with a thickness 
of 10-50 µm. These fragments contain one of the enantiomers in a large excess. 
From the NMR data one can also determine the average layer thickness through the 
relative ratio of the peaks unique for the unlike (RS) interface and the peaks unique for the like 
interface (RR and SS). The as-grown form III (figure 5c) shows some low intensity peaks that 
are characteristic for the RS interface. Based on the peak intensities one arrives at an average like 
layer thickness between 8 and 10 interfaces (comparable to 4-5 stacked unit cells of form III). 
This seems rather thin, compared with the layer thickness as seen in the SEM images. However, 
as was mentioned before, the isolation of single crystals of form III caused some difficulties, the 
result of the high solubility of Venlafaxine in heptane. Crystals isolated from the solution are 
covered with a layer of liquid with a high concentration of Venlafaxine. A layer of polymorph I 
and or II can crystallise on the surface of the crystal of form III before this liquid layer can be 
removed. Form I and II both contain RS interfaces and this would explain the existence of the 
low intensity peaks in figure 5c. To examine this idea, single crystals of form III were added to a 
flask with heptane and left there for some time to dissolve the outer layer, the part of the crystal 
were RS interfaces are likely to be present. After isolation and drying of the crystals the 
spectrum in figure 5d was recorded. The intensity of the RS interfacial peaks are much reduced, 
leading to an average enantiopure layer thickness of 40 layers (equivalent to 20 units cells of 
form III stacked along c). This is still much thinner than the 10-50 μm (which would be 5000 to 
25000 unit cells) which the SEM images suggested. It should be noted, however, that the layer 
thickness is an average over the entire crystal, enantiopure layers could be separated by thin 
layers of form I and/or II or single layers of one enantiomer can be interspersed within a thick 
layer of the other enantiomer. These thin layers of what would essentially be a single unit cell of 
form I would not show up in the X-ray diffraction, nor in the etching experiments. 
4.3.4 Solid-solid transition of polymorph I to III 
In a related paper18 the solid-solid transition of form I to III was followed in time using 
DSC, XRPD and solid state NMR. Especially the XRPD and NMR measurements showed a 
gradual transformation between the polymorphs. To realize such a transformation in the solid 
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state complete layers of R and/or S molecules have to be transferred, a process that on first sight 
seems very unlikely, see Figure 7.  
 
Figure 7: Annealing of a crystal of polymorph I at 75°C for 6 days leads to its 
transformation to form III. The R and S enantiomers need to migrate over 
surprisingly large distances during this process. 
For NMR, XRPD and DSC finely powdered material was used. Taking into account the 
large surface area and the acquired stress resulting from grinding, the solid-solid transition is 
imaginable. The question then arises, whether this transition could also be established in a single 
crystal. A comparable experiment was performed using a single crystal of polymorph I 
(dimensions approximately 2 mm in all directions). With single crystal X-ray diffraction the 
crystal structure was confirmed. The single crystal was subsequently transferred to a calorimeter 
and slowly heated to 74 °C which is 4 degrees below the melting temperature of form III, that is 
the eutectic temperature of the racemic conglomerate, and kept at that temperature for 6 days and 
then cooled to room temperature. According to single crystal structure determination, the starting 
material, polymorph I, was converted to form III; remarkably the shape of the crystal had not 
changed.  
To study the layered structure of this crystal in more detail an annealed crystal of 
polymorph I was etched in a similar way as for crystals of form III by adding it to a saturated 
solution of one of the pure enantiomers. SEM photos were taken from the isolated crystals after 
the etch experiment, see Figure 8.  
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Figure 8: SEM photographs of annealed (6 days, 74 oC) crystals of polymorph I after 
a dissolution experiment in a heptane solution saturated in one of the enantiomers.: 
left; scale bar = 1mm , magnification 25x, right; scale bar =0.1 mm, magnification 
100x, The orientation of the b-axis is indicated. 
Although the solution might lead to a reconstruction of the layered structures, it is clearly 
visible from the figure that the layers are built up in a mosaic fashion, contrary to the layered 
fragments of the etched crystals of form III as grown from solution, see Figure 6.  
The only way to transform form I into III is by the migration of molecules, inversion of the 
chiral centre is impossible. Furthermore, diffusion of complete layers in the solid state is also not 
very likely. To account for this phenomenon it is suggested that diffusion has to occur via a kind 
of molten phase. A possible explanation is local melting as a result of crystal defects, impurities 
and/or stress, several degrees below the melting point of the bulk solid. During the annealing a 
thin layer melts and after nucleation an R or S domain starts to grow. Like in the experiment of 
Gervais et al.9, after some time the supersaturation of the other enantiomer has reached the 
threshold for 2D nucleation and after nucleation an enantiopure domain starts to grow epitaxially 
on top of the underlying layer. For the present case it is probable that the pre-melting process 
starts at different spots in the crystal simultaneously. At some of these places R starts to nucleate 
and at others S will start to nucleate. In this way no enantiopure layer, as for the crystals of form 
III grown from solution, but a mosaically composed layer is formed for the annealed crystal. The 
molten fronts move through the crystal resulting in a crystal composed of enantiopure domains. 
The thickness of the domains is of the same order as for the layers of the grown crystals of form 
III. 
The difference between the volumes of the unit cells of the grown (1623 Å3) and the 
transformed form III (1630 Å3) confirm the view resulting from the above described experiment. 
During the transformation of polymorph I to form III the packing efficiency of the formed 
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mosaical crystal fragments differs slightly from that of grown crystals of form III, resulting in a 
slightly larger unit cell. This is also validated by the temperature factors of determined crystal 
structures. For the transformed form III they are slightly larger. 
4.3.5 Molecular modelling 
Looking at the remarkable solid-solid transition one can ask what is the driving force for 
this racemate-to-conglomerate transition. As the structures of the individual layers for all three 
forms are virtually the same the interactions between molecules inside a layer can be considered 
equal. For the inter-layer interactions it can be concluded that at lower temperatures, for which 
form I is stable, R-S interfaces are favored, whereas at higher temperatures (form III) R-R (and 
S-S) interfaces are dominant. Form II can be considered as an intermediate phase as 50 % of its 
interfaces are R-S and the remaining 50 % are R-R and S-S.  
To get an estimate of the energies involved in the interfacial energies were determined 
using molecular mechanics calculations of the lattice energies of a bulk crystal and a cleaved 
one. The results of these calculations are summarized in table 3. The lattice energies are the same 
within 0.4 kcal.mol-1 apart, thus within the error margin (roughly 2 kcal/mol) of the calculations. 
The differences in surface energy between form I and II is for the R-S layers 0.8 kcal.mol-1, 
which may indicate a small enthalpic favour for form I, which is in accordance with the fact that 
form I is formed at low temperatures. The difference in R-R surface energy for form II and III, 
however, is 0.7 kcal.mol-1, which hints at a small enthalpic favour for form III forming over form 
II, at lower temperatures, which is in contrast with the observations.  
Entropic contributions usually dominate the polymorphic stability more than the enthalpic 
contributions19. Assuming that the transition between the enantiotropically related forms are 
mainly entropy driven, in other words assuming that the enthalpies and entropies of the 
polymorphs differ but are only weakly dependent on temperature, the order of enthalpies is HI < 
HII < HIII, and the order of entropies follows SI < SII < SIII. The entropy has two contributions, a 
conformational part and a vibrational part. The conformational part is the same for all the three 
forms, while the vibrational part of the entropy will differ. Limiting our attention again to the 
interlayer interactions and form III having only interactions between R and R (or S and S) layers, 
this leads to the conclusion that there is more vibrational freedom in these interactions as 
compared to interactions between R and S layers.  
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Table 3: Calculated lattice and interface energies for forms I, II and III. 
 Form I Form II Form III 
Crystal [kcal.unitcell-1] 67.67 161.49 61.93 
Molecule 1 [kcal.mol-1] 44.4 48.44 43.27 
Molecule 2  - 47.64 - 
Lattice energy [kcal.mol-1] -27.49 -27.85 -27.78 
    
R-R surface - 178.19 77.97 
R-R excess energy - 16.70 16.04 
R-S surface 82.73 177.34 - 
R-S excess energy 15.03 15.85 - 
4.4 Conclusion 
Three different forms of the antidepressant Venlafaxine were identified and their crystal 
structures determined. The crystals of the three forms are composed of enantiopure layers. Form 
I consists of alternating bi-layers of R and S enantiomers while form II consists of two R bi-
layers alternating with two S bi-layers. Single  crystal X-ray diffraction experiments 
combined with dissolution experiments showed that crystals of form III are racemic 
conglomerates, composed of a stacking of relatively thick layers of R and S enantiomers. 
Therefore in Venlafaxine a unique combination of phenomena, polymorphism and chiral 
separation, is encountered in a single compound. The overall structure of the interfaces between 
the bi-layers in the three polymorphs is very similar, the sequence of the bi-layers, however, 
differs considerably for the different forms. From 13C solid state NMR experiments it emerged 
that each type of layer interface (RS and RR/SS) has a unique spectral signature. From these 
experiments the average (enantiopure) layer thickness for form III was calculated. Although this 
led to much thinner layers compared with the layer thickness found from SEM images, showing 
that etching of the crystals in the presence of one of the enantiomers resulted in lamellae of 10-
50 μm thickness, the results could be compared taking into account that the etching experiment 
will not reveal the thinnest lamellae present. Molecular modelling studies show that the 
differences in lattice enthalpy between the three structures is of the order of 1 kcal/mol, implying 
that the transitions between the three forms are entropy driven. Furthermore it was shown that a 
single crystal of Venlafaxine form I readily undergoes a topotactical solid-solid phase transition 
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to form III as the habit of the crystal did not change during this transformation. The experiments 
indicate that local melting is the underlying mechanism for this remarkable transformation as 
long range migration of molecules in the solid state needed to accomplish this transformation 
seems highly unlikely. Further investigations to gain insight in the dynamics of this process are 
underway. 
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Chapter 5
EXPERIMENTAL AND COMPUTATIONAL MORPHOLOGY OF THREE 
POLYMORPHS OF THE FREE BASE OF VENLAFAXINE. 
A COMPARISON OF MORPHOLOGY PREDICTION METHODS. 
 
 
 
Abstract 
 
In this paper the experimental and the computational studies of the morphology of three 
polymorphs of the free base of Venlafaxine ((N,N-dimethyl)-2-(1-hydroxy cyclohex-1-yl)-2- (4-
methoxyphenyl)-ethylamine) are reported. The morphology of all polymorphs has been predicted 
using the Bravais-Friedel-Donnay-Harker method, the attachment energy method and kinetic 
Monte Carlo growth simulations and these predictions have been compared with experimental 
observations. The Monte Carlo simulations allow for a detailed simulation of the growth process, 
including driving force and growth mechanism, which leads to a semiquantitative prediction of 
the growth morphologies of all three phases. 
For phase I two distinct growth habits are found experimentally under the same conditions. 
This is explained by the occurrence of a spiral growth mechanism in one of the two, which was 
observed using AFM and which is also supported by the Monte Carlo simulations. The habit of 
phase II could only be explained from simulations when a spiral growth mechanism is assumed; 
the shape of phase III could not be modeled accurately from the Monte Carlo simulations. 
Although the shape of the crystal is reproduced accurately, some of the indices of the faces 
predicted are not in agreement with the indices measured. The deviations are interpreted to be 
due to the presence of domains in the crystals as a result of the layered structure. 
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5.1 Introduction  
The study of polymorphism of pharmaceutical compounds is an important part in the 
development of a new drug1. As each polymorph has different metabolical characteristics, often 
only one polymorph can be used in a drug formulation2. Knowledge of the polymorphs and their 
relative stabilities is therefore indispensable for the development of drugs that are administered 
in crystalline form. Apart from formulation issues, each new polymorph can be patented, so also 
for protection of intellectual property adequate knowledge of polymorphism is needed. 
Polymorphs can have different crystal morphologies, because morphology is largely 
determined by the crystal packing at the molecular level and the crystallization process. It is 
desirable to be able to exert control over the morphology, because it determines among other 
things the bioavailability and the processability of the compound. The bioavailability depends on 
the dissolution rate of the crystals, which is in turn partly determined by the crystal morphology. 
Concerning processability, it can generally be said that block-like crystals habits are desired over 
plate-like crystals and needles because the latter forms tend to block filters, are more difficult to 
dry and give problems during tabletting. 
Crystal morphology can be predicted computationally using various methods of different 
complexity and demand for computing power. Well-known approaches are the method 
developed by Bravais, Friedel, Donnay and Harker (BFDH) based on the interplanar distances of 
crystallographic orientations3,4 and the method developed by Hartman and Perdok5,6,7 and later 
by Hartman and Bennema8, which uses the concept of the crystal graph to determine the slice 
and attachment energies of crystallographic orientations, and relates these energies to the growth 
rate of the orientations. 
The development of detailed crystal growth simulations, for instance using Monte Carlo 
techniques, has been facilitated by the ongoing development and availability of ever faster 
computers. A recent development is a program called Monty with which growth simulations can 
be performed for arbitrary crystal structures in any crystallographic orientation as a function of 
the driving force for crystallization9. 
Here the results are presented of a morphology prediction study for the three polymorphs 
of Venlafaxine using all three methods. A comparison with the morphologies observed 
experimentally is made. It is found that the predictions are semi-quantitative for phases I and II; 
for phase III the overall shape is reproduced, but some predicted indices do not match the indices 
observed experimentally. 
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5.2 Venlafaxine  
Venlafaxine is a bicyclic phenylethylamine-based anti-depressive drug, which is believed 
to work by simultaneously blocking the re-uptake of neuronal norepinephrine and serotonin10 
The Venlafaxine molecular structure is shown in Figure 1. It is administered as a racemic 
mixture, and the crystals of this mixture are the subject of this study.  
 
 
Figure 1: Molecular structure of Venlafaxine. 
Recently it has been found that the free base of Venlafaxine has superior processing 
characteristics over the hydrochloric acid salt, which is marketed worldwide. The free base is 
easier to handle as it is less aggressive towards equipment etc. compared to the hydrochloric acid 
salt. Also, the free base shows a low solubility and low dissolution rate in water, and is therefore 
suitable for the formulation of extended release dosage forms11. In the study of the free base, 
three polymorphs have been found, which are enantiotropically related12. Phase I is stable at 
room temperature, and can be converted into phase II above approximately 40ºC. Phase I and 
phase II can be converted into phase III above 60ºC. 
It can be seen from Figure 2 that the crystal structures12 of the three polymorphs are 
strongly related. When viewed along the b-axis, the unit cell of phase I consists of four 
molecules whose methoxyphenyl rings are oriented in a parallel fashion. In the crystal structure 
of phase III, the molecules stack with the methoxyphenyl rings in mutually perpendicular 
orientation. In the crystal structure of phase II these patterns of phase I and III are both 
incorporated; phase II can be thought of to be built of {002} layers of phase I and phase III. It 
must be noted, however, that this comparison only holds at a conceptual level, as due to packing 
details the crystal structures can not be overlaid exactly. 
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Figure 2: Crystal structures of phase I (left), phase II (middle) and phase III (right). 
The packing similarities can be seen, conceptually, as phase II being built up of layers 
of phase I and III. 
Thus all polymorphs are built up of two types of layers, and each layer consists of 
enantiopure molecules (R or S). The polymorphs differ in the way that the R- and S-layers are 
stacked. Phases I and II are racemates, having spacegroup P21/n and P21/c respectively. Phase I 
stacks with alternating R- and S-layers; Phase II with two R-layers followed by two S-layers. 
Interestingly, phase III has spacegroup P212121, a chiral spacegroup. Phase III can, 
however, be obtained from racemic solutions. It was shown using enantiomeric etch 
experiments12, that phase III is a conglomerate, built up of enantiopure macroscopic R- and S-
layers: upon immersion of a crystal of phase III in a supersaturated solution of one enantiomer, 
the other enantiomer is etched away, and mμ -thick layers of enantiopure material are left. The 
enantiomeric enrichment of the remaining solid was proven by determination of the optical 
rotation of a crystal dissolved after etching. 
As all polymorphs are enantiotropically related, the solid state conversion of phase I and II 
to phase III at higher temperatures is very remarkable, as that implies large movements of 
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molecules from a molecularly racemic configuration to an enantiomeric conglomerate. Still, the 
etch experiments showed that a crystal that had been transformed from phase I to phase III is 
indeed a conglomerate of enantiopure material. For further details, the reader is referred to the 
work of van Eupen et al12. 
5.3 Morphology prediction  
Generally speaking, growth morphologies can be constructed using a kinetic Wulff 
construction. In this construction the distance rhkl of a face (hkl) from the origin of the crystal is 
taken to be linearly related to the growth rate Rhkl of that face. 
 
rhkl ∝  Rhkl        (1) 
 
By constructing a three-dimensional set of faces perpendicular to the crystallographic 
orientations (hkl) the growth morphology can be constructed if the growth rates of the faces are 
known. Different theories have been developed to derive or compute expressions for the growth 
rate Rhkl. Three of these will be discussed below. 
5.3.1 BFDH method  
Although being an approach for predicting equilibrium morphology, the BFDH method is 
commonly used to relate the growth rate of a crystallographic orientation to the inverse of the 
interplanar distance dhkl. The relevant indices (hkl) are those allowed by the spacegroup selection 
rules. The distance from the center of the crystal to a surface (hkl) is then given by 
 
 1hkl
hkld
r =       (2) 
 
In retrospect, the rationale behind the method is that the larger dhkl is, the larger the energy 
content of the growth layer will be, and therefore the smaller the growth rate of the 
corresponding orientation will be. This limits the predictive power of the BFDH method in the 
case of anisotropic crystal structures. The determination of the values for dhkl, however, is trivial 
once the space group and lattice parameters are known, making the BFDH a very fast method. 
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5.3.2 Hartman Perdok theory and the determination of the crystal graph  
In the extension of the Hartman-Perdok theory by Hartman and Bennema, the concept of 
the crystal graph is introduced8. The crystal graph is a mathematical representation of the crystal 
structure as an infinite three dimensional graph, in which the graph vertices represent the growth 
units and the graph edges represent the interactions between the growth units. 
The crystal graph is used to determine Periodic Bond Chains (PBCs). PBCs are 
uninterrupted chains of bonds between symmetry-related growth units with an overall periodicity 
[uvw] = ua + vb + wc, (u, v, w ∈  Z) of the primitive lattice, which contains no other lattice 
translation. PBCs are stoichiometric with respect to the contents of the crystal unit cell. 
Combinations of two or more intersecting PBCs in non-parallel directions in a growth layer 
define so-called connected nets. 
Crystallographic orientations that have connected nets are likely to determine the growth 
morphology of the crystal13. In the Hartman-Perdok theory, the attachment energies of the 
connected nets in all crystallographic orientations determine the growth morphology. The bonds 
that are present in a crystal slice together make up the crystal's slice energy; the other bonds 
define the slice attachment energy. Together, they are equal to the crystallization energy: 
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E
E E E
φ
φ
=
=
= +
∑
∑       (3) 
 
Once the attachment energies for all orientations that have one or more connected nets 
have been computed, the attachment energies are related to growth rates Rhkl as 
 
att cryst slice
hkl hkl hklR E E E∝ = −      (4) 
 
allowing for the prediction of the attachment energy morphology. The attachment energy method 
can thus be considered as a refinement of the BFDH method using the slice energy as the 
parameter determining the growth. The BFDH method uses the interplanar distance, which is 
merely a geometrical parameter. 
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5.3.3 Monte Carlo growth simulations  
The methods described above give a reasonable approximation of the growth morphology 
in several cases. It is well-known, however, that the growth morphology depends on the driving 
force (i.e. the solution supersaturation) and growth mechanism during growth of the crystal14. 
This is not taken into account when a morphology is calculated using the BFDH approach nor 
when based on the Hartman-Perdok theory. Recently the program Monty was developed by 
Boerrigter et al. that is able to perform growth simulations on any crystal structure in any 
crystallographic orientation9. 
In these simulations a box with lateral periodic boundary conditions is prepared in a certain 
crystallographic orientation (hkl) on which particles may attach and detach with the following 
probabilities: 
 
( ) ( )( )( )
( )( ) ( )( )
exp 1
exp 1
ij ij
ij ij
U U
U U
Ρ βλ β λ μ
Ρ β λ βλ μ
+
−
= − Δ − Δ − − Δ
= − − Δ − Δ − Δ
   (5) 
 
where ij denotes a particle i having a bonding configuration j with surface bonding energy ijU  
and ( ) 1Bk Tβ −= . These probabilities ensure microscopic reversability at all times. The 
probabilities allow for a choice of the parameter 0 1λ≤ ≤ , which controls the contribution of 
μ+  vs. the surface bonding ijU+  to the probabilities. When λ = 0, the attachment probability,  
ijP
+  is completely determined by the driving force μ+  and the detachment probability ijP− is 
completely determined by the surface bonding energy ijU+ . This probability scheme is called 
`random rain' and has been shown to give good results for the simulation of crystal growth from 
solution15. This is the probability scheme used for all growth simulations in this paper , as the 
Venlafaxine crystals are obtained from a heptane solution. Growth rates can be computed 
directly from the Monte Carlo results, allowing for a kinetic Wulff construction of the growth 
morphology. 
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5.4 Computational methods  
5.4.1 Calculation of the crystal graphs  
The crystal graphs were calculated using crystal structures obtained from single crystal X-
ray diffraction12. The geometries of the molecular conformations from the experimental 
structures were optimized using Gaussian 94 with an HF/6-31G* basis set16. A self-consistent 
field (SCF) convergence criterion of 10-8 as well as a "Tight" minimization threshold was 
applied. Charges were fitted to the nuclei using a restricted electrostatic potential (RESP) charge 
fitting scheme17. This RESP procedure serves two goals: first of all, it is known that RESP 
charges are less sensitive to small perturbations in the geometry, that will happen when the 
crystal structure is minimized (vide infra). Secondly, the RESP procedure was applied to all 
polymorph conformers at the same time, in order to obtain a single charge set that describes all 
molecular electrostatic potentials. In this way lattice energies of the two polymorphs can be 
compared directly, instead of having to calculate, estimate or ignore the cost in energy for 
changing the charge distribution going from one conformation to the other. This procedure is 
based on the R.E.D. v1.0 procedure developed by Pigache et al18. 
The molecular structures thus obtained were used to build the crystal structures, which 
were consecutively minimized using the Dreiding force field19 and the "Smart Minimizer" of 
Cerius2, with Ewald sums for the van der Waals and Coulomb contributions and high 
convergence settings20. 
Pairwise interactions were calculated using the Dreiding forcefield in the Cerius2 program 
using a direct calculation of van der Waals and Coulomb contributions with a constant rε  value. 
In contrast, the default value of rε  in the Cerius2 implementation of the Dreiding forcefield 
scales linearly with the distance, to approximate solvent effects19. Crystal graphs were created 
from all pairwise interactions up to a certain cutoff radius. The resulting interactions were then 
scaled so that their sum was equal to the dissolution enthalpy in heptane of each polymorph. Any 
scaled interactions with bond strength below a certain cutoff-value (usually kT ) were discarded. 
5.4.2 Attachment energy calculations  
Once the energies of the bonds making up the crystal graph have been determined, 
attachment energies can be calculated from the crystal graph by the program Facelift21. This 
program finds all PBCs in the graph and subsequently combines them to form connected nets. 
The bonds that make up the connected net are the slice bonds; the bonds that attach connected 
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nets to each other are the attachment energy bonds. The Facelift routine is also implemented in 
the Hartman-Perdok module of Cerius2. 
5.4.3 Monte Carlo simulations  
The Monty simulations were performed on surfaces (hkl) for which a connected net was 
found using the Facelift program. All simulations were performed on a rectangular grid of unit 
cells parallel to the orientation (hkl). For all orientations a simulation box of 50*50 unit cells 
with lateral periodic boundary conditions was used. The sampling in the simulations was 
preceded by a period of relaxation, in which the surface was allowed to grow under the same 
driving force as during the simulation. This relaxation time was taken to be 100000 events in all 
simulations. The sampling to determine the growth rate was subsequently done at least 500 
times, with periods of 10000 events in between. When there was reason to believe that the 
simulations needed more sampling time, as judged from the development of height vs. number of 
events, the sampling time was increased to a maximum of 10000 sampling events all with 10000 
moves in between. In order to prevent long equilibration times at low driving forces, the 
simulations were performed on the same surface for decreasing driving force, i.e. the final 
surface configurations at higher / kTμ+ were used as the initial surface configuration for 
simulations at lower / kTμ+ . 
5.5 Results and discussion  
5.5.1 Crystal graph calculation  
Using the methods outlined above, the energies of the crystal structures were minimized 
using a single charge set for all conformers of the three polymorphs. The resulting lattice 
parameters and lattice energies are listed in Table 1. The lattice energies are very close, and 
given the error associated with the force field, no stability ranking can be made on the basis of 
these energies. The similarity of the crystal structures, as shown in Figure 2, is reflected in the 
fact that these lattice energies are so close. Next, all pairwise interactions were calculated. For all 
phases the unscaled interactions below -1.5 kcal/mol were used. The included bonds were 
subsequently scaled to the dissolution enthalpy. 
This procedure resulted in crystal graphs in which the total number of bonds between the 
growth units is equal to 11 for phase I and 12 for phases II and III. The bonds not related by 
symmetry are listed in Table 2. It must be noted that for phase II the maximum number of bonds 
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listed in this Table does not correspond to the total number of bonds between growth units, as 
some bonds are not present for all growth units. This is due to the fact that for this phase, the 
number of growth units in the asymmetric unit cell, Z’ is equal to two. 
Table 1: Lattice parameters and energies of the three phases before and after 
geometry optimization 
Structure Spacegroup Z a (Å) b (Å) c (Å) β Lattice energy 
kcal/mol 
Phase I 
-optimized 
P  21/n 4 8.21 
8.28 
8.86 
9.32 
21.79 
22.47 
92.79 
93.71 
 
- 28.6 
Phase II 
-optimized 
P  21/c 8 8.84 
9.28 
8.27 
8.35 
43.75 
44.63 
90.97 
92.41 
 
- 28.9 
Phase III 
-optimized 
P 212121 4 8.22 
8.25 
8.86 
9.27 
22.27 
22.74 
90.00 
90.00 
 
- 28.8 
Table 2: Crystal graph bonds for the three phases of Venlafaxine. In the first 
column the bond offset is listed, in the second the bond strength in kcal/mol. For 
example, the first line indicates a bond going from GU 1 to GU 2 in the same unit 
cell. This bond has an unscaled strength of -7.81 kcal/mol and a scaled bond 
strength of -3.20 kcal/mol. Bonds that are related by symmetry are not listed. 
 Phase I   Phase II   Phase III  
Bond Unscaled Scaled Bond Unscaled Scaled Bond Unscaled Scaled 
1-2[000] -7.81 -3.20 1-8[100]  -8.13 -5.44 1-3[000] -7.59 -4.02 
1-3[010] -5.98 -2.45 1-8[000] -7.58 -5.07 1-3[100] -4.55 -2.41 
1-2[100] -4.64 -1.90 1-5[10-1] -5.83 -3.90 1-4[0-11] -3.84 -2.04 
1-3[000] -3.98 -1.63 1-5[00-1] -4.78 -3.19 1-1[-100] -3.50 -1.85 
1-1[-100] -3.58 -1.47 1-8[110] -4.54 -3.04 1-1[0-10] -2.70 -1.43 
1-1[0-10] -2.58 -1.05 1-8[010] -4.52 -3.02 1-4[001] -2.69 -1.42 
1-3[-100] -1.67 -0.68 1-1[0-10] -3.49 -2.34    
   1-1[-100] -2.54 -1.70    
   1-5[0-1-1] -1.60 -1.07    
   2-4[0-10] -4.00 -2.67    
   2-2[0-10] -3.20 -2.14    
   2-4[-1-10] -2.75 -1.84    
   2-2[-100] -2.72 -1.82    
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5.5.2 Experimentally observed habits  
Phase I exhibits two distinct morphologies, both displayed in Figure 3. The (hkl) indices 
were determined using an optical goniometer. Both morphologies have the faces {002}, {10-1} 
and {012}, one has {002} as the largest faces (Figure 3(a)), the other has {10-1} as the largest 
faces (Figure 3(b)). The difference between the two habits is attributed to the presence of a 
dislocation on the {002} face leading to a spiral growth mechanism for the crystals shown in 
Figure 3(b). The presence of the typical spiral growth pattern on the {002} surface was 
confirmed experimentally using Differential Interference Contrast Microscopy (DICM) for the 
crystals having the morphology of Figure 3(b) and no spirals were found on the {002} surface of 
the crystals having the morphology displayed in Figure 3(a). These microscopy images are 
displayed in Figure 4. 
 
                
(a)                                                                                (b) 
Figure 3: Experimental habits of phase I grown from heptane solution. Figure 3(a) 
shows the rectangular morphology without a spiral pattern on {002}, Figure 3(b) 
shows the morphology with a spiral growth mechanism on {002}, leading to a more 
plank-like morphology with relatively large {-101} faces. 
The indices of the experimental habit of phase II could not be determined using the optical 
goniometer, so the experimental habit, shown in Figure 5, has no indices. Still, it can be seen that 
also this phase has a plank-like shape, with similar top faces as phase I. The crystals of phase II 
consist of domains parallel to the basal face, which is, very likely, {002} (vide infra). These 
domains were found using a polarization microscope as alternating extinct and bright striped 
patterns on the side faces, depending on the orientation of the crossed polarizers. These domains 
were interpreted as twin domains typical for the monoclinic spacegroup P 21/c  of this phase in 
combination with its layered crystal structure (see Figure 2). As a result we can conclude that the 
basal face is {002} and the b-axis is parallel to the long axis of the crystals. The presence of 
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these domains and the corresponding domain walls gives rise to a lot of macrosteps and striations 
on the side and top faces, as can be seen in the lower image of Figure 5. Such striations can act 
as sources for growth steps leading to vicinal orientations. This explains the problem with 
indexing the habit of phase II. 
The experimental habit of phase III is also a flat plank-like shape, displayed in Figure 6. 
The indices are {002} (the basal face), {101} (side faces) and {012} (top face). 
 
        
 (a) (b) 
Figure 4: Differential interference contrast microscopy (DICM) images of phase I 
shows (a) the presence of 2D islands and (b) spiral growth hillocks. The 
magnification factor is 200x. These micrographs were taken of the {002} surface for 
samples corresponding to the two different morphologies as displayed in Figure 3. 
       
Figure 5: Experimental habit of phase II grown from heptane solution. This habit 
could not be indexed on a goniometer, so no indices are given. 
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Figure 6: Experimental habit of phase III grown from solution. 
5.5.3 Prediction of morphologies  
5.5.3.1 BFDH  
The morphologies were first predicted using the BFDH theory. The results for the three 
phases of Venlafaxine are displayed in Figure 7.  
         
 (a) BFDH morphology of phase I  (b) BFDH morphology of form II 
 
    (c) BFDH morphology of form III 
Figure 7: The BFDH morphologies of the three phases of Venlafaxine. 
As can be seen in these figures, the predicted morphologies of phase I and III are very 
similar, due to the fact that the lattice parameters are quite similar. Differences are mainly caused 
by the difference in spacegroup, P21/c for phase I and P212121 for phase III. As the unit cell of 
phase II has a c-axis that is about twice as long as the c-axes of phase I and III, the predicted 
shape of phase II is more plate-like. None of the predictions of the BDFH theory are very good 
however, as square shapes are predicted, instead of the experimentally observed plank-like 
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morphologies. Also, for phase I and III, the predicted shapes are too thick in the {002} 
orientations. 
5.5.3.2 Attachment energies  
For phase I the Facelift procedure results in a set of 170 PBCs and 63 connected nets in 13 
crystallographic forms; for phase II however, these numbers are much higher because of the 
larger number of particles in the unit cell. For phase II 36922 PBCs and 4427 connected nets in 
25 crystallographic forms were found. For phase III, 288 PBCs were found which could be 
combined to form 57 connected nets in 9 crystallographic forms. 
The connected net attachment energies of phases I, II and III are shown in Table 3.  
Table 3: F-faces and corresponding attachment energies of the three phases of 
Venlafaxine. 
Phase I  Phase II  Phase III  
(hkl) Eatt (kcal/mol) (hkl) Eatt (kcal/mol) (hkl) Eatt (kcal/mol) 
{002) -23.25 {00-2} -24.41 {00-2} -26.14 
{-101} -36.21 {0-1-1} -79.73 {-10-1} -45.25 
{01-1} -46.50 {012} -86.38 {01-1} -45.83 
{01-2} -46.83 {10-4} -92.11 {01-2} -48.13 
{-10-1} -48.88 {013} -93.03 {-10-2} -51.33 
{110} -59.15 {10-2} -93.19 {-1-10} -62.12 
{-11-1} -61.15 {-100} -94.33 {111} -64.81 
{11-1} -62.81 {-10-2} -95.47 {1-1-2} -68.65 
{1-12} -63.46 {104} -100.47 {-11-3} -73.20 
{-10-3} -65.46 {0-1-4} -102.04   
{11-2} -67.45 {111} -122.02   
{11-3} -71.27 {-1-10} -123.08   
{-11-4} -79.08 {-1-11} -125.74   
  {-1-1-2} -126.02   
  {-1-12} -128.49   
  {-1-1-3} -130.02   
  {1-1-3} -131.23   
  {1-1-4} -134.41   
  {-1-1-4} -135.09   
  {-115} -138.40   
  {-1-1-5} -140.16   
  {1-1-6} -142.40   
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Phase I  Phase II  Phase III  
  {-1-1-6} -147.76   
  {1-1-7} -150.50   
  {117} -155.37   
 
The predicted morphologies obtained from these data are shown in Figure 8. This 
prediction is much better than that of the BFDH method; for phase I, the {002} and {10-1} 
orientations are both predicted correctly. The attachment energy of the {011} orientation is very 
close to that of {012} orientation, so the former is favored over the latter in the predicted 
morphology. The observed rectangular plank-like is not reproduced, however, as the predicted 
morphology is almost square. Phase II also has an almost square attachment energy morphology, 
and orientations {002}, {100}, {-102} and {011} are predicted. The third phase has the 
orientations {002}, {101} and {011} correctly predicted, and {110} predicted but not observed. 
The general shape is too thick and square, as opposed to the elongated plank-like shape of form 
III, observed experimentally. 
 
       
(a) Attachment energy morphology of phase I   (b) Attachment energy morphology of phase 
II  
   (c) Attachment energy morphology of phase III 
Figure 8: The Attachment energy morphologies of the three phases of Venlafaxine. 
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5.5.3.3 Monte Carlo growth simulations  
The growth rates of all connected net orientations of phase I as a function of the relative 
driving force / kTμ+  are displayed in Figure 9.  
 
Figure 9: Monte Carlo growth rate simulations for phase I. 
As can be seen from the figure the three experimentally observed orientations have the 
lowest growth rate in the right order R{002} < R{10-1} < R{012}. The habit at a relative driving force 
of / kTμ+ =2.4, the lowest value simulated where the {002} form shows growth, is displayed in 
Figure 10. 
 
Figure 10: Predicted morphology for phase I at / kTμ+  =2.4. 
The existence of two distinct habits in one single crystallization batch (see Figure 3) can be 
explained by the fact that the {002} orientation grows either via a spiral growth mechanism or 
via a 2D nucleation mechanism. To test this hypothesis, simulations of the {002} orientation 
with a spiral growth mechanism were also performed. This is accomplished by using a 
dislocation line bounded by two dislocations with opposite Burger's vectors (see also Figure 11). 
The height of the Burger's vector is equal to the length of the c-axis. 
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Figure 11: Spiral growth scheme used in Monty. Two dislocations with opposite 
Burger's vector (indicated with arrows) create a dislocation line from which two 
opposite spirals can grow. 
The resulting growth morphology of phase I, also at a relative driving force of 2.4, with the 
{002} form having a spiral growth mechanism, is displayed in Figure 12. The morphological 
importance of the {002} face is much lower then without a spiral growth mechanism (see Figure 
10) and the {10-1} face becomes dominant, as was also seen experimentally. 
 
Figure 12: Predicted morphology at / kTμ+  =2.4 for phase I with the {002} 
orientation having a spiral growth mechanism. 
For phase II, the simulated growth rate as a function of / kTμ+  is displayed in Figure 13. 
At / kTμ+ > 7.0, the {002} orientation starts to grow. The morphology at that value for / kTμ+  
displayed in Figure 14. As can be seen from this figure, when comparing it to the experimental 
morphology, the predicted morphology is not correct. An octagonal flat crystal is predicted, with 
the large face being {002}, and the side faces {10-4}, {110} and {011}. Either R10-4 or R011 is 
too large, resulting not in a plank-like morphology, but in this octagonal shape. 
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Figure 13: Monte Carlo growth rate simulations for phase II. 
 
Figure 14: Predicted morphology for phase II at / kTμ+ =7.0. 
The high driving force at which phase II is predicted to start growing, i.e. / kTμ+ > 7.0, 
hints at the fact that another growth mechanism may be dominant on the {002} orientation. To 
see the effect of spiral growth, simulations were run using a spiral growth mechanism. Using the 
spiral growth mechanism for phase II a more plank-like morphology is predicted at lower driving 
force value, / kTμ+ =4.0 (see Figure 15). This shape corresponds better to the experimentally 
observed morphology. Comparing, however, the orientation of the top faces with the 
experimentally observed ones (see Figure 5); the prediction seems to be incorrect. As discussed 
before, the presence of domains in this phase leading to striations on the top and side faces 
probably gives rise to ill-defined orientations, which could not be indexed. The growth of these 
faces is then determined mainly by the domain boundaries acting as step sources, rather than by a 
2D nucleation mechanism. Such an effect of domain walls has been observed for, e.g., gibbsite 
crystals22. 
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Figure 15: Predicted morphology at / kTμ+ =4.0 for phase II with the {002} 
orientation having a spiral growth mechanism. The side faces are {104} and the top 
faces are {014}. 
The simulated growth rates of phase III are displayed in Figure 16 and the predicted 
morphology at / kTμ+ =4.0 is displayed in Figure 17.  
 
Figure 16: Monte Carlo growth rate simulations for phase III. 
 
Figure 17: Predicted morphology for phase III at / kTμ+ =4.0. 
Although the predicted morphology is quite close to the experimentally observed habit, the 
predicted indices of the side faces are not correct. The short edges of the rectangle are predicted 
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to be {101}, but actually they are {012}, and vice versa. As phase III grows as a conglomerate of 
stacked domains of both enantiomorphs12 the relative morphological importance of these two 
faces might be influenced by that. Face indexation on a goniometer shows that both the 
conglomerate and the enantiopure crystals have the same indices and morphological importance, 
in contrast to phase II. This is explained by the difference in space group symmetry for the 
phases: phase II has a monoclinic space group (P 21/c) with its unique axis parallel to the long 
axis of the crystal. This gives rise to mutually inclined microfacets on the top faces for the twin 
domains. This, together with the domain boundaries acting as step sources explains the inability 
to index the crystals of phase II. Phase III, on the other hand, has an orthorhombic space group 
(P212121) leading to no inclination between the microfacets on the top faces. The presence of the 
domains, however, can still lead to different growth rates for the topfaces, as well as the side 
faces, compared to the predictions. 
5.6 Conclusions  
From the free base form of the anti-depressive drug Venlafaxine, the dominant 
morphologies of three polymorphs were studied experimentally. Using theories with different 
levels of complexity, the observed growth morphologies were correlated with the predicted 
morphologies. For all polymorphs the predicted morphology according to the BFDH theory does 
not give good results. The Hartman-Perdok theory does better, but fails to predict some indices 
and - more importantly fails to predict the rectangular plank-like habits of the polymorphs and 
instead predicts square plank or cube-like morphology. 
The results of the Monte Carlo growth simulations, which account for both the driving 
force and the growth mechanism, are very promising. For phase I the predictions reproduce the 
experimentally observed morphology using a 2D nucleation mechanism. A second habit, also 
observed experimentally, in which {-101} is the dominant face, is found for phase I when a 
spiral growth mechanism is used for the {002} orientation. 
The simulated growth rate of the {002} orientations of phase II was very low until high 
driving forces. Consequently, the predicted morphology did not agree very well with the 
experimentally observed morphology. When a spiral growth mechanism was used here, the 
morphology could be predicted at lower / kTμ+ values. This reproduced the experimentally 
observed morphology more accurately. The observed domains in the crystal structure of phase II, 
interpreted as twin domains, may explain the differences between the morphologies obtained 
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using simulations of 2D nucleation and the observed morphology. The twin domains may act as 
step sources, facilitating growth at lower driving force. 
The simulations of phase III also show a rectangular plate-like habit, in close correlation 
with the observed habit. The relative morphological importance of the {101} and {012} faces is 
not reproduced however; the {101} faces are predicted to be at the short end of the rectangle, 
whereas the {012} faces are experimentally observed to be the short side of the rectangle, and 
vice versa. 
It can thus be concluded that the Monty simulations are a promising tool for studying 
crystal growth. Although not all indices of phase III could be predicted correctly, all phases did 
give a semi-quantitative agreement between the experimentally observed habit and the predicted 
morphology, as far as the overall shape is concerned. The inability of the BFDH method and 
attachment energy method to predict the morphology correctly for any of the phases shows that 
the Monte Carlo simulations are a welcome addition to the set of tools for morphology 
prediction. It is not surprising that when crystals show a more complicated growth behavior than 
that captured by the mechanisms used by Monty, e.g. when twinning causes striations and 
macrosteps, which in turn act as step sources, the simulations no longer show a good agreement 
with the observed growth behavior. 
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Chapter 6
ONDANSETRON FREE BASE: POLYMORPHISM OR ORDERED DISORDER? 
 
 
 
Abstract 
 
For Ondansetron free base, an active pharmaceutical ingredient that is used to inhibit 
vomiting and nausea during chemotherapy, two solid forms grown from solution have been 
claimed as polymorphic forms. Characterization using X-ray powder diffraction, DSC and solid 
state NMR, however, turns out to be insufficient to decide if one deals with polymorphism. From 
the combination of a badly resolved crystal structure of a vapour grown single crystal of a third 
form and molecular modelling we concluded that these forms are best interpreted as locally 
ordered solid solutions of enantiomers. Different local occupations of enantiomers, induced by 
the amount of water present during crystal growth, give rise to the slightly different forms of 
Ondansetron free base. The results of the present study show that subtle but significant 
differences in X-ray powder diffraction do not automatically imply polymorphism. 
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6.1 Introduction 
Many pharmaceutical active ingredients can crystallize in more than one crystal structure. 
This phenomenon is called polymorphism. McCrone defines a polymorph as ‘a solid crystalline 
phase of a given compound resulting from the possibility of at least two different arrangements 
of the molecules of that compound in the solid state’1. The amorphous state is sometimes also 
regarded as a polymorph, but this is not correct. Which polymorph is obtained depends on the 
conditions during crystallization: solvent, concentration, temperature and pressure. Also the 
crystallization method can have an effect on the polymorphic outcome, e.g. cooling 
crystallization, evaporative crystallization, anti-solvent addition and vapour growth. A general 
overview of analytical methods to examine polymorphs was published by Threlfall2.  
Polymorphism is of importance in several areas but especially for the pharmaceutical 
industry3. As polymorphs have different crystal structures they can display different physical 
properties, in particular they can have a different bio-availability. Because finding a new 
polymorph with advantageous properties is regarded as an invention, such polymorphs can be 
patented. It is therefore important to understand what constitutes a polymorph and to know when 
we are dealing with polymorphism4.  
Normally it is clear if one is dealing with polymorphism, but there are borderline cases in 
which this it is not the case. Examples are found in case of mesomerism, tautomerism, faulted 
layer stacking and other kinds of disorder. Recently it was demonstrated that barbituric acid 
could be converted mechanically into a mesomeric structure, the trihydroxy form, as was 
demonstrated using X-ray powder diffraction and solid state NMR5. Dissolved, the new phase 
converts immediately back to the starting configuration. A question arises whether this is 
polymorphism or a matter of different compounds in the solid state. In case of tautomers 
(molecules with different electronic structures), one can ask the question if tautomers are the 
same or different molecules or compounds. A recent example is encountered in the drug 
omeprazole for which 5 different single crystals could be obtained that contain variable amounts 
of the two tautomers, the 5- and the 6 –metoxy derivative6. The crystal packing of both 
tautomers is the same and any crystal can be modelled as a solid solution of the two tautomers. 
Another borderline example, concerning faulted layer stacking, is Aspirin. Recently a second 
polymorph of Aspirin was claimed7. Both forms are composed of almost identical layers of 
Aspirin dimers. The distinction between the two forms is the way the layers are stacked. 
According to Desiraju the newly claimed form of Aspirin is not adequately described by the 
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form II structure alone, but it is better regarded as intergrowth of structural domains of the two 
forms of stacked layers8,9,10. Different form II crystals contain different amounts of the two 
domains which implies that an infinite number of Aspirin polymorphs would exist. Very recently 
it was shown that different X-ray diffraction patterns of Eniluracil samples could be better 
rationalized by disorder than by polymorphism11. From these examples it is clear that the 
distinction between polymorphism and other possible structural differences found for many 
organic molecules is not always straightforward. Because of patent protection of different solid 
forms of the same compound, this has also legal implications. 
In the present study the structural relation between two claimed polymorphs, ODS-1 and 
ODS-2, of solution grown Ondansetron free base12,13 , and a vapour grown third form is 
investigated. Ondansetron is on the market as the dihydrate of the hydrochloric acid salt. It is a 
member of the therapeutic class of antiemetic drugs and it is used to inhibit vomiting and nausea 
by decreasing the gastric motility, mainly during cancer chemotherapy and radiotherapy and 
post-operative states. The compound has one chiral centre and is on the market as a racemate. 
The official IUPAC name is: (±)1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-
yl)methyl]-4H-carbazol-4-one. For the chemical structure see figure 1. 
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Figure 1: Molecular structure of Ondansetron and carbon numbering used. 
From the results of the present study we propose that the structure of Ondansetron free 
base is a locally ordered solid solution of enantiomers, and that the differences in the X-ray 
diffraction patterns (XRPD) can be explained by small differences in the structure on a 
mesoscopic scale, possibly related to a small difference in water content present during crystal 
growth. 
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6.2 Experimental Procedures 
6.2.1 Sample preparation 
Racemic Ondansetron with a purity of 99.9%, according to High Pressure Liquid 
Chromatography (HPLC), was supplied by Synthon BV. The solvents used (pa) were purchased 
from Aldrich and were used without further purification. 
Two samples were prepared via crystallization from solution. For the preparation of ODS-
1 the following procedure was used: 0.5 g of Ondansetron was dissolved in a mixture of 25 ml of 
ethanol and 10 ml of water while heating. The clear solution was cooled to room temperature and 
left at that temperature for a few days. The formed crystals were filtered off and dried in air for 2 
days. Solution NMR showed that no ethanol was present in the sample. For the preparation of 
ODS-2, the following procedure was used: 0.3 g of Ondansetron was dissolved in 50 ml of 
methanol while heating. The clear solution was cooled to room temperature and left at that 
temperature for a few days. The formed crystals were filtered off and dried in air for 2 days. 
Solution NMR showed that no methanol was present in the sample. A third form of Ondansetron, 
ODS-3, was prepared in single crystalline form using vapour growth, at a temperature of 433 K 
and a pressure of 1.9 .10-4 bar in a glass tube. The starting material was placed at the lower end 
of the glass tube, which was positioned in the hot part of a horizontal furnace. Crystals were 
deposited at the colder end of the tube. 
6.2.2 Sample characterization 
Differential scanning calorimetry (DSC) was performed using a Mettler Toledo DSC 822e 
apparatus. Nitrogen was used as an inert purge gas. The samples were analyzed using 40 μl 
aluminium pans with a pierced lid. The heating rates used were:  0.1, 1 and 10 °C/min.  
Thermo gravimetric analysis (TGA) analyses were performed using a Mettler Toledo 
TGA/SDTA851e analyser. Nitrogen was used as an inert purge gas. The samples were analyzed 
using 40 μl aluminium pans with a pierced lid and the heating rate was 10 ºC/min. 
Karl Fisher measurements were performed using a Mettler Toledo DL39 coulometer or a 
Mettler Toledo DL 58 titrator.  
Optical microscopy images were made using a Zeiss Axioplan2 microscope. For that the 
samples were suspended in oil.  
XRPD was performed using a Bruker D8 Advance X-ray diffractometer equipped with a 
VÅNTEC detector. The diffractometer was equipped with a Johansson type monochromator. 
The data were collected in reflection, transmision or capillary mode, using monochromatic Cu 
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Kα1 radiation. The X-ray diffraction experiments in a climate chamber were performed using a 
heating rate of 1 ºC/min, while keeping the temperature constant during 10 minutes after each 
heating step of 10 ºC. Upon heating, the sample was flushed with dry nitrogen; upon cooling 
with ambient air. 
For the single-crystal X-ray diffraction experiments, a single crystal, dimensions 0.19 x 
0.05 x 0.03 mm3 was mounted in air on a glass fibre. Intensity data were collected at a 
temperature of -65°C. A Nonius Kappa CCD single-crystal diffractometer was used (ϕ and ω 
scan mode) using graphite monochromated Mo-Kα radiation. Unit cell dimensions were 
determined from the angular setting of 17 reflections. Intensity data were corrected for Lorentz 
and polarization effects. For absorption correction the Siemens Area Detector ABSorption 
correction program (SADABS)14 was applied. The structure of ODS-3 was solved using the 
program CRUNCH15 and was refined with standard methods using SHELXL9716 with 
anisotropic parameters for the non-hydrogen atoms. The hydrogens were placed at calculated 
positions and were refined riding on the parent atoms.  
Solution NMR was performed using an Avance 400 instrument with DMSO-d6 as solvent. 
Cross Polarization Magic Angle Spinning (CPMAS) 13C solid state NMR spectra17,18 were 
acquired on a 400 MHz Chemagnetics Infinity spectrometer. A 4 mm and a 3.2 mm double 
resonant probe were used, tuned to 100.58 MHz for carbon and 399.95 MHz for protons. 
Measurements on ODS-1 and ODS-2 were done on the 4 mm probe with 8.0 kHz MAS. Here 
variable amplitude cross polarisation (VACP)19 with a contact time of 2 ms was used with a 
radio frequency (RF) field strength of 64 kHz on protons and 56 kHz on carbon and a +1 to -
1 kHz linear ramp on protons. During acquisition the protons were decoupled with a two pulse 
phase modulation (TPPM) pulse sequence20 with a 110 kHz RF field, a pulse duration of 5.3 μs 
and a phase modulation of 15 degrees. For proton decoupling the continuous modulation (CM) 
scheme21 was used with a modulation amplitude of 0.12 radians, a period of 8.4 μs and an RF 
field strength of 110 kHz. Peak intensities were obtained by deconvolution of the spectra using a 
Voigt lineshape. The data were processed using the MatNMR processing package which runs 
under Matlab22 
Molecular mechanics modelling was performed using the Dreiding v2.21 force field23, as 
implemented in the Cerius2 modelling environment24. Atomic partial charges were generated 
using the Gasteiger charge equilibrium method25. The geometry of the crystal structures was 
optimized using Ewald summation for the van der Waals and electrostatic interactions. A 
constant value of εr was used in the electrostatic calculations. Energies of individual molecules 
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were calculated without a cut-off distance for van der Waals and electrostatic interactions. 
Lattice energies were calculated by subtracting the total energy of the individual molecules from 
the total energy of the crystal structure. 
6.3 Results and Discussion 
In order to determine the structure differences between the two solution grown forms of 
Ondansetron free base, the characterization of the two samples was started using optical 
microscopy. These observations showed that both samples, ODS-1 and ODS-2, consist of 
needle-like crystals, see figure 2. 
       
   ODS-1      ODS-2 
Figure 2: Optical microscopy images of ODS-1 and ODS-2 using oil immersion. 
In figure 3 the XRPD patterns of the samples crystallized from an ethanol/water mixture, 
ODS-1, and crystallized from methanol, ODS-2 are presented. Although the two XRPD patterns 
are very similar, they show significant peak shifts and intensity differences. This is an indication 
for polymorphism. TGA and Karl-Fisher measurements showed a mass loss of 1.8 % for ODS-1 
and of 1.6 % for ODS-2. As a first check to find the influence of the water on the crystal 
structure, both samples were subjected to a climate chamber experiment, in which temperature 
and humidity can be controlled separately. The samples were heated to 155 ºC, during which the 
samples were expected to dehydrate completely, and possibly become more similar. Interestingly 
however, the difference between the XRPD patterns of the two “anhydrate” samples at elevated 
temperatures (figure 4) increases. Upon cooling under ambient conditions, however, both 
patterns reverted back to their original “hydrated” pattern. 
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Figure 3: XRPD  patterns of samples of ODS-1 and ODS-2, including a difference plot. 
The difference plot is shifted downwards for clarity to prevent overlap of difference 
and XRPD patterns. 
 
Figure 4: XRPD patterns of samples of ODS-1 and ODS-2 heated to 155 ºC, including 
a difference plot. The difference plot is shifted downwards for clarity. 
Because the XRPD patterns do not yield a clear picture, DSC thermograms were recorded 
for ODS-1 and ODS-2 using different heating rates, see figure 5. Using a heating rate of 10 
ºC/min the temperature difference in the onset of the melting endotherm for the two samples is 
small; 246 ºC in case of ODS-1and 245 ºC in case of ODS-2. The melting endotherm is followed 
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in both samples by a degradation endotherm, as was confirmed using solution NMR. Using a 
heating rate of 1 ºC/min the onset temperature of the melting endotherms has the same value for 
both samples, and also in this case the melting endotherm is followed by a degradation 
endotherm, although more clearly visible for ODS-1. Lowering the heating rate to 0.1 ºC/min 
results in two different thermograms; the melting endotherm is split into a doublet in case of 
ODS-1, while for ODS-2 the melting endotherm is still a singlet. The onset temperature of the 
first endotherm for ODS-1 is almost the same as the onset temperature for ODS-2; 215 versus 
217 ºC. The second endotherm of the ODS-1 sample is a degradation endotherm, which could 
point at a less stabilizing surrounding of the molecules in ODS-1 crystals. In all thermograms a 
thermal event between 50 and 150 ºC is visible. This can be attributed to the loss of water. As 
can be expected, the water loss takes place at lower values when using lower heating rates, the 
same is valid for the onset temperatures of the melting and degradation endotherms. 
      
Figure 5: DSC thermograms of ODS-1 (left panel) and ODS-2 (right panel) recorded 
with different heating rates. 
To obtain an impression of the mutual stability of the two crystalline phases, slurry 
experiments were performed. Judging from the XRPD patterns, ODS-1 could be transformed to 
ODS-2, by stirring the sample for 3 days at room temperature in methanol. Conversely stirring 
ODS-2 in a 2.5/1 mixture of ethanol/water for 3 days resulted in the formation of ODS-1. These 
results indicate that ODS-1 and ODS-2 are not real polymorphs, but that perhaps different levels 
of water have incorporated. 
Several attempts were made to grow single crystals of Ondansetron free base, but because 
of the high nucleation barrier and the extreme fast growth in the needle direction it was not 
possible to obtain single crystals that were large enough to perform a single crystal structure 
determination. Using vapour growth, however, small single crystals of Ondansetron could be 
obtained. The resulting crystal structure is presented in figure 6, for crystal data see table 1.  
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Initial refinement showed exceptional large and anisotropic thermal ellipsoids for carbon atoms 2 
and 3 (in both molecules in the asymmetric unit) together with a bad geometry for these atoms. 
This indicated that these atoms are disordered over two positions which correspond to two 
possible conformers of the Ondansetron molecules. A suitable model describing this disorder 
could be defined and refinement in spacegroup P-1 (Z = 4) led to acceptable geometries for the 
resulting positions of atoms 2 and 3. Refinement of the occupancy factors for the possible 
conformers of the Ondansetron molecules showed that for both symmetry independent molecules 
the two conformers are present in almost equal amount. This disorder model allows either 
enantiomer to be present at both independent positions of the asymmetric unit and, at the same 
time, restricts the possible conformers to combinations of a particular enantiomer with one of the 
two conformations of the six-membered ring. In case of the R-enantiomer the six-membered ring 
is up, compared to the plane through the indole part of the Ondansetron molecule, in case of the 
S-enantiomer the six-membered ring is down, see figure 6.  
 
Figure 6: One of the two Ondansetron molecules in the asymmetric unit of ODS-3. 
The carbons 2 and 3 are disordered over two positions, indicated by the dashed 
lines, corresponding with the six-membered ring “up” or “down” compared to the 
plane through the indole part of the molecule. Note, that these two ring orientations 
correspond to different enantiomers. 
The (2-methyl-1H-imidazole-1-yl)-methyl sidegroup of one of the Ondansetron molecules 
is badly defined by the data and could only be refined by restraining its geometry to the 
corresponding sidegroup of the other molecule. Apparently, the disorder in the conformation in 
the six-membered ring, formed by atoms 1,2,3,4,4a and 9a, also influences the orientation of this 
sidegroup. From a difference Fourier map a water molecule was found with an occupancy factor 
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of around 50 %. The water molecule was found to bridge the imidazole side groups of the 
Ondansetron in the solid state. As the sample was obtained using growth from the vapour phase, 
at low pressure and high temperature, it is very unlikely that this water was present during the 
crystal formation. The presence of the water in the structure was confirmed using Karl-Fisher 
titrations and determined to be approximately one molecule of water per unit cell, which is in 
accordance with the occupancy of 50 %. Comparing the XRPD pattern, calculated from the 
crystal structure, with the measured XRPD patterns of ODS-1 and ODS-2 revealed that the 
calculated pattern shows large similarity with the pattern of ODS-2, that is the crystals grown in 
a water poor environment.  
Table 1: Crystal data of ODS-3. 
Identification code 
Crystal colour 
Crystal shape 
Crystal size 
Emperical formula 
Formula weight 
Temperature 
Radiation/Wavelenght 
Crystal system/ space group 
Unit cell dimensions 
 
 
Volume 
Z/ calculated density 
Zjak22 
Translucent colourless 
Rough rod 
0.19x0.05x0.03 mm 
C18H19N3O 
293 
208(2) K 
MoKα/0.71073 Å 
Triclinic/ P-1 
a= 7.3325(15) Å, α= 68.76(11) º 
b= 13.06(2) Å, β= 89.46(4) º 
c= 16.871(13) Å, γ= 86.47(6) º 
1502(3) Å mm3 
 4, 1.315 Mg/m3 
 
It is important to realize that in solution both enantiomers are present in the two possible 
ring conformations. These four possibilities are presented in figure 7 and labelled ‘R-up’, ‘R-
down’, ‘S-up’, and ‘S-down’. These conformers could be responsible for the structural 
differences of ODS-1, or even ODS-2, with respect to ODS-3. 
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Figure 7: Two conformers for each enantiomer of Ondansetron, depending on the 
orientation of the puckered six-membered ring, which are present in solution. 
To get a better insight in the possible conformations of the Ondansetron molecules in the 
solid state, molecular modeling was performed. Because the XRPD patterns of the three forms 
are too close to allow for truly different packings, as a starting point the (badly resolved) single-
crystal X-ray structure from the vapour grown crystal was taken, but now allowing all four 
conformations to occur. This structure was refined in space group P-1, i.e. having an inversion 
centre. The four conformations of the two molecules in the asymmetric unit then lead to a total 
of 16 different possible unit cell structures. It should be mentioned, however, that the molecular 
modelling was performed without incorporating water in the crystal structure. 
For the four conformations of figure 7, a starting configuration was determined from a 
conformer search in which the two dihedral angles of the bonds between carbons 3 and 1” and 
between carbon 1” and the imidazole nitrogen were varied systematically. Each generated 
conformer was minimized, thus yielding the combination of the two dihedral angles having the 
lowest energy. These four starting conformers were used two at a time to generate the 
asymmetric unit of the crystal structure, by aligning the well-resolved conjugated indole ring 
system from the single X-ray-strcucture with the molecules generated from the conformer 
search. After rebuilding the crystals the lattice energy was minimized. This last minimization 
was performed in a two-step procedure: first the newly placed molecules were allowed to find 
their minimum energy geometry in the crystal structure without changing the cell parameters and 
in a second minimization run, the cell parameters were allowed to relax too. This was done to 
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prevent large changes in the cell parameters upon minimization of the newly placed molecules in 
the crystal, which might have unfavourable intermolecular interactions due to their initial 
conformations. From the building of the crystals and the subsequent minimization, it was found 
that only combinations of the R enantiomer having the ‘up’ ring-puckering and the S enantiomer 
having the ‘down’ puckering led to crystal structures in which 1) crystal structures could be 
obtained without molecules overlapping, 2) the ring puckering was left unchanged upon 
minimization and 3) the lattice parameters did not change much compared to the known lattice 
parameters. This implies that for all three forms of ODS, these are the only possible 
combinations. As can be seen from table 2, four possible crystal structures are found when the R-
up molecules and S-down molecules are positioned in any combination, without significant 
differences in lattice energy: the four lattice energies are within 1 kcal/mol, which is within the 
error associated with the force field used.  This indicates that there is no combination that is 
strongly favoured energetically. This then leads to the hypothesis that the structure of 
Ondansetron, ODS-3, is in fact a solid solution-like packing of enantiomers.  
Table 2: The four fillings of the assymmetric unit for Ondansetron with the lowest 
and comparable lattice energies after minimization. 
Molecule 1 Molecule 2 Lattice energy 
(kcal/mol) 
R up 
R-up 
S-down 
S-down 
R-up 
S-down 
R-up 
S-down 
-33.13 
- 33.57 
-33.01 
-33.69 
 
The obtained results of the molecular modelling were used to further refine the crystal 
structure of ODS-3. One of the four possible crystal structures of ODS-3 is presented in figure 8. 
Calculated XRPD patterns of ODS-3 and of the four possible crystal structures are presented in 
figure 9. Because only very small peak shifts and intensity differences can be observed between 
the calculated XRPD patterns, this supports the hypothesis that the structure of ODS-3 is a solid 
solution-like packing of enantiomers. 
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Figure 8. One of the four possible sequences for the R and S enantiomers for 
centrosymmetric cases. In this case positions 1 and 2 are occupied by R molecules 
and positions 1’and 2’ by S molecules. 
 
Figure 9. Calculated XRPD patterns of ODS3 and of the four possible crystal 
structures. The labeling of the traces refers to occupation of sites 1, 2, 1' and 2' (cf. 
figure 8) by S  and R molecules. 
Such solid solution behaviour should be apparent using ss NMR spectroscopy. Therefore 
ss CPMAS C-13 NMR spectra of powders of ODS-1 and ODS-2 were recorded. The C-13 
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spectra of both samples are presented in figure 10, showing quite broad peaks. The carbon peak 
assignments are given in table 3. As can be seen from the spectra and the table there are no big 
differences in peak positions between the two forms. The signal for carbon 5”, at approximately 
13 ppm for both samples, is split in multiple peaks, which means that different surroundings 
exist for this carbon atom. This observation is also valid for carbon 1, at around 21 ppm, carbon 
2 at around 25 ppm and carbon 1” at around 45 ppm. The results of the solid state NMR 
experiments confirm the solid solution-like packing. From the carbons influenced by the 
conformation of the 6-membered ring, the 1” and the 5” carbon, in the side group, are mostly 
affected. Both show three different peaks, which can be associated with three different 
surroundings of these carbons in the solid state, originating from the four different combinations 
giving rise to three different types of neighbours: R-up next to R-up, R-up next to S-down and S-
down next to S-down.\ 
    
Figure 10: ss CPMAS C-13 NMR spectra of ODS-1 and ODS-2. 
Considering the resemblance between the XRPD patterns of ODS-3, ODS-2 and ODS-1 it 
can be argued that all Ondansetron samples have comparable structures. The differences in the 
XRPD patterns between ODS-1 and ODS-2 can now be explained by differences in mesoscopic 
structure, as a result of different packing sequences of the two enantiomers, probably induced by 
different amounts of water present in the structure during crystal growth. ODS-2 and ODS-3 
were both grown under “water free” conditions; in case of ODS-2 methanol with only a small 
amount of water was used, in case of ODS-3 elevated temperatures and high vacuum were used. 
This is contrary to the case of ODS-1, where a large amount of water was present during 
crystallization. Once the packing structure is formed it is not altered anymore as was 
demonstrated by the climate chamber experiments: the de-hydrated forms revert back to the 
original hydrated forms upon cooling under ambient conditions. 
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The morphology of the crystals supports the disordered hypothesis. As is shown in figure 2 
the crystals obtained from ODS-1 and ODS-2 are needle-like. Growth is fast in the needle 
direction because of very low barriers for the incorporation of molecules, even at very low 
supersaturations26,27,28. When molecules are incorporated that fast into the solid, the likelihood 
for the occurrence of defects is larger. In this case the ‘defect’ occurs because the lattice does not 
discriminate between the different enantiomers when they are built in as long as the 
conformation of the molecule is adapted to conform to the two possibilities, R-up and S-down.  
Thus the different forms of Ondansetron are instead of two polymorphs probably two 
manifestation of a locally ordered solid solution as was demonstrated by the various techniques 
used. 
Table 3: C-13 NMR peak assignments for ODS-1 and ODS-2. 
Carbon ODS-1 
(ppm) 
ODS-2 
(ppm) 
5” 
5” 
5” 
13.25 
14.03 
15.39 
12.72 
14.00 
15.33 
1 
1 
20.76 
21.60 
20.81 
21.58 
2 
2 
24.57 
25.48 
24.57 
25.05 
1’ 28.52 28.42 
1” 
1” 
1” 
43.28 
45.37 
48.51 
43.32 
45.40 
48.48 
3 46.63 46.55 
6.4 Conclusions 
From the combination of all techniques used we conclude that ODS-3 is best interpreted as 
a locally ordered solid solution of enantiomers; at each site in the structure either an R-up or an 
S-down Ondansetron molecule can be placed. Because the XRPD patterns of ODS-3 and ODS-2 
are very similar, and in turn quite similar to the powder pattern of ODS-1, we assume that also 
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for ODS-2 and ODS-1 a locally ordered solid solution of enantiomers is present in the solid state. 
Different combinations of enantiomers in the solid state give rise to slightly different forms of 
Ondansetron. The amount of water present during the crystal growth induces subtle but 
important local order in the disorder.  
Although the various forms of ODS show different physical properties, one cannot speak 
of polymorphism. More generally, the results show that subtle but significant differences in X-
ray powder diffraction patterns do not automatically imply polymorphism. 
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SUMMARY 
 
In this thesis different aspects of polymorphism, the ability of a substance to crystallize in 
more than one crystal form, are studied. Because physical properties, e.g. melting enthalpy, heat 
capacity, and solubility, of two polymorphs can differ, the pharmaceutical industry spends a lot 
of money and effort in studying the phenomenon of polymorphism, because especially the 
solubility difference between two polymorphs can  have influence on the effectivity, the bio-
availability and the safety of drugs.  A lot of effort is invested to find the most stable polymorph, 
although one is never certain that the most stable polymorph has been found. A recent example, 
in which the difference in bio-availability was of importance, is ritonavir. After having been on 
the market for almost two years, a more stable polymorph with a lower solubility and, therefore, 
a lower bio-availability was found. Especially the thermodynamic aspects, that play an important 
role concerning polymorphism of active pharmaceutical ingredients of drugs, are studied in this 
thesis.  
After a general introduction about the phenomenon of polymorphism, the thermodynamic 
theory of solubility of compounds in solvents is described, with the emphasis on compounds 
exhibiting polymorphism. The relation between phase diagrams and solubility is treated. Starting 
with simple models describing the thermodynamics of solutions, assuming no mixing between 
the solvent and the solute in the solid state, the large variety of possible solubility curves, 
describing the temperature dependent solubility, are explained. In addition, pseudo polymorphs, 
that is solvates, are treated. The models result in a formula which makes it possible to estimate 
the transition temperature for an enatiotropically related system. For this only the melting 
temperature and the melting enthalpy of the two polymorphs are needed. Both are simply 
determined using  Differential Scanning Calorimetry (DSC). 
In the third chapter the phase behaviour of the free base of Venlafaxine, the active 
ingredient of a drug used to treat stress, is described. Both the polymorphic phase diagram as 
well as the thermodynamic relations between the three forms are studied, using DSC, X-ray 
Powder Diffraction (XRPD), slurry experiments and solubility measurements. The solubility of 
Venlafaxine was determined in several solvents, focussing on deviations of the solubility as 
compared to the ideal solubility according to the van ’t Hoff equation. The nature of the 
deviation of the solubility was such that attributing the stability regions for polymorphs I and II, 
on the basis of solubility data would lead to a wrong attribution of these regions. This turned out 
to be the  result of the concave shape of the solubility curves, a form that, from a theoretical 
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viewpoint, is described in more detail in chapter 2. The transition temperature of polymorph I 
and II of Venlafaxine free base was calculated using the earlier mentioned equation to estimate 
the transition temperature and compared with the values extracted from the solubility data. The 
concave shape of the solubility curves is the result of a non neglectable temperature dependence 
of the melting enthalpy. 
In chapter 4 the remarkable behaviour of the free base of Venlafaxine with respect to 
polymorphism and chiral resolution is studied. Using different complementary techniques, the 
three forms of Venlafaxine free base were characterized. The crystals of all the three forms are 
composed of almost identical enantiomerically pure layers, only the stacking of the layers is 
different. In case of form I alternating bi-layers of R and S layers were found, while form II 
consisted of alternating double bi-layers of R and S enantiomers. In case of form III, the form 
with the highest melting point, the enantiomer separation is complete, resulting in a racemic 
conglomerate. The racemic conglomerate can be obtained from solution, or via a solid-solid 
phase transition of the lowest melting form. Remarkably, during this phase transition the shape 
of the crystal is conserved. It is hypothesized that, during the phase transition occurring, the 
chiral separation takes place via a local melting process. Locally the melting point is lower as the 
result of crystal defects. Because of the local melting process, molecules are able to migrate over 
relatively large distances between the layers in the crystal.  
The results of a morphology prediction for the three forms of the free base of Venlafaxine 
are presented in chapter 5. Three different methods, the Bravais-Friedel-Donnay-Harker method, 
the attachment-energy method and a Monte Carlo growth simulation are used for that. A 
comparison of the predicted and the experimentally found morphologies shows that the Monte 
Carlo simulation gives a semi-quantitative result for form I and II. In case of form III the correct 
morphology was found, but some of the predicted indices did not correspond with the 
experimentally found indices.  
In chapter 6 the polymorphic behaviour of the free base of Ondansetron is studied. For 
Ondansetron, an active pharmaceutical ingredient used to treat vomiting and nausea during 
chemotherapy, two different crystalline forms are known: ODS-1 and ODS-2. Both forms have 
been grown from solution. Even using different techniques; XRPD, Nuclear Magnetic 
Resonance (NMR), and DSC turned out to be not sufficient to determine if Ondansetron shows 
polymorphism or not. Using a combination of a badly resolved crystal structure of a vapour 
grown crystal, ODS-3, and molecular modelling, it was hypothesized that the crystal structure of 
ODS-3 best can be interpreted as a locally ordered solid solution of enantiomers.  Because the 
similarities between the XRPD patterns of the three batches it was assumed that also ODS-1 and 
Summary 
 - 147 - 
ODS-2 are locally ordered solid solutions of enantiomers. Different incorporations of 
enantiomers on a mesoscopic scale, in the solid state give rise to slightly different forms of 
Ondansetron. The amount of water present during the crystal growth induces subtle but 
important local order in the disorder. The results show in this case that although different ODS 
forms show different physical properties, one cannot speak of polymorphism.  
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SAMENVATTING 
 
In dit proefschrift worden verschillende aspecten van polymorfie, het verschijnsel waarbij 
verbindingen in meer dan een kristalvorm kunnen uitkristalliseren, bestudeerd. Omdat de 
fysische eigenschappen, o.a. smeltwarmte, warmtecapaciteit en oplosbaarheid, van twee 
polymorfen kunnen verschillen, wordt er door de farmaceutische wereld veel onderzoek gedaan 
aan het verschijnsel polymorfie. Dit omdat vooral het oplosbaarheidsverschil van twee 
polymorfen invloed kan hebben op de effectiviteit, de biobeschikbaarheid en de veiligheid van 
het medicijn. Veel moeite wordt er dan ook gedaan om de meest stabiele polymorf te vinden, 
hoewel men nooit helemaal zeker is dat deze gevonden is. Een recent, voorbeeld waarbij het 
verschil in biobeschikbaarheid van twee polymorfen van belang was, is ritonavir. Nadat het 
medicijn al bijna twee jaar op de markt was ontstond er een thermodynamisch stabielere 
polymorph met een lagere oplosbaarheid en dus een lagere biobeschikbaarheid. 
Met name de thermodynamische aspecten die een rol spelen bij polymorfie van aktieve 
bestanddelen van medicijnen worden in dit proefschrift bestudeerd.  
Na een algemene inleiding over het fenomeen polymorfie, wordt in hoofdstuk 2 de 
thermodynamische theorie van de oplosbaarheid van stoffen in oplosmiddelen behandeld, met de 
nadruk op stoffen die polymorfie vertonen. De relatie tussen fasediagrammen en oplosbaarheid 
komt daarbij aan de orde. Uitgaande van eenvoudige modellen voor de thermodynamica van 
oplossingen, waarbij wordt aangenomen dat er geen menging optreedt tussen oplosmiddel en 
opgeloste stof in de vaste fase, wordt de grote variëteit aan mogelijke vormen van oploscurven, 
die het temperatuurgedrag van oplosbaarheid beschrijven, verklaard. Pseudopolymorfen, oftewel 
solvaten, worden ook behandeld. De modellen monden uit in een formule die het mogelijk maakt 
om de overgangstemperatuur voor een enantiotroop stelsel van polymorfen te schatten. Hiervoor 
zijn alleen de smelttemperatuur en de smeltwarmte van de twee polymorfen, beide eenvoudig te 
bepalen met behulp van Differential Scanning Calorimetry (DSC),  nodig. 
In het derde hoofdstuk wordt het fasegedrag van de vrije base van Venlafaxine, het aktieve 
bestandeel van een medicijn dat gebruikt wordt voor de behandeling van stress, bestudeerd. 
Zowel het polymorfie fasediagram als de thermodynamische relatie tussen de drie vormen wordt 
bestudeerd. Gebruikte methoden zijn DSC, X-ray Powder Diffraction (XRPD), slurrie 
experimenten en oplosbaarheidsmetingen. De oplosbaarheid van Venlafaxine werd bepaald in 
verschillende oplosmiddelen. Er werd vooral gekeken naar de afwijkingen van de oplosbaarheid 
ten opzichte van de ideale oplosbaarheid volgens de vergelijking van van ‘t Hoff.  De 
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afwijkingen van de oplosbaarheid bleken van dien aard dat het toekennen van de 
stabiliteitsgebieden van polymorf I en II, op basis van oplosbaarheidsdata, zou leiden tot een 
verkeerde toekenning van deze gebieden. Dit is het gevolg van de concave vorm van de 
oplosbaarheidscurven, een vorm die, vanuit theoretisch standpunt, in meer detail is beschreven in 
hoofdstuk 2. De overgangstemperatuur voor de polymorfen van Venlafaxine vrije base werd 
berekend met gebruikmaking van de eerder genoemde vergelijking voor het benaderen van de 
overgangstemperatuur voor twee polymorfen en vergeleken met de waarden die volgen uit de 
oplosbaarheidsdata. De concave vorm van de oplosbaarheidscurve is het gevolg van een niet te 
verwaarlozen temperatuurafhankelijkheid van de smeltwarmte.  
In hoofdstuk 4 wordt het opmerkelijke gedrag van de vrije base van Venlafaxine met 
betrekking tot de polymorfie en chirale resolutie beschreven. Met gebruikmaking van 
verschillende complementaire technieken werden de drie vormen van de vrije base van 
Venlafaxine gekarakteriseerd. De kristallen van alle drie de vormen zijn opgebouwd uit 
nagenoeg identieke enantiomeer zuivere lagen, maar verschillen in stapeling; voor vorm I 
alternerende bi-lagen van R en S enantiomeren, in het geval van vorm II alternerende dubbele bi-
lagen van R en S enantiomeren. Voor vorm III, de vorm met het hoogste smeltpunt, is de 
enantiomere scheiding volledig, wat leidt tot de vorming van een racemisch conglomeraat. Het 
racemisch conglomeraat kan worden gegroeid uit een oplossing of via een vast-vast fase 
overgang van de laagst smeltende polymorf, polymorf I, naar vorm III. Opmerkelijk is dat de 
vorm van het kristal behouden blijft tijdens de fase overgang. Verondersteld wordt dat de tijdens 
deze fase overgang optredende chirale scheiding plaatsvindt via een lokaal smeltproces, als 
gevolg van aanwezige kristalfouten. Het lokale smeltproces maakt het mogelijk dat de molekulen 
over relatief grote afstanden kunnen migreren tussen de lagen in het kristal. 
De resultaten van een morfologie voorspelling voor de drie vormen van de vrije base van 
Venlafaxine worden gepresenteerd in hoofdstuk 5. Drie verschillende voorspellingsmethoden, te 
weten de Bravais-Friedel-Donnay-Harker methode, de attachment-energie methode en Monte 
Carlo groeisimulaties worden gebruikt. Een vergelijking van de voorspelde en de experimenteel 
gevonden morfologieën laat zien dat de Monte Carlo simulaties een semi-kwantitatief resultaat 
geven voor polymorf I en II. Voor vorm III wordt de juiste morfologie gevonden maar sommige 
voorspelde indices komen niet overeen met de experimenteel gevonden indices. 
In hoofdstuk 6 wordt het polymorfiegedrag van de vrije base  van Ondansetron bestudeerd. 
Van Ondansetron, een farmaceutisch aktief ingrediënt dat gebruikt wordt om overgeven en 
misselijkheid tijdens chemotherapie te behandelen, zijn twee verschillende kristallijne vormen 
bekend; ODS-1 en ODS-2. Beide vormen zijn gegroeid uit de oplossing. Zelfs toepassen van 
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verschillende technieken, XRPD, Nuclear Magnetic Resonance (NMR) en DSC, was niet 
voldoende om te kunnen bepalen of in er in dit geval sprake is van polymorfie. Met 
gebruikmaking van de combinatie van een slecht opgeloste kristalstructuur van een uit de damp 
gegroeid eenkristal, ODS-3, en molecular modeling wordt geconcludeerd dat de kristalstructuur 
van ODS-3 het beste kan worden geïnterpreteerd als een lokaal geordend mengkristal van 
enantiomeren.  Omdat de overeenkomsten tussen de XRPD patronen van de drie monsters groot 
zijn, wordt aangenomen dat ook ODS-1 en ODS-2 lokaal geordende mengkristallen van 
enantiomeren zijn. Verschillende combinaties van enantiomeren, geïnduceerd door de 
hoeveelheid water aanwezig tijdens de kristalgroei, veroorzaken mogelijk de verschillende 
vormen die gevonden worden voor de vrije base van Ondansetron. Uit de resultaten van de 
studie van de vrije base van Ondansetron kan worden geconcludeerd dat kleine, maar duidelijk 
aanwezige verschillen niet noodzakelijkerwijs betekenen dat er sprake is van polymorfie.  
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DANKWOORD 
 
Een promotie onderzoek is normaal gesproken een vervolg van een doctoraal opleiding, en 
volgt meestal direct na het succesvol afsluiten van deze opleiding. In mijn geval is het iets anders 
verlopen: na ruim 7 jaar gewerkt te hebben bij het Laboratorium voor Grote Schaal en Service 
Synthese (LGSS) van de Katholieke Universiteit Nijmegen vervolgde ik mijn carrière in 1994 bij 
Synthon BV, een farmaceutisch bedrijf werkzaam in het generieke segment. 
Om de kennis over polymorfie te verhogen werd in het jaar 2000 professor Piet Bennema 
aangetrokken als adviseur. Om het niveau op een hoger plan te tillen zou het volgens Piet beter 
zijn als er diepgaander onderzoek betreffende polymorfie zou worden verricht. Hij dacht aan een 
samenwerking met de afdeling vaste stof chemie van de Radboud Universiteit in de vorm van 
een promotieonderzoek.  
Liever nog: twee promotieplaatsen, een die zich zou bezig houden met de theoretische 
kant, een computer modeller, en een die zich zou bezighouden met de praktische kant, het 
kristalliseren en meten aan de verkregen kristallen. In overleg met Bertus Thijs, het toenmalige 
afdelingshoofd chemische R&D van Synthonen Jacques Lemmens, directeur van Synthon,  werd 
besloten om de samenwerking gestalte te geven. Op dat moment gaf ik Bertus en Jacques te 
kennen dat ik wel geïnteresseerd was om de praktische promotieplaats in te vullen.  
Na een kort beraad werd akkoord gegaan met dit idee. Ik werd promovendus, zij het dat ik 
in dienst bleef bij Synthon en gedurende 4 jaar bijna uitsluitend aan onderzoek van voor Synthon 
interessante verbindingen kon werken. Uiteindelijk duurde het o.a. vanwege persoonlijke 
omstandigheden iets langer.  
Na deze korte inleiding wil ik verschillende mensen bedanken die het uiteindelijk mogelijk  
hebben gemaakt om mijn onderzoek uit te voeren en af te sluiten met dit proefschrift. 
Te beginnen met Jacques Lemmens en Bertus Thijs, die me deze unieke kans hebben 
geboden om te promoveren. Vanaf het begin hadden zij er het volste vertrouwen in dat het 
onderzoek succesvol zou worden afgesloten. In een adem wil ik Piet Bennema noemen, die de 
eigenlijke architect is geweest van het samenwerkingsproject en mij binnen Synthon altijd 
enthousiast en betrokken heeft begeleid. 
Mijn directe collega’s van de afdeling chemische R&D, Arjanne, René, Judith, Henar, Jie, 
Jordy, Rens, Rolf (het huidige hoofd van de afdeling), Jan, Gert Jan en Raymond die altijd vol 
interesse informeerden naar de voortgang van het onderzoek, wil ik bedanken. Zelfs tijdens de 
lange periode van het schrijven bleven ze geïnteresseerd.  
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Eén collega wil ik extra bedanken: Walter Elffrink, steun en toeverlaat als het over 
computer problemen ging. Hij was onvermoeibaar om voor de zoveelste keer uit te leggen hoe al 
die voor mij onbegrijpelijk zaken eigenlijk heel simpel op te lossen waren. Zonder zijn hulp had 
het schrijven nog veel langer geduurd. Verder was hij ook altijd bereid om samples voor mij te 
meten op de momenten dat ik werkzaam was op de universiteit.  
Ook veel collega’s van andere afdelingen wil ik bedanken voor hun niet aflatende interesse 
gedurende de promotietijd. Teveel om op te noemen, maar Gerry Ariaans wil ik niet onvermeld 
laten. Dank zij zijn hulp en specifieke kennis van Word staan alle hoofdstukken, headers, footers 
en inhoudsopgave in het proefschrift op hun goede plaats. 
Van de personen werkzaam bij de afdeling vaste stof chemie wil ik natuurlijk als eerste 
professor Elias Vlieg bedanken. Vanaf het begin zag je de samenwerking met Synthon wel zitten 
en hoewel ik geen “normale” promovendus was stond je volledig achter de keuze van Synthon 
om mij voor deze positie voor te dragen. Gedurende de promotietijd hebben we altijd plezierig 
samengewerkt en liet je me altijd vrij om zelf richting te geven aan mijn onderzoek. De 
dagelijkse begeleiding nam Hugo Meekes op zich. In verband met allerlei redenen is een betere 
begeleider nauwelijks denkbaar. Behalve onze regelmatige discussies over klassieke muziek, 
allebei zijn we liefhebbers van Mahler en Shostakovich , en de besprekingen over de teloorgang 
van het middelbare school onderwijs, was je ook altijd bereid om voor de zoveelste keer de 
theorie achter iets uit te leggen of hoe een apparaat werkte. Je nam ook het grootste gedeelte van 
de berekeningen van de oplosbaarheidcurven, gepresenteerd in hoofdstuk 2 en 3 voor je 
rekening. Maar nog belangrijker was dat je, bijna als enige, er altijd van overtuigd was dat het 
allemaal wel goed zou komen. Dus Hugo bedankt, zonder jou was dit proefschrift er niet 
gekomen.  
De tweede promovendus die deel uit maakte van de samenwerking met de universiteit was 
Menno Deij. Je hield je voornamelijk bezig met computerwerkzaamheden, modelleren en 
programmeren, beide zaken die niet mijn grootste interesse hadden en hebben. Gedurende de 
promotietijd hebben we altijd goed en plezierig samengewerkt, wat resulteerde in een mooie 
publicatie, hoofdstuk 5, hiervoor mijn dank.  
Vervolgens wil ik Jan van Kessel niet onvermeld laten, want zonder een heerlijk bakje 
koffie kon de dag eigenlijk niet beginnen. Ik denk nog regelmatig terug aan deze koffiepauzes. 
Verder verzorgde je altijd alle bestellingen en kon ik altijd een beroep op je doen als ik hulp 
nodig had. Eveneens wil ik Elizabeth Salem bedanken voor haar interesse en voor het afhandelen 
van alle mogelijke administratieve rompslomp.  
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Willem van Enckevort wil ik, behalve voor zijn humor en onorthodoxe manier van 
lesgeven, bedanken voor zijn hulp met het vinden van groeispiralen op het oppervlak van 
kristallen van Venlafaxine. Na enige uren vruchteloos naar de kristallen te hebben gekeken vroeg 
ik Willem of hij even mee kon kijken. Na twee minuten had hij al groeispiralen gevonden op het 
kristaloppervlak. 
René de Gelder en Jan Smits wil ik bedanken voor het ophelderen van de vele 
kristalstructuren en René in het bijzonder ook voor de vele discussies over hoe de verschillende 
data te interpreteren. De resultaten hiervan staan vermeld in hoofdstuk 4 en 6.  
Dankzij de inzet van Ernst van Eck en professor Arno Kentgens van de afdeling vaste stof 
NMR konden onze resultaten betreffende Venlafaxine en Ondansetron beter worden 
geïnterpreteerd. 
Van de afdeling gemeenschappelijk instrumentarium wil ik Geert-Jan Janssen bedanken 
voor de hulp bij het maken van de elektronenmicroscopische opnamen. 
Vanzelfsprekend wil ik ook de mede promovendi en medewerkers van de afdeling te weten 
Herma, Marianne, Neda, Cristina, Sander, Edwin, Daniel, Paul Poodt, Maurits, Joanne, Natalia, 
Paul Verwer, Jan Los en Wiesiek bedanken die allemaal hebben bijgedragen aan de plezierige 
sfeer op de afdeling. Speciaal Jelena, Ismael, Rienk en Wim die als voormalige kamergenoten 
door hun persoonlijke betrokkenheid nog meer hebben bijgedragen aan mijn welbehagen. 
Hierbij wil ik de studenten die ik tijdens mijn promotietijd heb begeleid bedanken: Gerbe, 
Fieke, Mirjam en Bas tijdens een snuffelstage, en Hannie tijdens een hoofdvakstage. Helaas voor 
Hannie werd ik tijdens haar afronding van de stage ziek, maar mijn taak werd uitstekend 
waargenomen door Hugo. 
Verder wil ik alle familie, vrienden en andere bekenden bedanken voor de interesse in mijn 
werk tijdens de promotietijd. Speciaal wil ik Vincent bedanken voor zijn wekelijkse bezoekjes 
om te informeren of alles nog wel goed ging, ook kon ik altijd een beroep op hem doen als er 
weer eens thuis iets kapot was. Ik wil ons Marriet extra bedanken voor de etentjes  op 
maandagavond die, nu het proefschrift klaar is, nog gewoon doorgaan. Ook een speciaal 
bedankje voor Herman en Riny, vrienden en studiegenoten vanaf de mentorgroep. Hoewel op 
afstand, waren zij altijd erg geïnteresseerd in de stand van zaken betreffende het onderzoek. 
Helaas heeft Riny het eindresultaat niet meer mogen meemaken. Anderhalf jaar geleden moest 
zij haar strijd tegen haar ziekte opgeven. 
Als laatste, maar ook als belangrijkste wil ik mijn dochter Sam bedanken. Ik keek en kijk 
altijd uit naar de momenten dat je bij mij bent. Jij met je altijd aanstekelijke goede humeur leert 
mij op die momenten waar het allemaal echt om gaat. 
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 Synthon is a Dutch pharmaceutical company, founded in 1991, which develops and 
manufactures generic medicines. The creative vision of the founders led to a rapid 
international growth. Currently Synthon employs over 1000 people worldwide.  
Synthon’s vision is to develop, produce and sell high-quality alternatives to 
innovative medicines. Synthon prefers to concentrate on medicines with complex 
chemical structures and on medicines which are difficult to formulate.  
Synthon structurally invests in talented researchers and strives to be an excellent 
employer, offering opportunities for their professional growth and providing job 
satisfaction. Synthon’s strength lies in the commitment of its employees. 
In addition to chemical and pharmaceutical research, Synthon also carries out 
analytical and clinical research at locations in The Netherlands, Czech Republic, Spain 
and the United States. Before product development is started, extensive intellectual 
property research is carried out to avoid infringing an existing patent, but also to identify 
potential opportunities to claim a new patent. 
Synthon deliberately chose to be a vertically integrated company, which means that 
our work does not stop at the laboratory, but continues through production. In this way, 
the active substances are produced in the Czech Republic and Argentina, while the several 
dosage forms are formulated in Spain. The medicines are subsequently packed in Spain or 
in the United States. Synthon products are made marketed via cooperation with several 
leading pharmaceutical companies. Synthon products are thus available in all European 
countries, the United states, Canada, Australia, New Zealand, Argentina, Brazil, Chile, 
Russia, Israel and South Africa. Synthon’s customers are provided with a finished 
product, including registration files which comply with the chemical, pharmaceutical and 
clinical requirements of authorities such as the EMEA, FDA and TGA. 
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Currently Synthon is developing a range of promising new products which will be 
ready for the market in the coming years. 
In 2007 Synthon made a first step in the direct sales to customers by acquiring 
Laboratorios Rider Ltda in Chile. In the same year Synthon started the development of 
biopharmaceutical products, in addition to its existing portfolio of chemical entities. 
 
 
 
 
 
 
 
 
 
 
 
